Page last updated: 2024-10-29

ifosfamide and Sarcoma, Epithelioid

ifosfamide has been researched along with Sarcoma, Epithelioid in 496 studies

Research Excerpts

ExcerptRelevanceReference
"The results of the association of doxorubicin plus ifosfamide in the treatment of locally advanced and/or metastatic adult soft tissue sarcomas as reported in the literature from 1986 up to the present time are reviewed."10.17Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas. ( Palumbo, R; Santi, L; Sogno, G; Toma, S; Venturino, A, 1992)
"This randomised phase II/III trial aimed to determine whether perioperative chemotherapy with gemcitabine plus docetaxel (GD) is non-inferior to the standard Adriamycin plus ifosfamide (AI) in terms of overall survival (OS) in patients with soft tissue sarcoma (STS)."9.51Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306. ( Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T, 2022)
"This prospective single-arm phase II clinical trial aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS)."9.51Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. ( Chen, H; Chen, Y; Huang, M; Jiang, S; Liu, X; Luo, Z; Miao, J; Wang, C; Wang, H; Wang, J; Wu, X; Xia, J; Xu, Y; Yan, W; Yao, W; Yu, L; Zhang, X, 2022)
"Pazopanib and gemcitabine have shown good tolerability, albeit modest single-agent activity in pretreated soft tissue sarcoma."9.41Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. ( Crysandt, M; Cygon, F; Egerer, G; Eigendorff, E; Heißner, K; Kasper, B; Kessler, T; Kopp, HG; Kunitz, A; Lindner, LH; Mayer-Steinacker, R; Meinert, F; Niederwieser, D; Petersen, I; Reichardt, P; Rüssel, J; Schmoll, HJ; Steighardt, J; Stein, A, 2021)
"EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS)."9.41Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC- ( Bovée, JVMG; Brahmi, M; Charon-Barra, C; Cousin, S; de Haan, J; De Meulemeester, L; Domènech, M; Dudzisz-Śledź, M; Estival, A; Gelderblom, H; Karavasilis, V; Litière, S; Marquina, G; Marreaud, S; Olungu, C; Schöffski, P; Steeghs, N; Toulmonde, M; Wozniak, A, 2021)
" This phase II trial was performed to evaluate the activity and the safety of NPLD and ifosfamide combination in patients with metastatic soft tissue sarcoma."9.20Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial. ( Basso, U; Bertuzzi, A; Colombo, P; Comandone, A; De Sanctis, R; Giordano, L; Lutman, RF; Marchetti, S; Marrari, A; Santoro, A, 2015)
" Patients aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Group performance status of 0-2, and who had previously received treatment with anthracycline and ifosfamide were randomly assigned (1:1) to intravenous infusion of ombrabulin 25 mg/m(2) plus cisplatin 75 mg/m(2) or intravenous infusion of placebo plus cisplatin 75 mg/m(2) every 3 weeks."9.20Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. ( Babovic, N; Blay, JY; Bompas, E; Chawla, SP; Cohen, P; Cupissol, D; Demetri, GD; Franke, FA; Isambert, N; Italiano, A; Le-Guennec, S; López-Pousa, A; Pápai, Z; Penel, N; Saâda-Bouzid, E; Santoro, A; Staddon, AP; Tolcher, AW, 2015)
"Doxorubicin and ifosfamide (AI) is standard therapy for high-risk soft tissue sarcoma (STS) but often causes severe toxicities resulting in hospitalisation."9.20A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L, 2015)
"This phase I trial assessed safety, pharmacokinetics (PK), dose limiting toxicity (DLT), maximum tolerated dose and recommended dose (RD) of the combination of sorafenib plus ifosfamide in patients with advanced sarcoma."9.19Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. ( Brendel, E; Broto, JM; Cubedo, R; del Muro, XG; Gallego, O; López-Pousa, A; Martín-Liberal, J; Tirado, OM, 2014)
"Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role."9.19Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. ( Alcindor, T; Blay, JY; dei Tos, AP; Fisher, C; Gelderblom, H; Hartmann, JT; Hermans, C; Hogendoorn, PC; Hohenberger, P; Judson, I; Kerst, JM; Krarup-Hansen, A; Litière, S; Marreaud, S; Schöffski, P; Sufliarsky, J; van der Graaf, WT; Verweij, J; Whelan, J, 2014)
" Perioperative chemotherapy with adriamycin plus ifosfamide is the current standard treatment for T2bN0M0 high-grade non-round cell soft tissue sarcoma."9.19A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306. ( Araki, N; Fukuda, H; Hiraga, H; Iwamoto, Y; Kataoka, K; Kawai, A; Kimura, A; Matsumine, A; Matsunobu, T; Mizusawa, J; Oda, Y; Tanaka, K, 2014)
"The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy."9.17Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. ( Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013)
"This multicenter, phase II trial evaluated the efficacy and safety of everolimus, an mTOR inhibitor, in patients with metastatic or recurrent bone and soft-tissue sarcoma after the failure of anthracycline- and ifosfamide-containing regimens."9.17Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. ( Ahn, JH; Kim, TM; Kim, YJ; Lee, HJ; Lee, J; Lee, KH; Park, KH; Rha, SY; Yoo, C, 2013)
"Doxorubicin and ifosfamide are highly active drugs for the treatment of high-grade sarcomas, but little is known on the optimal management of young patients who develop such malignancies during pregnancy."9.16Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. ( Berrada, N; Bonvalot, S; Boulet, B; Cioffi, A; Domont, J; Le Cesne, A; Lokiec, F; Mir, O; Terrier, P; Trichot, C, 2012)
"Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft-tissue sarcoma showed no benefit in relapse-free survival or overall survival."9.16Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. ( Azzarelli, A; Bonvalot, S; Bramwell, VH; Hoekstra, HJ; Hogendoorn, PC; Hohenberger, P; Le Cesne, A; Leahy, M; Marreaud, S; Ouali, M; Reichardt, P; Van Coevorden, F; Verweij, J; Woll, PJ, 2012)
"Ifosfamide and doxorubicin combination is an active regimen for patients with advanced soft tissue sarcomas (STS) but is burdened by high toxicity."9.15Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination. ( Boni, C; Boselli, S; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Frustaci, S; Noberasco, C; Radice, D; Rosati, G; Scalamogna, R; Spitaleri, G; Toffalorio, F; Tucci, A; Vecchio, F, 2011)
"This phase II clinical trial aims to evaluate the efficacies and toxicities of pre- and postoperative chemotherapy with adriamycin plus ifosfamide on the patients with soft-tissue high-grade sarcomas."9.14Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304. ( Fukuda, H; Iwamoto, Y; Kawamoto, H; Saito, I; Tanaka, K; Yoshimura, K, 2009)
"To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense doxorubicin and ifosfamide in first-line treatment of advanced soft tissue sarcoma."9.14Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. ( Andrés, R; Balañá, C; Buesa, JM; Casado, A; Cruz, J; Cubedo, R; de la Cruz, JJ; de Las Peñas, R; Del Muro, XG; Fra, J; Gallego, O; Gómez, MA; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Poveda, A; Rubió, J; Rubio-Viqueira, B; Sevilla, I, 2009)
"The aim of this study was to evaluate the maximum tolerated dose (MTD) and safety of the combination of non- pegylated liposomal doxorubicin (Myocet) and ifosfamide in patients with metastatic soft tissue sarcomas."9.14Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. ( Barbato, A; Bertuzzi, A; Di Comite, G; Lutman, RF; Mussi, C; Santoro, A; Stroppa, E, 2010)
"Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma."9.14Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010)
"The objective of this study is to assess the effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma (STS) and provide a relative ranking of regimens for STS."9.12Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis. ( Hua, Q; Xu, G; Zhang, T; Zhao, L, 2021)
"High-dose ifosfamide plus doxorubicin is an active regimen for all subtypes of gynecological sarcomas."9.12Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. ( Cerny, T; Dietrich, D; Fey, M; Honegger, HP; Jundt, G; Leyvraz, S; Lissoni, A; Sessa, C; Zweifel, M, 2006)
"To determine clinical activity and toxic effects of ifosfamide when used to treat cats with vaccine-associated sarcoma (VAS)."9.12Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas. ( Chaffin, K; Khanna, C; Kristal, O; Page, RL; Rassnick, KM; Rodriguez, CO; Rosenberg, MP, 2006)
"In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12)."9.12Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience. ( Billups, CA; Cain, AM; Furman, WL; Hale, GA; Merchant, TE; Navid, F; Pappo, AS; Rao, BN; Santana, VM; Spunt, SL, 2006)
"Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen."9.12Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ( Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E, 2007)
"This phase I study evaluated the toxicity of first-line combined pegylated liposomal doxorubicin (Caelyx) and ifosfamide in patients with advanced and/or metastatic soft tissue sarcomas."9.12Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. ( Blay, J; Christensen, TB; Daugaard, S; Hermans, C; Judson, I; Marreaud, S; Nielsen, OS; Pink, D; Reichardt, P; van Glabbeke, M, 2006)
"Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term results of a phase II trial in advanced soft-tissue sarcomas."9.12Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. ( Cerny, T; Christinat, A; Dietrich, D; Fey, MF; Guillou, L; Herrmann, R; Honegger, HP; Leyvraz, S; Pestalozzi, B; Sessa, C; Wernli, M, 2006)
"This randomized prospective multicenter phase III trial was designed to compare progression-free survival of patients with advanced soft tissue sarcoma receiving either regimen of standard doxorubicin 75 mg/m2 every 21 days, ifosfamide 9 g/m2 over 3 days continuous infusion, or ifosfamide 3 g/m2 per day in 3 hours over 3 days."9.12Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. ( Blay, JY; Hogendoorn, PC; Kirkpatrick, A; Le Cesne, A; Leahy, MG; Lorigan, P; Papai, Z; Radford, JA; Rodenhuis, S; Van Glabbeke, MM; Verweij, J, 2007)
"Combinations of high-dose ifosfamide (IF; 10-12 g/m2) plus doxorubicin (DX; 50-90 mg/m2) have been administered to patients with advanced soft tissue sarcoma (ASTS) in an attempt to improve therapeutic efficacy."9.11Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). ( Balañá, C; Buesa, JM; Casado, A; de las Peñas, R; Fra, J; García del Muro, X; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J, 2004)
"5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy."9.11Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. ( Abdel-Rahman, S; Fahn, W; Fiegl, M; Issels, RD; Schlemmer, M; Wendtner, CM, 2004)
"Children with recurrent/refractory sarcoma were treated with ifosfamide (1,800 mg/m2/day on day 0-4), carboplatin (400 mg/m2/day on day 0-1), etoposide (100 mg/m2/day on day 0-4) and either rhG-CSF (10 microg/kg/day vs."9.11Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. ( Anderson, B; Angiolillo, A; Cairo, MS; Cheung, YK; Davenport, V; Krailo, M; Reaman, G; Van Winkle, P, 2005)
"The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear."9.11Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005)
"Ifosfamide and doxorubicin are the most effective agents in the treatment of sarcomas, although their contributions to survival are usually limited."9.11High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas. ( Akbulut, H; Buyukcelik, A; Demirkazik, A; Icli, F; Pamir, A; Utkan, G; Yalcin, B, 2004)
"To describe the response rate and survival of children and adolescents with unresected or metastatic nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) treated with vincristine, ifosfamide, and doxorubicin."9.11Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. ( Devidas, M; Gebhardt, M; Grier, HE; Jenkins, J; Marcus, R; Pappo, AS; Pratt, C; Rao, B; Thomas, P, 2005)
"Doxorubicin and ifosfamide are the two most active agents used to treat soft tissue sarcomas."9.11Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas. ( Abe, S; Araki, N; Beppu, Y; Hasegawa, T; Ihara, K; Ishii, T; Isu, K; Kawai, A; Ozaki, T; Sugiura, H; Tsugane, S; Umeda, T; Wada, T; Yabe, H, 2005)
"The anthracycline/ifosfamide combination is the most effective chemotherapy in soft tissue sarcoma."9.11Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. ( Deckert, PM; Hütter, G; Keilholz, U; Schmittel, A; Siehl, JM; Szelényi, H; Thiel, E, 2005)
"This randomized study compared the efficacy of epirubicin-based adjuvant chemotherapy on the disease-free interval (DFI) and overall survival of patients with high-risk soft-tissue sarcomas."9.10Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. ( Civitelli, S; Coratti, A; Correale, P; D'Aniello, C; Francini, G; Grimaldi, L; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pirtoli, L; Tanzini, G, 2002)
"The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy."9.10Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002)
"The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone."9.10Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003)
"We conducted our study to determine the pharmacokinetics (PK) and clinical efficacy of oral mesna in patients receiving ifosfamide for soft tissue sarcoma."9.10Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. ( Baker, LH; Bernardy, H; Demetri, G; Junge, K; Keohan, ML; Mace, JR; Mueller, U; Niebch, G; Romeis, P; Thoma, A; Wagner, T, 2003)
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery."9.10Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002)
"To determine whether a prolonged 12-day continuous infusion allows the administration of high-dose ifosfamide (IFO) with an acceptable toxicity profile when combined with full-dose doxorubicin (Adriamycin; ADM) as first-line chemotherapy in patients with advanced soft tissue sarcomas."9.10Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. ( Boni, C; Catania, C; Comandone, A; Curigliano, G; de Braud, F; De Pas, T; Marrocco, E; Masci, G; Pagani, O; Tucci, A, 2002)
"This phase II study was designed to verify the activity and safety of an intensive epirubicin/ifosfamide schedule in untreated soft tissue sarcoma (STS) patients by using both the agents at the identified maximal tolerated doses."9.09Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. ( Bertero, G; Cosso, M; Neumaier, C; Palumbo, R; Pastorino, M; Raffo, P; Spadini, N; Toma, S; Valente, S; Villani, G, 1999)
"The aim of this study was to assess the pharmacology, toxicity and activity of high-dose ifosfamide mesna +/- GM-CSF administered by a five-day continuous infusion at a total ifosfamide dose of 12-18 g/m2 in adult patients with advanced sarcomas."9.09Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). ( Boddy, AV; Brunner, J; Cerny, T; Honegger, P; Küpfer, A; Leyvraz, S; Schaad, R; Schmitz, SF; Sessa, C; von Briel, T, 1999)
"In this phase II study the effect of high-dose ifosfamide (HDI) given as a 3-day continuous infusion at a dose of 12 g/m2 repeated every 4 weeks with adequate mesna protection and hydration was evaluated in patients with advanced soft tissue sarcomas."9.09Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. ( Blay, JY; Hermans, C; Judson, I; Keizer, HJ; Krzemienlecki, K; le Cesne, A; Nielsen, OS; Oosterhuis, JW; Radford, JA; Svancárová, L; van Glabbeke, M; van Hoesel, Q; van Oosterom, A; Verweij, J, 2000)
"The Soft Tissue and Bone Sarcoma Group (STBSG) of the EORTC ran a phase II study to assess the therapeutic activity of high-dose ifosfamide in patients with advanced soft tissue sarcomas by means of response rate (RR)."9.09Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group. ( Gwyther, SJ; Judson, IR; Nielsen, OS; van Glabbeke, M; Verweij, J, 2000)
"The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)."9.09A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001)
"The Epirubicin (EPI) and ifosfamide (IFO) combination has been widely tested in soft tissue sarcomas, even though the optimal schedule of drug administration has still to be defined."9.09Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules. ( Cognetti, F; Nardoni, C; Pacetti, U; Papaldo, P; Serrone, L; Zeuli, M, 2001)
"Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study."9.09Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001)
"The population pharmacokinetics and pharmacodynamics of the cytostatic agent ifosfamide and its main metabolites 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were assessed in patients with soft tissue sarcoma."9.09Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. ( Beijnen, JH; Keizer, HJ; Kerbusch, T; Mathĵt, RA; Ouwerkerk, J; Rodenhuis, S; Schellens, JH, 2001)
"The study was designed to assess the toxicity and activity of high-dose ifosfamide (HDI) administered by continuous infusion at a dose of 4 g/m2/d over 3 days every 4 weeks in adult patients with advanced soft tissue sarcomas (ASTS) pretreated with doxorubicin and/or a standard-dose ifosfamide (SDI)-containing regimen."9.08High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. ( Antoine, E; Brain, E; Fontaine, F; Genin, J; Janin, N; Kayitalire, L; Le Cesne, A; Le Chevalier, T; Spielmann, M; Toussaint, C, 1995)
"Ifosfamide, an oxazaphosphorine analogue, is now commonly used in first-line anthracycline-containing regimens for advanced soft tissue sarcomas, based on its demonstrated single-agent activity in previously treated patients."9.08High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. ( Tursz, T, 1996)
" ifosfamide (5 g/m2), carboplatin (300 mg/m2), and etoposide given with WBH, as well as, day 2 and 3 post-WBH (100 mg/m2) for adult patients with refractory sarcoma."9.08Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma. ( Crahé, R; Deeken, M; Eleftheriadis, S; Gutsche, S; Katschinski, DM; Mentzel, M; Robins, HI; Storer, B; Wagner, T; Weiss, C; Wiedemann, GJ, 1996)
"To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas."9.08High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. ( Benjamin, RS; Burgess, MA; Hays, C; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1997)
"This Phase I/II study investigates increasingly high doses of ifosfamide combined with full dose doxorubicin chemotherapy supported with peripheral blood stem cells (PBSC) and granulocyte-colony stimulating factor (G-CSF) in patients with metastatic soft tissue sarcoma (STS)."9.08A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. ( Arseniev, L; Bokemeyer, C; Franzke, A; Hartmann, JT; Kanz, L; Link, H; Metzner, B; Schmoll, HJ; Schöber, C, 1997)
"The purpose of this study was to evaluate tumour response and toxicity to ifosfamide and continuous infusion etoposide in metastatic or locally advanced soft tissue sarcoma, with dose escalations under G-CSF (granulocyte colony-stimulating factor) support."9.08Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study. ( Alvegård, TA; Erlanson, M; Hannisdal, E; Klepp, R; Monge, OR; Raabe, N; Saeter, G; Söderberg, M; Solheim, OP; Strander, H; Turesson, I; Wist, E, 1997)
"Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent."9.08Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. ( Antimi, M; Gatti, C; Palmeri, S; Palumbo, R; Raffo, P; Toma, S; Villani, G, 1997)
"The authors evaluate the efficacy and feasibility of dose-intensive doxorubicin and ifosfamide combination chemotherapy in patients with sarcomas."9.08Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. ( Benjamin, RS; Burgess, MA; Jenkins, J; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1998)
"The agent Ifosfamide (IFOS) is active against soft tissue sarcomas (STS), and patients who progress to IFOS at doses < or = 10 g/m2 show remissions when exposed to high-dose ifosfamide (HDI) (i."9.08Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) ( Antón, A; Arranz, F; Bellmunt, J; Buesa, JM; Casado, A; Escudero, P; García del Muro, J; López-Pousa, A; Martín, J; Menéndez, D; Poveda, A; Valentí, V, 1998)
"Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship."9.08Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998)
"Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship."9.08High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998)
"Ifosfamide is an active chemotherapeutic agent in the treatment of soft tissue sarcoma."9.07Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. ( Baker, LH; Blair, SC; Zalupski, MM, 1994)
"The purpose of this review is to characterize the nephrotoxicity noted in newly diagnosed patients under 21 years of age after treatment with ifosfamide-containing chemotherapy regimens and local irradiation for localized gross residual rhabdomyosarcoma or undifferentiated sarcoma."9.07Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. ( Ensign, LG; Foreman, J; Khan, F; Maurer, H; Newton, W; Ortega, J; Ragab, A; Raney, B; Wharam, M; Wiener, E, 1994)
"5 g/m2 mesna was administered for 7 days, both by continuous infusion, in combination with 50 mg/m2/d oral etoposide for 8 days in 21 patients with sarcomas or other solid tumors."9.07Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. ( Hamdan, H; Skubitz, KM; Thompson, RC, 1993)
"To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients."9.07Epirubicin and ifosfamide in advanced soft tissue sarcomas. ( Buonadonna, A; Carbone, A; Crivellari, D; De Paoli, A; Foladore, S; Frustaci, S; Monfardini, S; Morassut, S; Sorio, R, 1993)
"This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin."9.07Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. ( Blum, RH; Brooks, JS; Edmonson, JH; Frytak, S; Parkinson, DR; Ryan, LM; Shiraki, M, 1993)
"Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas."9.07An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. ( Antman, K; Balcerzak, SP; Barlogie, B; Cooper, RM; Crowley, J; Elias, A; Natale, RB; Rivkin, SE; Trump, DL; Weiss, GR, 1993)
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft-tissue sarcoma."9.07Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Steward, W; Thomas, D; van Oosterom, AT; Verweij, J, 1993)
"A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna."9.07Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. ( Azzarelli, A; Casali, P; Fissi, S; Montalto, F; Quagliuolo, V; Santoro, A, 1993)
"The Southwest Oncology Group (SWOG) performed a phase II trial of a combination of ifosfamide/mesna/cisplatin in patients with metastatic soft-tissue sarcoma who had previously received one chemotherapeutic regimen."9.07Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study. ( Balcerzak, SP; Budd, GT; Fabian, C; Metch, B; Stephens, RL; Weick, JK; Weiss, SA, 1993)
"On the basis of ifosfamide's demonstrated single-agent activity in adult soft-tissue sarcoma, the Eastern Cooperative Oncology Group (ECOG) tested whether ifosfamide would add to the efficacy of doxorubicin in a three-regimen, controlled phase III trial."9.07Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. ( Blum, RH; Edmonson, J; Pelletier, L; Ryan, L, 1993)
"A total of 37 adult patients with locally advanced or metastatic soft-tissue sarcoma (STS) entered a pilot study of combination chemotherapy based on the CYVADIC (cyclophosphamide, vincristine, doxorubicin, and dacarbazine) regimen, in which cyclophosphamide was replaced by ifosfamide and mesna (1 g/m2 ifosfamide given daily on days 1-5 as 2-h infusions, 1."9.07Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma. ( Blomqvist, CP; Elomaa, I; Virolainen, M; Wiklund, TA, 1992)
"Doxorubicin and ifosfamide are the two most active agents used in the treatment of advanced inoperable soft-tissue sarcoma, but their use in combination produces dose-limiting myelosuppression."9.07Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. ( Blackledge, G; Clavel, M; Greifenberg, B; Soedirman, J; Somers, R; Steward, WP; Thomas, D; Van Glabbeke, M; Van Oosterom, AT; Verweij, J, 1991)
"European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas."9.06Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989)
"In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID)."9.06Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. ( Aisner, J; Antman, KH; Collins, J; Elias, A; Ryan, L; Sulkes, A, 1989)
"Between April 1986 and March 1987, 42 patients with advanced sarcoma were entered in this multi-institutional trial evaluating ifosfamide plus doxorubicin."9.06Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. ( Braun, TJ; Hainsworth, JD; Loehrer, PJ; Martelo, OJ; Nicaise, C; Omura, G; Sledge, GW; Usakewicz, J, 1989)
"The regimen of doxorubicin (DOX), ifosfamide (IFF), and dacarbazine (DTIC) (AID) for previously untreated inoperable or metastatic sarcoma has acceptable toxicity with significant activity."9.06Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study. ( Antman, KH; Elias, AD, 1986)
"One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i."9.06Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986)
"Ifosfamide and Mesna are currently given to patients for 14 days continuous home-based infusion for the treatment of soft tissue sarcoma."8.93Evaluation of the stability profile of anticancer drugs: A review of Ifosfamide and Mesna regimen for the treatment of metastatic soft tissue sarcoma. ( Barton, S; Nabhani-Gebara, S; Peron, JM; Salman, D; Swinden, J, 2016)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."8.91Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2015)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."8.88Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2012)
"Independent favourable prognostic factors for overall survival (OS) were good performance status, female gender, low histological grade, extremity primary tumour site and locally advanced disease; for progression-free survival (PFS), the combination of doxorubicin and ifosfamide, locally advanced disease, and tumour entity with a lower risk to progress for synovial sarcoma patients compared to leiomyosarcoma."8.86Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr ( Blay, JY; Hogendoorn, PC; Krarup-Hansen, A; Le Cesne, A; Ouali, M; Rodenhuis, S; Sleijfer, S; van Glabbeke, M; Verweij, J, 2010)
"Ifosfamide is a chemotherapeutic prodrug used in the treatment of several tumor entities, including bone and soft-tissue sarcoma."8.86Palifosfamide, a bifunctional alkylator for the treatment of sarcomas. ( Jung, S; Kasper, B, 2010)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."8.86Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2010)
"This meta-analysis examines the role of ifosfamide-based combination chemotherapy in patients with advanced soft tissue sarcoma."8.84Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. ( Blackstein, M; Haynes, AE; Stys-Norman, D; Verma, S; Younus, J, 2008)
"Ifosfamide and anthracyclines are the only active agents in advanced soft tissue sarcomas."8.82Ifosfamide in the adjuvant therapy of soft tissue sarcomas. ( Berretta, M; Bidoli, E; Boz, G; Buonadonna, A; De Paoli, A; Frustaci, S; Gherlinzoni, F; La Mura, N, 2003)
"The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas."8.81Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001)
"Ifosfamide is one of the three most active agents in the treatment of soft tissue sarcomas."8.79Ifosfamide in the treatment of soft tissue sarcomas. ( Budd, GT; Connelly, EF, 1996)
"Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease."8.79High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. ( Demetri, GD, 1996)
"We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985."8.78Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. ( Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993)
"Doxorubicin and ifosfamide are currently the two main drugs for the treatment of soft tissue sarcomas in adults."8.78Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. ( Azzarelli, A; Bertulli, R; Casali, P; Devizzi, L; Pastorino, U; Santoro, A; Zucchinelli, P, 1993)
"Ifosfamide is an analogue of cyclophosphamide that has been extensively investigated in sarcomas."8.78The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. ( Dirix, LY; Van Oosterom, AT, 1990)
"The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas."8.77The role of ifosfamide in the treatment of sarcomas. ( Dirix, LY; Van Oosterom, AT, 1989)
"We conducted a multi-institutional retrospective study, identifying sarcoma patients who received anthracyclines and/or ifosfamide during pregnancy."8.12Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. ( Agulnik, M; Davis, LE; Godbole, S; Hirbe, AC; Livingston, JA; Miller, D; Park, Y; Parkes, A; Posey, K; Robinson, SI; Skubitz, K; Van Tine, BA, 2022)
"To investigate the value of contrast-enhanced computed tomography (CECT) radiomics features in predicting the efficacy of epirubicin combined with ifosfamide in patients with pulmonary metastases from soft tissue sarcoma."8.12Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features. ( Jiang, X; Li, M; Ma, ST; Miao, L; Wang, YM; Zhang, HH, 2022)
"To compare long-term outcomes of high-grade, primary soft-tissue-sarcoma (STS), using Ifosfamide-Doxorubicin vs local therapy alone, in histology-specific sarcomas."8.02The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience. ( Burchette, RJ; Goy, BW; Helmstedter, CS; Padmanabhan, A; Syed, S, 2021)
"For Ewing sarcoma, interval-compressed vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide administered every 2 weeks rather than every 3 weeks has been shown to improve event-free survival in pediatric patients."7.96Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide. ( Bassale, S; Davis, LE; Lim, JY; Lu, E; Ryan, CW, 2020)
"We compared the outcomes in soft tissue sarcoma (STS) treated with olaratumab and doxorubicin (OD) versus doxorubicin, ifosfamide, and mesna (AIM) to assess whether OD could supersede AIM in STS therapy."7.96Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas. ( Copeland, VC; Cranmer, LD; Hammer, KJ; Loggers, ET; Pollack, SM; Wagner, MJ, 2020)
"The objective of this study was to analyze outcomes for patients with soft tissue sarcoma of the extremities using neoadjuvant ifosfamide-based chemotherapy and hypofractionated reduced dose radiotherapy, followed by limb-sparing surgery."7.88Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. ( Bernthal, NM; Bukata, SV; Chmielowski, B; Dry, SM; Eckardt, JJ; Eilber, FC; Eilber, FR; Federman, N; Kalbasi, A; Kamrava, M; Luu, M; Nelson, SD; Pennington, JD; Reed, JP; Selch, MT; Singh, AS; Steinberg, ML; Wang, PC, 2018)
"A retrospective search of the Royal Marsden Sarcoma Unit Database was performed to identify patients initially treated with ifosfamide (as single agent or in combination) and who were subsequently rechallenged with single-agent ifosfamide."7.88Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. ( Benson, C; Constantinidou, A; Jones, RL; Judson, I; Messiou, C; Miah, A; Noujaim, J; Thway, K, 2018)
"Anthracycline and ifosfamide-based chemotherapy represents a widely used regimen both in early and advanced settings in soft tissue sarcoma (STS)."7.85Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). ( Amadori, D; Bongiovanni, A; De Vita, A; Di Iorio, V; Foca, F; Ibrahim, T; Liverani, C; Mercatali, L; Miserocchi, G; Monti, M; Recine, F; Riva, N, 2017)
"We retrospectively reviewed outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma (STS)."7.85VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. ( Baek, SW; Choi, YS; Jo, DY; Kim, S; Lee, HJ; Moon, JY; Ryu, H; Song, IC; Yun, HJ, 2017)
"Ifosfamide is an alkylating agent, frequently used in the treatment of sarcoma."7.77Ifosfamide nephropathy in patients with sarcoma. ( Keikhaei, M; Mashhadi, MA; Sanadgol, H, 2011)
"We retrospectively examined the incidence, severity, and risk factors of ifosfamide encephalopathy in 61 Japanese patients with bone and soft tissue sarcomas at our institution."7.76Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. ( Kikuchi, S; Konno, S; Tajino, T; Takeda, A; Yamada, H, 2010)
"To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management."7.76Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010)
"Ifosfamide is currently used to treat pediatric sarcomas and increasing its dosage may be associated with a better response rate."7.76Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma. ( Casanova, M; Cefalo, G; Favini, F; Ferrari, A; Luksch, R; Massimino, M; Meazza, C; Podda, M, 2010)
"To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas."7.73Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. ( Piura, B; Rabinovich, A, 2005)
"To assess the impact of different factors on response rate (RR), time to tumor progression (TTP), and overall survival time (OS) in patients with locally advanced or metastatic soft tissue sarcoma (ASTS), included in three protocols with high-dose ifosfamide (HDIF)."7.72Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS). ( Balañá, C; Buesa, J; Casado, A; de Las Peñas, R; del Muro, XG; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Quintana, MJ, 2004)
"Adriamycin, dacarbazine and ifosfamide are three effective chemotherapy drugs in treating progressive soft tissue sarcoma."7.71[Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma]. ( Chen, LK; Liang, Y; Liu, JL; Teng, XY; Xu, GC; Zhou, XM, 2002)
"Ifosfamide is a leading drug in soft tissue sarcoma therapy."7.70Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998)
"Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas."7.70Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy. ( Altundağ, K; Baltali, E; Barişta, I; Celik, I; Firat, D; Güler, N; Güllü, I; Kars, A; Ozişik, Y; Tekuzman, G; Türker, A; Uner, A; Yalçin, S; Zengin, N, 2000)
"Between 1992 and 1999, 13 consecutive patients with completely resected moderate- to high-grade uterine sarcoma received three cycles of adjuvant ifosfamide (1."7.70Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000)
"A total of 33 patients (median age, 44 years) with high-grade, adult soft-tissue sarcoma were treated with etoposide given at 600 mg/m2 in a 72-h continuous infusion and ifosfamide given at 1500 mg/m2 per day for 3 days every 3 weeks."7.69Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. ( Saeter, G; Solheim, OP; Talle, K, 1995)
"Four patients with metastatic ovarian mixed Müllerian sarcoma (2 homologous, 2 heterologous) were treated with mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy."7.69Mesna, doxorubicin, ifosfamide, and dacarbazine chemotherapy for ovarian mixed müllerian sarcoma: report of four cases. ( Greenberg, S; Patsner, B, 1995)
"Twenty patients with advanced sarcomas entered a pilot study with ifosfamide (IF) and mercaptoethane sulfonate sodium (Mesna) as a second-line treatment for six planned cycles."7.69High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas. ( Alkiş, N; Baltali, E; Barişta, I; Celik, I; Güler, N; Güllü, I; Kars, A; Tekuzman, G; Yalçin, S; Zengin, N, 1996)
"From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)."7.69[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997)
"A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects."7.68[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993)
"Between 1982 and 1986, 38 patients with soft-tissue sarcomas were treated with the combination doxorubicin/dacarbazine (group A); between 1986 and 1990, another 46 patients received doxorubicin/ifosfamide (group B); and between 1990 and 1991, 11 patients received an alternating regimen of doxorubicin and ifosfamide (group C)."7.68Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide. ( Agarwal, K; Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Zornig, C, 1993)
"Two trials using ifosfamide-based combination chemotherapy for advanced soft-tissue sarcoma have been completed."7.68Ifosfamide combination regimens for soft-tissue sarcoma. ( Bell, DR; Dalley, D; Levi, J; Simes, RJ; Stuart-Harris, R; Wiltshaw, E, 1993)
"The response of ifosfamide-based chemotherapeutic regimens was retrospectively analyzed in adult patients with advanced soft-tissue sarcoma who were treated at the West German Tumor Center, Essen, between 1978 and 1990."7.68Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. ( Kellner, R; Schütte, J; Seeber, S, 1993)
"Currently, anthracyclines and ifosfamide are the most effective drugs for the treatment of disseminated soft-tissue sarcoma."7.68A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. ( Anagnou, J; Bokemeyer, C; Harstrick, A; Knipp, H; Köhne-Wömpner, CH; Neumann, S; Poliwoda, H; Schmoll, HJ; Schöffski, P; Wipperman, B, 1993)
"A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)."7.68Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993)
"Twenty-eight patients with non-pretreated metastatic soft tissue sarcomas were entered on a treatment protocol of rapidly alternating epirubicin/dacarbazine and ifosfamide: Epirubicin 100 mg/m2 d1, dacarbazine 500 mg/m2 d1 + d2, ifosfamide 6000 mg/m2 24-h infusion d15; repeated d29."7.68Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. ( Bokemeyer, C; Harstrick, A; Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöffski, P, 1992)
"From July 1986 to 1990, 65 patients with deep-seated, advanced sarcomas (43 soft-tissue sarcomas, 12 Ewing's sarcomas, 7 chondrosarcomas and 3 osteosarcomas) were entered in a protocol involving regional hyperthermia (RHT) combined with systemic ifosfamide and etoposide."7.68Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients. ( Denzlinger, C; Gerl, A; Issels, RD; Mittermüller, J; Ortmaier, A; Sauer, H; Simon, W; Wilmanns, W, 1991)
"The mesna, doxorubicin, ifosfamide, dacarbazine regimen produced a 47% response rate (including 10% complete responses) in 105 eligible adults with advanced sarcoma."7.68Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. ( Aisner, J; Antman, KH; Elias, A; Ryan, L, 1990)
"From July 1986 to July 1989, 40 patients (92% pretreated) with deep-seated, advanced soft tissue sarcomas (STS, 25 patients), Ewing's sarcomas (ES, eight patients), osteosarcomas (OS, three patients) and chondrosarcomas (ChS, four patients) were treated at the University of Munich in a protocol involving regional hyperthermia (RHT) combined with ifosfamide plus etoposide."7.68Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. ( Berger, H; Boehm, E; Denecke, H; Issels, RD; Jauch, KW; Nagele, A; Peter, K; Prenninger, SW; Sauer, H; Wilmanns, W, 1990)
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma."7.68Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990)
"The combination of ifosfamide (IFO) and epirubicin (EPI) has been found to be an effective regimen in the treatment of metastatic tumours and shows remarkable activity in heavily pretreated breast cancer patients."7.68Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. ( Hoffmann, W; Könner, J; Migeod, F; Seeber, S; Weidmann, B, 1990)
"Forty-three adult patients with locally advanced or metastatic soft tissue sarcoma entered a pilot study of combination chemotherapy comprising 50 mg of doxorubicin/m2 by intravenous bolus, 850 mg of dacarbazine/m2 by 1-hour infusion, and 5 g of ifosfamide/m2 by 24-hour infusion with mesna uroprotection."7.67Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group. ( Bramwell, V; Eisenhauer, E; Knowling, M; Quirt, I; Verma, S; Warr, D; Young, V, 1989)
"Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients."7.67Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986)
"One hundred twenty-four children and young adults with recurrent tumors, predominantly sarcomas, were treated with the combination of ifosfamide, etoposide, and the uroprotector, mesna (2-mercaptoethane sulphonate), in a phase II trial."7.67Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. ( Forquer, R; Jarosinski, P; Kinsella, TJ; Magrath, I; Miser, JS; Triche, TJ; Tsokos, M; Wesley, R, 1987)
"Fifty-four patients with advanced soft tissue sarcoma were treated with a combination of ifosfamide (5 g/m2) and adriamycin (40-60 mg/m2) at 3 weekly intervals."7.67A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. ( Fisher, C; King, M; MacMillan, S; Mansi, JL; Stuart-Harris, R; Wiltshaw, E, 1988)
"We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors."7.67A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986)
" Hemorrhagic cystitis was not observed in patients treated with 400-500 mg of mesna iv every 4 hours during ifosfamide treatment."7.67Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. ( Antman, KH; Montella, D; Rosenbaum, C; Schwen, M, 1985)
"In a phase II study, 42 patients with advanced soft-tissue sarcoma were treated with ifosfamide by 24-h infusion and mesna by 4-h IV bolus, repeated every 3 weeks."7.66High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. ( Gowing, NF; Harper, PG; Kaye, SB; Mooney, CA; Parsons, CA; Stuart-Harris, RC; Wiltshaw, E, 1983)
"The efficacy of ifosfamide combination chemotherapy was studied in 164 patients, 94 with advanced testicular carcinoma and 70 with metastatic sarcoma."7.66Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. ( Cremer, M; Niederle, N; Scheulen, ME; Schmidt, CG; Schütte, J; Seeber, S, 1983)
"Patients with Stage III non-round cell soft tissue sarcomas in the extremities were eligible."6.80Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). ( Araki, N; Chuman, H; Fukuda, H; Hatano, H; Hiruma, T; Iwamoto, Y; Mizusawa, J; Morioka, H; Ozaki, T; Takahashi, M; Tanaka, K; Tsuchiya, H, 2015)
"Ifosfamide is a chemotherapeutic agent that requires cytochrome P450 3A (CYP3A) for bioactivation and metabolism."6.73Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. ( Baker, LH; Chugh, R; Griffith, KA; Leu, KM; Taylor, JM; Thomas, DG; Wagner, T; Worden, FP; Zalupski, MM, 2007)
" Samples for pharmacokinetic analysis were obtained after the MTD was reached."6.72Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas. ( Beaulieu, BB; Kristal, O; Lewis, LD; Moore, AS; Northrup, NC; Page, RL; Rassnick, KM, 2006)
"Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy."6.72Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. ( Abdel-Rahman, S; Baumert, J; Falk, M; Hentrich, M; Hiddemann, W; Issels, RD; Licht, T; Salat, C; Schlemmer, M; Straka, C; Wendtner, CM, 2006)
"Etoposide monotherapy was successful in 8%; the effectiveness of cisplatin was 5-23%."6.69The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. ( Bodoky, G; Eckhardt, S; Láng, I; Pápai, Z; Poller, I; Rahóty, P; Szántó, J; Szendroi, M, 2000)
"Gemcitabine was administered as a 360 min infusion on days 1, 8 and 15 of a 28 day cycle."6.69Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. ( Dietzmann, A; Genvresse, I; Grunewald, R; Koschuth, A; Possinger, K; Späth-Schwalbe, E, 2000)
"Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation."6.69Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. ( Bejkos, D; Bischof-Delaloye, A; Chassot, PG; Chiolero, R; Genton, A; Guillou, L; Landry, M; Lejeune, FJ; Leyvraz, PF; Leyvraz, S; Liénard, D; Mirimanoff, RO; Mosimann, F; Pujol, N; Raffoul, W, 2000)
"In advanced soft tissue sarcomas of adults, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared."6.68Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. ( Buesa, J; Casali, P; Mouridsen, H; Rankin, E; Santoro, A; Somers, R; Spooner, D; Steward, W; Tursz, T; Verweij, J, 1995)
" No clinical evidence of renal failure was attributed to the high dosage of the drug in the course of assays of biochemical components of the blood, blood- and urine-beta-2-microglobulins, N-acetyl-D-hexoaminidase (NAG) level in urine, creatinine clearance and complex renoscintigraphy data."6.68[High-dose ifosfamide in the treatment of patients with soft tissue sarcoma]. ( Averinova, SG; Garin, AM; Kashkadaeva, AV; Liubimova, NV; Romanova, LF; Shiriaev, SV; Sidorova, NI; Tiuliandin, SA, 1996)
"Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1."6.67Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Bramwell, VH; Dombernowsky, P; Mouridsen, HT; Onsrud, M; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Verweij, J, 1993)
"Ifosfamide dosage was not increased."6.67Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study. ( Chevallier, B; Facchini, T; Fargeot, P; Leyvraz, S; Olivier, JP; Vo Van, ML, 1993)
"For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival."6.42Ifosfamide with regional hyperthermia in soft-tissue sarcomas. ( Issels, RD; Schlemmer, M; Wendtner, CM, 2003)
"The results of the association of doxorubicin plus ifosfamide in the treatment of locally advanced and/or metastatic adult soft tissue sarcomas as reported in the literature from 1986 up to the present time are reviewed."6.17Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas. ( Palumbo, R; Santi, L; Sogno, G; Toma, S; Venturino, A, 1992)
"Thoracic sarcomas are rare malignancies, with limited data for unresectable/advanced scenarios."5.91Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas. ( Alatorre-Alexander, JA; Carrasco-CaraChards, S; Cruz-Zermeño, M; de Jesús Rodríguez-Zea, I; Godina-Flores, A; Green-Renner, D; Guzmán-Casta, J; Guzmán-Huesca, J; Imaz-Olguin, V; Juarez-Vignon Whaley, JJ; Martínez-Barrera, LM; Riera-Sala, R; Rodriguez-Cid, JR; Sánchez-Domínguez, G; Sánchez-Ríos, CP; Santillán-Doherty, PJ; Seidman-Sorsby, A; Sosa-Sánchez, R, 2023)
"This randomised phase II/III trial aimed to determine whether perioperative chemotherapy with gemcitabine plus docetaxel (GD) is non-inferior to the standard Adriamycin plus ifosfamide (AI) in terms of overall survival (OS) in patients with soft tissue sarcoma (STS)."5.51Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306. ( Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T, 2022)
"This prospective single-arm phase II clinical trial aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS)."5.51Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. ( Chen, H; Chen, Y; Huang, M; Jiang, S; Liu, X; Luo, Z; Miao, J; Wang, C; Wang, H; Wang, J; Wu, X; Xia, J; Xu, Y; Yan, W; Yao, W; Yu, L; Zhang, X, 2022)
"Olaratumab (OLA), a monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), has recently been used against soft-tissue sarcoma (STS) combined with doxorubicin (DOX), with limited efficacy."5.51Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model. ( Bouvet, M; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Razmjooei, S; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N; Zhang, Z, 2019)
"Pazopanib and gemcitabine have shown good tolerability, albeit modest single-agent activity in pretreated soft tissue sarcoma."5.41Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. ( Crysandt, M; Cygon, F; Egerer, G; Eigendorff, E; Heißner, K; Kasper, B; Kessler, T; Kopp, HG; Kunitz, A; Lindner, LH; Mayer-Steinacker, R; Meinert, F; Niederwieser, D; Petersen, I; Reichardt, P; Rüssel, J; Schmoll, HJ; Steighardt, J; Stein, A, 2021)
"EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS)."5.41Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC- ( Bovée, JVMG; Brahmi, M; Charon-Barra, C; Cousin, S; de Haan, J; De Meulemeester, L; Domènech, M; Dudzisz-Śledź, M; Estival, A; Gelderblom, H; Karavasilis, V; Litière, S; Marquina, G; Marreaud, S; Olungu, C; Schöffski, P; Steeghs, N; Toulmonde, M; Wozniak, A, 2021)
"As adjuvant chemotherapy (AC) for soft tissue sarcomas is controversial, we performed a retrospective analysis of patients seen at Washington University in St."5.40Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy. ( Adkins, DR; Luo, J; Montgomery, L; Morgensztern, D; Schenone, AD; Van Tine, BA, 2014)
"Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity."5.37High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011)
"Breast stromal sarcoma is very rare, accounting for less than 1% of mammary neoplasms, and the treatment strategy is not well established, especially regarding chemotherapy."5.37Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case. ( Inoue, K; Iwase, H; Kuriwaki, K; Sueta, A; Yamamoto, Y, 2011)
"This study was aimed at determining whether patients with high-risk soft tissue sarcoma (STS), as identified using the nomogram Sarculator, benefitted from adjuvant chemotherapy in the EORTC-STBSG 62931 randomised controlled trial (RCT), which failed to detect an impact for adjuvant doxorubicin plus ifosfamide (Adj) over observation (Obs)."5.30The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. ( Casali, PG; Dei Tos, AP; Gelderblom, H; Gronchi, A; Judson, I; Kasper, B; Litiere, S; Marreaud, S; Pasquali, S; Pizzamiglio, S; Stacchiotti, S; Touati, N; Verderio, P; Woll, PJ, 2019)
" So we compared VAC protocol and ifosfamiide for toxic effects."5.30Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide). ( Erman, O; Simşek, T; Trak, B; Uner, M; Zorlu, GC, 1998)
"Ifosfamide was escalated from 5 to 10 g/m2 with a fixed carboplatin dose of 480 mg/m2."5.29Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. ( Bucsky, P; d'Oleire, F; Eleftheriadis, S; Feddersen, S; Geisler, J; Klouche, M; Knop, E; Mentzel, M; Schmucker, P; Wiedemann, GJ, 1994)
"From November 1990 to September 1991, 23 adults with high-risk, nonmetastatic sarcomas (20 soft-tissue sarcomas and 3 chondrosarcomas) were entered in a pilot protocol (RHT-91) involving regional hyperthermia combined with systemic chemotherapy followed by surgery."5.29Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study. ( Abdel-Rahman, S; Berger, H; Bosse, D; Issels, RD; Jauch, KW; Panzer, M; Peter, K; Sauer, H; Starck, M; Stiegler, H, 1993)
"The model systems were human breast carcinoma (MX1/3) and human sarcoma (S117) grown in nude mice."5.28Local hyperthermia enhances cyclophosphamide, ifosfamide and cis-diamminedichloroplatinum cytotoxicity on human-derived breast carcinoma and sarcoma xenografts in nude mice. ( Biersack, A; Roszinski, S; Wagner, T; Weiss, C; Wiedemann, G, 1992)
"Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990."5.28Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. ( Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M, 1990)
"The European Organization for Research and Treatment of Cancer (EORTC) 62012 study was a Phase III trial of doxorubicin versus doxorubicin-ifosfamide chemotherapy in 455 patients with advanced soft tissue sarcoma (STS)."5.24Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. ( Collin, F; Daugaard, S; Fisher, C; Gronchi, A; Grünwald, V; Hogendoorn, PCW; Judson, I; Lia, M; Litière, S; Mechtersheimer, G; Messiou, C; Sciot, R; van der Graaf, W; Wardelmann, E; Young, RJ, 2017)
"Patients with high-grade soft tissue sarcomas were treated with 2 cycles of ifosfamide, mitomycin, doxorubicin, and cisplatin plus GM-CSF subcutaneous followed by 45 Gy irradiation with concurrent 2 cycles of mitomycin, doxorubicin, and cisplatin followed by surgery +/- intraoperative radiation or brachytherapy."5.22Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively. ( Haddock, M; Mahoney, M; Maples, W; Markovic, SN; O'Connor, MI; Okuno, S; Petersen, I; Shives, T; Sim, F, 2016)
" This phase II trial was performed to evaluate the activity and the safety of NPLD and ifosfamide combination in patients with metastatic soft tissue sarcoma."5.20Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial. ( Basso, U; Bertuzzi, A; Colombo, P; Comandone, A; De Sanctis, R; Giordano, L; Lutman, RF; Marchetti, S; Marrari, A; Santoro, A, 2015)
" Patients aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Group performance status of 0-2, and who had previously received treatment with anthracycline and ifosfamide were randomly assigned (1:1) to intravenous infusion of ombrabulin 25 mg/m(2) plus cisplatin 75 mg/m(2) or intravenous infusion of placebo plus cisplatin 75 mg/m(2) every 3 weeks."5.20Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. ( Babovic, N; Blay, JY; Bompas, E; Chawla, SP; Cohen, P; Cupissol, D; Demetri, GD; Franke, FA; Isambert, N; Italiano, A; Le-Guennec, S; López-Pousa, A; Pápai, Z; Penel, N; Saâda-Bouzid, E; Santoro, A; Staddon, AP; Tolcher, AW, 2015)
"Doxorubicin and ifosfamide (AI) is standard therapy for high-risk soft tissue sarcoma (STS) but often causes severe toxicities resulting in hospitalisation."5.20A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L, 2015)
"This phase I trial assessed safety, pharmacokinetics (PK), dose limiting toxicity (DLT), maximum tolerated dose and recommended dose (RD) of the combination of sorafenib plus ifosfamide in patients with advanced sarcoma."5.19Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. ( Brendel, E; Broto, JM; Cubedo, R; del Muro, XG; Gallego, O; López-Pousa, A; Martín-Liberal, J; Tirado, OM, 2014)
"To study feasibility, safety and activity of the combination of high-dose long-infusion ifosfamide (HLI) and radiotherapy (RT) as preoperative treatment for resectable localised retroperitoneal sarcoma (RPS)."5.19Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. ( Bertola, G; Bruzzi, P; Buonadonna, A; Casali, PG; Dani, C; De Paoli, A; De Sanctis, R; Dei Tos, AP; Fiore, M; Giorello, L; Grignani, G; Gronchi, A; Merlo, DF; Navarria, P; Quagliuolo, V; Sanfilippo, R; Sangalli, C; Stacchiotti, S, 2014)
"Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role."5.19Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. ( Alcindor, T; Blay, JY; dei Tos, AP; Fisher, C; Gelderblom, H; Hartmann, JT; Hermans, C; Hogendoorn, PC; Hohenberger, P; Judson, I; Kerst, JM; Krarup-Hansen, A; Litière, S; Marreaud, S; Schöffski, P; Sufliarsky, J; van der Graaf, WT; Verweij, J; Whelan, J, 2014)
" Perioperative chemotherapy with adriamycin plus ifosfamide is the current standard treatment for T2bN0M0 high-grade non-round cell soft tissue sarcoma."5.19A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306. ( Araki, N; Fukuda, H; Hiraga, H; Iwamoto, Y; Kataoka, K; Kawai, A; Kimura, A; Matsumine, A; Matsunobu, T; Mizusawa, J; Oda, Y; Tanaka, K, 2014)
"The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy."5.17Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. ( Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013)
"This multicenter, phase II trial evaluated the efficacy and safety of everolimus, an mTOR inhibitor, in patients with metastatic or recurrent bone and soft-tissue sarcoma after the failure of anthracycline- and ifosfamide-containing regimens."5.17Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. ( Ahn, JH; Kim, TM; Kim, YJ; Lee, HJ; Lee, J; Lee, KH; Park, KH; Rha, SY; Yoo, C, 2013)
"Doxorubicin and ifosfamide are highly active drugs for the treatment of high-grade sarcomas, but little is known on the optimal management of young patients who develop such malignancies during pregnancy."5.16Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. ( Berrada, N; Bonvalot, S; Boulet, B; Cioffi, A; Domont, J; Le Cesne, A; Lokiec, F; Mir, O; Terrier, P; Trichot, C, 2012)
"From July 1995 to June 2003, 457 previously untreated patients with incompletely resected embryonal rhabdomyosarcoma (RMS), undifferentiated sarcoma, and soft tissue primitive neuroectodermal tumor at all sites except paratesticular, vagina, and uterus, or with alveolar RMS were randomly assigned to receive either ifosfamide, vincristine, and dactinomycin (IVA) or a six-drug combination (IVA plus carboplatin, epirubicin, and etoposide) both delivered over 27 weeks."5.16Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatr ( Bergeron, C; Bouvet, N; Ellershaw, C; Jenney, ME; Kelsey, A; Martelli, H; Merks, JH; Oberlin, O; Rey, A; Sanchez de Toledo, J; Scopinaro, M; Spooner, D; Stevens, MC, 2012)
"Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft-tissue sarcoma showed no benefit in relapse-free survival or overall survival."5.16Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. ( Azzarelli, A; Bonvalot, S; Bramwell, VH; Hoekstra, HJ; Hogendoorn, PC; Hohenberger, P; Le Cesne, A; Leahy, M; Marreaud, S; Ouali, M; Reichardt, P; Van Coevorden, F; Verweij, J; Woll, PJ, 2012)
"Ifosfamide and doxorubicin combination is an active regimen for patients with advanced soft tissue sarcomas (STS) but is burdened by high toxicity."5.15Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination. ( Boni, C; Boselli, S; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Frustaci, S; Noberasco, C; Radice, D; Rosati, G; Scalamogna, R; Spitaleri, G; Toffalorio, F; Tucci, A; Vecchio, F, 2011)
"This phase II clinical trial aims to evaluate the efficacies and toxicities of pre- and postoperative chemotherapy with adriamycin plus ifosfamide on the patients with soft-tissue high-grade sarcomas."5.14Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304. ( Fukuda, H; Iwamoto, Y; Kawamoto, H; Saito, I; Tanaka, K; Yoshimura, K, 2009)
"To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense doxorubicin and ifosfamide in first-line treatment of advanced soft tissue sarcoma."5.14Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. ( Andrés, R; Balañá, C; Buesa, JM; Casado, A; Cruz, J; Cubedo, R; de la Cruz, JJ; de Las Peñas, R; Del Muro, XG; Fra, J; Gallego, O; Gómez, MA; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Poveda, A; Rubió, J; Rubio-Viqueira, B; Sevilla, I, 2009)
"The aim of this study was to evaluate the maximum tolerated dose (MTD) and safety of the combination of non- pegylated liposomal doxorubicin (Myocet) and ifosfamide in patients with metastatic soft tissue sarcomas."5.14Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. ( Barbato, A; Bertuzzi, A; Di Comite, G; Lutman, RF; Mussi, C; Santoro, A; Stroppa, E, 2010)
"Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma."5.14Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010)
"Dynamic PET studies with (18)F-FDG were performed in patients with metastatic soft tissue sarcomas who received conventional chemotherapy with doxorubicin hydrochloride (Adriamycin) and ifosfamide (AI-G)."5.14Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. ( Dimitrakopoulou-Strauss, A; Egerer, G; Haberkorn, U; Kasper, B; Schmitt, T; Strauss, LG; Vasamiliette, J, 2010)
"The evaluation included 31 patients with nonmetastatic soft-tissue sarcomas, who were treated with neoadjuvant chemotherapy consisting of etoposide, ifosfamide, and doxorubicin."5.14Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. ( Dimitrakopoulou-Strauss, A; Egerer, G; Haberkorn, U; Kasper, B; Lehner, B; Mechtersheimer, G; Schmitt, T; Strauss, LG; Stroebel, P; Vasamiliette, J, 2010)
"The authors studied a dose-intense regimen of epirubicin and ifosfamide with hypofractionated preoperative radiotherapy for high-risk soft tissue sarcomas."5.13Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. ( Hayden, JB; Hosenpud, JR; Hung, AY; Mansoor, A; Montag, AG; Mundt, AJ; Peabody, TD; Ryan, CW; Samuels, B; Undevia, S, 2008)
"The objective of this study is to assess the effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma (STS) and provide a relative ranking of regimens for STS."5.12Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis. ( Hua, Q; Xu, G; Zhang, T; Zhao, L, 2021)
"Perioperative three cycles of full-dose of anthracycline and ifosfamide should be proposed on an individual basis, in reference sarcoma centres, to high-risk localized STS of limbs or trunk-wall in certain histologies."5.12What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma? ( Hindi, N; Martin-Broto, J, 2021)
"High-dose ifosfamide plus doxorubicin is an active regimen for all subtypes of gynecological sarcomas."5.12Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. ( Cerny, T; Dietrich, D; Fey, M; Honegger, HP; Jundt, G; Leyvraz, S; Lissoni, A; Sessa, C; Zweifel, M, 2006)
"To determine clinical activity and toxic effects of ifosfamide when used to treat cats with vaccine-associated sarcoma (VAS)."5.12Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas. ( Chaffin, K; Khanna, C; Kristal, O; Page, RL; Rassnick, KM; Rodriguez, CO; Rosenberg, MP, 2006)
"In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12)."5.12Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience. ( Billups, CA; Cain, AM; Furman, WL; Hale, GA; Merchant, TE; Navid, F; Pappo, AS; Rao, BN; Santana, VM; Spunt, SL, 2006)
"Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen."5.12Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ( Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E, 2007)
"This phase I study evaluated the toxicity of first-line combined pegylated liposomal doxorubicin (Caelyx) and ifosfamide in patients with advanced and/or metastatic soft tissue sarcomas."5.12Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. ( Blay, J; Christensen, TB; Daugaard, S; Hermans, C; Judson, I; Marreaud, S; Nielsen, OS; Pink, D; Reichardt, P; van Glabbeke, M, 2006)
"Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term results of a phase II trial in advanced soft-tissue sarcomas."5.12Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. ( Cerny, T; Christinat, A; Dietrich, D; Fey, MF; Guillou, L; Herrmann, R; Honegger, HP; Leyvraz, S; Pestalozzi, B; Sessa, C; Wernli, M, 2006)
"This randomized prospective multicenter phase III trial was designed to compare progression-free survival of patients with advanced soft tissue sarcoma receiving either regimen of standard doxorubicin 75 mg/m2 every 21 days, ifosfamide 9 g/m2 over 3 days continuous infusion, or ifosfamide 3 g/m2 per day in 3 hours over 3 days."5.12Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. ( Blay, JY; Hogendoorn, PC; Kirkpatrick, A; Le Cesne, A; Leahy, MG; Lorigan, P; Papai, Z; Radford, JA; Rodenhuis, S; Van Glabbeke, MM; Verweij, J, 2007)
" The patients were treated between 1/1/1998 and 6/30/1999 according to the sarcoma protocols COSS-96, CWS-96, and EICESS-92, the median cumulative doses of the focussed drugs were for cisplatin: 360 mg/m(2), for doxorubicin: 270 mg/m(2), and for ifosfamide: 24 g/m(2)."5.11Late effects surveillance system for sarcoma patients. ( Beck, JD; Bielack, S; Langer, T; Paulussen, M; Stöhr, W; Treuner, J, 2004)
"Combinations of high-dose ifosfamide (IF; 10-12 g/m2) plus doxorubicin (DX; 50-90 mg/m2) have been administered to patients with advanced soft tissue sarcoma (ASTS) in an attempt to improve therapeutic efficacy."5.11Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). ( Balañá, C; Buesa, JM; Casado, A; de las Peñas, R; Fra, J; García del Muro, X; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J, 2004)
"5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy."5.11Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. ( Abdel-Rahman, S; Fahn, W; Fiegl, M; Issels, RD; Schlemmer, M; Wendtner, CM, 2004)
"Children with recurrent/refractory sarcoma were treated with ifosfamide (1,800 mg/m2/day on day 0-4), carboplatin (400 mg/m2/day on day 0-1), etoposide (100 mg/m2/day on day 0-4) and either rhG-CSF (10 microg/kg/day vs."5.11Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. ( Anderson, B; Angiolillo, A; Cairo, MS; Cheung, YK; Davenport, V; Krailo, M; Reaman, G; Van Winkle, P, 2005)
"The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear."5.11Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005)
"Ifosfamide and doxorubicin are the most effective agents in the treatment of sarcomas, although their contributions to survival are usually limited."5.11High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas. ( Akbulut, H; Buyukcelik, A; Demirkazik, A; Icli, F; Pamir, A; Utkan, G; Yalcin, B, 2004)
"To describe the response rate and survival of children and adolescents with unresected or metastatic nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) treated with vincristine, ifosfamide, and doxorubicin."5.11Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. ( Devidas, M; Gebhardt, M; Grier, HE; Jenkins, J; Marcus, R; Pappo, AS; Pratt, C; Rao, B; Thomas, P, 2005)
"Doxorubicin and ifosfamide are the two most active agents used to treat soft tissue sarcomas."5.11Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas. ( Abe, S; Araki, N; Beppu, Y; Hasegawa, T; Ihara, K; Ishii, T; Isu, K; Kawai, A; Ozaki, T; Sugiura, H; Tsugane, S; Umeda, T; Wada, T; Yabe, H, 2005)
"The anthracycline/ifosfamide combination is the most effective chemotherapy in soft tissue sarcoma."5.11Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. ( Deckert, PM; Hütter, G; Keilholz, U; Schmittel, A; Siehl, JM; Szelényi, H; Thiel, E, 2005)
"This randomized study compared the efficacy of epirubicin-based adjuvant chemotherapy on the disease-free interval (DFI) and overall survival of patients with high-risk soft-tissue sarcomas."5.10Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. ( Civitelli, S; Coratti, A; Correale, P; D'Aniello, C; Francini, G; Grimaldi, L; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pirtoli, L; Tanzini, G, 2002)
"The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy."5.10Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002)
"The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone."5.10Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003)
"Cohorts of six patients with sarcoma (66 assessable patients) were treated sequentially with doxorubicin and ifosfamide (AI), with rhTPO by a fixed dose and varying schedules being administered before and/or after chemotherapy in cycle 2 and subsequent cycles."5.10Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. ( Benjamin, RS; Broemeling, LD; Broxmeyer, HE; Bueso-Ramos, C; Burgess, A; Folloder, J; Papadopolous, N; Patel, S; Vadhan-Raj, S, 2003)
"We conducted our study to determine the pharmacokinetics (PK) and clinical efficacy of oral mesna in patients receiving ifosfamide for soft tissue sarcoma."5.10Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. ( Baker, LH; Bernardy, H; Demetri, G; Junge, K; Keohan, ML; Mace, JR; Mueller, U; Niebch, G; Romeis, P; Thoma, A; Wagner, T, 2003)
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery."5.10Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002)
"To determine whether a prolonged 12-day continuous infusion allows the administration of high-dose ifosfamide (IFO) with an acceptable toxicity profile when combined with full-dose doxorubicin (Adriamycin; ADM) as first-line chemotherapy in patients with advanced soft tissue sarcomas."5.10Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. ( Boni, C; Catania, C; Comandone, A; Curigliano, G; de Braud, F; De Pas, T; Marrocco, E; Masci, G; Pagani, O; Tucci, A, 2002)
"This phase II study was designed to verify the activity and safety of an intensive epirubicin/ifosfamide schedule in untreated soft tissue sarcoma (STS) patients by using both the agents at the identified maximal tolerated doses."5.09Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. ( Bertero, G; Cosso, M; Neumaier, C; Palumbo, R; Pastorino, M; Raffo, P; Spadini, N; Toma, S; Valente, S; Villani, G, 1999)
"This study was conducted to determine the maximum tolerated dose of an intensified MAID (mesna, adriamycin, ifosfamide, dacarbazine) regimen with the support of lenograstim in patients with advanced soft tissue sarcomas."5.09Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS). ( Bui, BN; Chevallier, B; Chevreau, C; Coindre, JM; Cour-Chabernaud, V; Gil, B; Krakowski, I; Maugard, C; Mihura, J, 1999)
"The aim of this study was to assess the pharmacology, toxicity and activity of high-dose ifosfamide mesna +/- GM-CSF administered by a five-day continuous infusion at a total ifosfamide dose of 12-18 g/m2 in adult patients with advanced sarcomas."5.09Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). ( Boddy, AV; Brunner, J; Cerny, T; Honegger, P; Küpfer, A; Leyvraz, S; Schaad, R; Schmitz, SF; Sessa, C; von Briel, T, 1999)
"Twenty-four children and adolescents with metastatic sarcomas received VACIME chemotherapy, consisting of eight courses of vincristine 2 mg/m(2) on day 0; doxorubicin 20 mg/m(2)/day on days 0-3; cyclophosphamide 360 mg/m(2)/day on days 0-4; ifosfamide 1,800 mg/m(2)/day on days 0-4; mesna 2,400 mg/m(2)/day; and etoposide 100 mg/m(2)/day on days 0-4."5.09Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas. ( Conrad, EU; Felgenhauer, J; Hawkins, D; Lindsley, K; Miser, JS; Pendergrass, T, 2000)
"In this phase II study the effect of high-dose ifosfamide (HDI) given as a 3-day continuous infusion at a dose of 12 g/m2 repeated every 4 weeks with adequate mesna protection and hydration was evaluated in patients with advanced soft tissue sarcomas."5.09Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. ( Blay, JY; Hermans, C; Judson, I; Keizer, HJ; Krzemienlecki, K; le Cesne, A; Nielsen, OS; Oosterhuis, JW; Radford, JA; Svancárová, L; van Glabbeke, M; van Hoesel, Q; van Oosterom, A; Verweij, J, 2000)
"Twenty-four patients with soft tissue or bone sarcoma who were treated with high dose ifosfamide-based chemotherapy were enrolled in this study."5.09Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma. ( Akbulut, H; Demirkazik, A; Dinçol, D; Içli, F; Onur, H; Pamir, A; Samur, M; Sencan, O; Senler, FC; Yalçin, B, 2000)
"This study investigated the population pharmacokinetics of ifosfamide in 15 patients treated for soft tissue sarcoma with 9 or 12 g m-2 ifosfamide by means of a 72 h continuous i."5.09Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. ( Beijnen, JH; Huitema, AD; Keizer, HJ; Kerbusch, T; Mathôt, RA; Ouwerkerk, J; Schellens, JH, 2000)
"The Soft Tissue and Bone Sarcoma Group (STBSG) of the EORTC ran a phase II study to assess the therapeutic activity of high-dose ifosfamide in patients with advanced soft tissue sarcomas by means of response rate (RR)."5.09Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group. ( Gwyther, SJ; Judson, IR; Nielsen, OS; van Glabbeke, M; Verweij, J, 2000)
"The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)."5.09A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001)
"The aim of this study was to examine the strategy, feasibility and outcome of neo-adjuvant chemotherapy, with doxorubicin and ifosfamide, in adult patients with 'high-risk' soft-tissue sarcomas."5.09A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. ( Azzarelli, A; Bramwell, VH; Buesa, J; Ezzat, A; Gortzak, E; Kirkpatrick, A; Oosterhuis, JW; Santoro, A; van Coevorden, F; van Geel, AN; van Glabbeke, M; Verweij, J, 2001)
"The Epirubicin (EPI) and ifosfamide (IFO) combination has been widely tested in soft tissue sarcomas, even though the optimal schedule of drug administration has still to be defined."5.09Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules. ( Cognetti, F; Nardoni, C; Pacetti, U; Papaldo, P; Serrone, L; Zeuli, M, 2001)
"Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study."5.09Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001)
"The population pharmacokinetics and pharmacodynamics of the cytostatic agent ifosfamide and its main metabolites 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were assessed in patients with soft tissue sarcoma."5.09Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. ( Beijnen, JH; Keizer, HJ; Kerbusch, T; Mathĵt, RA; Ouwerkerk, J; Rodenhuis, S; Schellens, JH, 2001)
"The study was designed to assess the toxicity and activity of high-dose ifosfamide (HDI) administered by continuous infusion at a dose of 4 g/m2/d over 3 days every 4 weeks in adult patients with advanced soft tissue sarcomas (ASTS) pretreated with doxorubicin and/or a standard-dose ifosfamide (SDI)-containing regimen."5.08High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. ( Antoine, E; Brain, E; Fontaine, F; Genin, J; Janin, N; Kayitalire, L; Le Cesne, A; Le Chevalier, T; Spielmann, M; Toussaint, C, 1995)
"The Intergroup Rhabdomyosarcoma Study (IRS) initiated an escalating-dose cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine (Vcr) and actinomycin-D (Amd), known as VAC, to establish a Cyc dose with myelotoxicity comparable to an ifosfamide (Ifos), Vcr, and Amd combination regimen (VAI)."5.08Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response. ( Gehan, E; Maurer, H; Newton, WA; Ruymann, FB; Vietti, T; Wharam, M; Wiener, E, 1995)
"This two-arm, double-blind, randomized trial was conducted to determine the effects of lenograstim, a glycosylated recombinant human granulocyte colony-stimulating factor (rHu-G-CSF), on the hematologic tolerance of patients with sarcoma treated with mesna, doxorubicin, ifosfamide, and doxorubicin (MAID) chemotherapy."5.08Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. ( Bonichon, F; Bui, BN; Chevallier, B; Chevreau, C; Cupissol, D; Fargeot, P; Krakowski, I; Maugard-Louboutin, C; Peny, AM; Thyss, A, 1995)
"Ifosfamide, an oxazaphosphorine analogue, is now commonly used in first-line anthracycline-containing regimens for advanced soft tissue sarcomas, based on its demonstrated single-agent activity in previously treated patients."5.08High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. ( Tursz, T, 1996)
"Since dose intensity of doxorubicin is correlated with the clinical response of patients with soft tissue sarcomas and since doxorubicin dose intensity may be compromised in combination chemotherapy, we evaluated the use of recombinant granulocytemacrophage colony-stimulating factor (rGM-CSF) to ameliorate myelosuppression and allow doxorubicin dose escalation in a phase I trial utilizing the MAID combination [Mesna 2."5.08GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial. A Southwest Oncology Group study. ( Balcerzak, SP; Hicks, LG; Zalupski, M, 1996)
"Ten patients (three males and seven females) were treated for sarcoma with high-dose ifosfamide (IFO) according to a 4 g/m2 1 h i."5.08Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. ( Lokiec, F; Santoni, J; Tubiana-Hulin, M; Weill, S, 1996)
" ifosfamide (5 g/m2), carboplatin (300 mg/m2), and etoposide given with WBH, as well as, day 2 and 3 post-WBH (100 mg/m2) for adult patients with refractory sarcoma."5.08Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma. ( Crahé, R; Deeken, M; Eleftheriadis, S; Gutsche, S; Katschinski, DM; Mentzel, M; Robins, HI; Storer, B; Wagner, T; Weiss, C; Wiedemann, GJ, 1996)
"Ifosfamide is one of the most efficient antimitotic in soft tissue sarcoma."5.08[High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients]. ( Baranzelli, MC; Deligny, N; Demaille, MC; Gourmel, B; N'Guyen, M; Pichon, F, 1997)
"To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas."5.08High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. ( Benjamin, RS; Burgess, MA; Hays, C; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1997)
"A phase I study was designed for the amalgamation of two previously studied antisarcoma regimens (ifosfamide+doxorubicin and mitomycin+doxorubicin+cisplatin) supported by molgramostim."5.08Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas? ( Edmonson, JH; Grill, JP; Kvols, LK; Long, HJ; Mann, BS, 1997)
"This Phase I/II study investigates increasingly high doses of ifosfamide combined with full dose doxorubicin chemotherapy supported with peripheral blood stem cells (PBSC) and granulocyte-colony stimulating factor (G-CSF) in patients with metastatic soft tissue sarcoma (STS)."5.08A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. ( Arseniev, L; Bokemeyer, C; Franzke, A; Hartmann, JT; Kanz, L; Link, H; Metzner, B; Schmoll, HJ; Schöber, C, 1997)
"The purpose of this study was to evaluate tumour response and toxicity to ifosfamide and continuous infusion etoposide in metastatic or locally advanced soft tissue sarcoma, with dose escalations under G-CSF (granulocyte colony-stimulating factor) support."5.08Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study. ( Alvegård, TA; Erlanson, M; Hannisdal, E; Klepp, R; Monge, OR; Raabe, N; Saeter, G; Söderberg, M; Solheim, OP; Strander, H; Turesson, I; Wist, E, 1997)
"Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent."5.08Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. ( Antimi, M; Gatti, C; Palmeri, S; Palumbo, R; Raffo, P; Toma, S; Villani, G, 1997)
"The authors evaluate the efficacy and feasibility of dose-intensive doxorubicin and ifosfamide combination chemotherapy in patients with sarcomas."5.08Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. ( Benjamin, RS; Burgess, MA; Jenkins, J; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1998)
"The agent Ifosfamide (IFOS) is active against soft tissue sarcomas (STS), and patients who progress to IFOS at doses < or = 10 g/m2 show remissions when exposed to high-dose ifosfamide (HDI) (i."5.08Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) ( Antón, A; Arranz, F; Bellmunt, J; Buesa, JM; Casado, A; Escudero, P; García del Muro, J; López-Pousa, A; Martín, J; Menéndez, D; Poveda, A; Valentí, V, 1998)
"Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship."5.08Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998)
"Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship."5.08High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998)
"Ifosfamide is an active chemotherapeutic agent in the treatment of soft tissue sarcoma."5.07Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. ( Baker, LH; Blair, SC; Zalupski, MM, 1994)
"The purpose of this review is to characterize the nephrotoxicity noted in newly diagnosed patients under 21 years of age after treatment with ifosfamide-containing chemotherapy regimens and local irradiation for localized gross residual rhabdomyosarcoma or undifferentiated sarcoma."5.07Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. ( Ensign, LG; Foreman, J; Khan, F; Maurer, H; Newton, W; Ortega, J; Ragab, A; Raney, B; Wharam, M; Wiener, E, 1994)
"5 g/m2 mesna was administered for 7 days, both by continuous infusion, in combination with 50 mg/m2/d oral etoposide for 8 days in 21 patients with sarcomas or other solid tumors."5.07Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. ( Hamdan, H; Skubitz, KM; Thompson, RC, 1993)
"To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients."5.07Epirubicin and ifosfamide in advanced soft tissue sarcomas. ( Buonadonna, A; Carbone, A; Crivellari, D; De Paoli, A; Foladore, S; Frustaci, S; Monfardini, S; Morassut, S; Sorio, R, 1993)
"This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin."5.07Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. ( Blum, RH; Brooks, JS; Edmonson, JH; Frytak, S; Parkinson, DR; Ryan, LM; Shiraki, M, 1993)
"Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas."5.07An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. ( Antman, K; Balcerzak, SP; Barlogie, B; Cooper, RM; Crowley, J; Elias, A; Natale, RB; Rivkin, SE; Trump, DL; Weiss, GR, 1993)
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft-tissue sarcoma."5.07Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Steward, W; Thomas, D; van Oosterom, AT; Verweij, J, 1993)
"A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna."5.07Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. ( Azzarelli, A; Casali, P; Fissi, S; Montalto, F; Quagliuolo, V; Santoro, A, 1993)
"The Southwest Oncology Group (SWOG) performed a phase II trial of a combination of ifosfamide/mesna/cisplatin in patients with metastatic soft-tissue sarcoma who had previously received one chemotherapeutic regimen."5.07Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study. ( Balcerzak, SP; Budd, GT; Fabian, C; Metch, B; Stephens, RL; Weick, JK; Weiss, SA, 1993)
"On the basis of ifosfamide's demonstrated single-agent activity in adult soft-tissue sarcoma, the Eastern Cooperative Oncology Group (ECOG) tested whether ifosfamide would add to the efficacy of doxorubicin in a three-regimen, controlled phase III trial."5.07Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. ( Blum, RH; Edmonson, J; Pelletier, L; Ryan, L, 1993)
"A total of 37 adult patients with locally advanced or metastatic soft-tissue sarcoma (STS) entered a pilot study of combination chemotherapy based on the CYVADIC (cyclophosphamide, vincristine, doxorubicin, and dacarbazine) regimen, in which cyclophosphamide was replaced by ifosfamide and mesna (1 g/m2 ifosfamide given daily on days 1-5 as 2-h infusions, 1."5.07Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma. ( Blomqvist, CP; Elomaa, I; Virolainen, M; Wiklund, TA, 1992)
"Doxorubicin and ifosfamide are the two most active agents used in the treatment of advanced inoperable soft-tissue sarcoma, but their use in combination produces dose-limiting myelosuppression."5.07Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. ( Blackledge, G; Clavel, M; Greifenberg, B; Soedirman, J; Somers, R; Steward, WP; Thomas, D; Van Glabbeke, M; Van Oosterom, AT; Verweij, J, 1991)
"In a phase II trial of ifosfamide 2 g/m2 days 1 to 4 with mesna uroprotection in 124 patients who had previously failed treatment for sarcomas, 3% achieved a complete response (CR), and 18% had a CR or partial response (PR)."5.06Dana-Farber Cancer Institute studies in advanced sarcoma. ( Antman, KH; Elias, A, 1990)
"European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas."5.06Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989)
"In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID)."5.06Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. ( Aisner, J; Antman, KH; Collins, J; Elias, A; Ryan, L; Sulkes, A, 1989)
"Between April 1986 and March 1987, 42 patients with advanced sarcoma were entered in this multi-institutional trial evaluating ifosfamide plus doxorubicin."5.06Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. ( Braun, TJ; Hainsworth, JD; Loehrer, PJ; Martelo, OJ; Nicaise, C; Omura, G; Sledge, GW; Usakewicz, J, 1989)
"The regimen of doxorubicin (DOX), ifosfamide (IFF), and dacarbazine (DTIC) (AID) for previously untreated inoperable or metastatic sarcoma has acceptable toxicity with significant activity."5.06Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study. ( Antman, KH; Elias, AD, 1986)
"One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i."5.06Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986)
"43 patients with metastasizing sarcomas were treated with a combination of either vincristin, adriamycin and cis-platinum (n = 21) or ifosfamide and cis-platinum at three weeks' intervals in each case."5.05[Chemotherapy in advanced sarcomas (author's transl)]. ( Bierbaum, W; Bremer, K; Firusian, N; Higi, M; Niederle, N; Scheulen, ME; Schmidt, CG; Seeber, S, 1981)
"A marginal interaction between sex and the type of alkylating agent was observed for event-free survival in the Euro-EWING99-R1 randomized controlled trial (RCT) comparing cyclophosphamide and ifosfamide in Ewing sarcoma."4.95Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study). ( Anderson, JR; Boddy, AV; De Vathaire, F; Dirksen, U; Fresneau, B; Gaspar, N; Gelderblom, H; Hackshaw, A; Hawkins, DS; Judson, I; Le Deley, MC; Le Teuff, G; Lewis, I; Litière, S; Paulussen, M; Pignon, JP; van den Berg, H; Wheatley, K; Whelan, J, 2017)
"Ifosfamide and Mesna are currently given to patients for 14 days continuous home-based infusion for the treatment of soft tissue sarcoma."4.93Evaluation of the stability profile of anticancer drugs: A review of Ifosfamide and Mesna regimen for the treatment of metastatic soft tissue sarcoma. ( Barton, S; Nabhani-Gebara, S; Peron, JM; Salman, D; Swinden, J, 2016)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."4.91Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2015)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."4.88Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2012)
"Independent favourable prognostic factors for overall survival (OS) were good performance status, female gender, low histological grade, extremity primary tumour site and locally advanced disease; for progression-free survival (PFS), the combination of doxorubicin and ifosfamide, locally advanced disease, and tumour entity with a lower risk to progress for synovial sarcoma patients compared to leiomyosarcoma."4.86Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr ( Blay, JY; Hogendoorn, PC; Krarup-Hansen, A; Le Cesne, A; Ouali, M; Rodenhuis, S; Sleijfer, S; van Glabbeke, M; Verweij, J, 2010)
"Ifosfamide is a chemotherapeutic prodrug used in the treatment of several tumor entities, including bone and soft-tissue sarcoma."4.86Palifosfamide, a bifunctional alkylator for the treatment of sarcomas. ( Jung, S; Kasper, B, 2010)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."4.86Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2010)
" Therefore, gemcitabine should be considered as the best option after doxorubicin failure in leiomyosarcoma patients."4.86[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines]. ( Bui-Nguyen, B; Italiano, A; Toulmonde, M, 2010)
"We describe a case of SP that occurred during chemotherapy with ifosfamide and doxorubicin in a patient with an advanced pleomorphic sarcoma."4.86Spontaneous pneumothorax during chemotherapy: a case report. ( Cathomas, R; Fehr, M; Furrer, M; von Moos, R, 2010)
"In summary, female sex, low total bilirubin, albumin and haemoglobin levels, and obesity appear to be associated with ifosfamide-induced encephalopathy."4.84Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature. ( Beri, R; Shord, SS; Sweiss, KI, 2008)
"This meta-analysis examines the role of ifosfamide-based combination chemotherapy in patients with advanced soft tissue sarcoma."4.84Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. ( Blackstein, M; Haynes, AE; Stys-Norman, D; Verma, S; Younus, J, 2008)
"Doxorubicin-based chemotherapy does not appear to offer a survival benefit to patients who have high-risk primary extremity soft tissue sarcomas, whereas ifosfamide-based chemotherapy does."4.83Advances in chemotherapy for patients with extremity soft tissue sarcoma. ( Eckardt, JJ; Eilber, FC; Eilber, FR; Nelson, SD; Tap, WD, 2006)
"Ifosfamide and anthracyclines are the only active agents in advanced soft tissue sarcomas."4.82Ifosfamide in the adjuvant therapy of soft tissue sarcomas. ( Berretta, M; Bidoli, E; Boz, G; Buonadonna, A; De Paoli, A; Frustaci, S; Gherlinzoni, F; La Mura, N, 2003)
"Few cytotoxic agents are active for the treatment of soft tissue sarcomas of adults: drugs active in monotherapy are doxorubicin, ifosfamide, dacarbazine and ET743."4.81[High-dose chemotherapy in soft tissue sarcomas of adults]. ( Biron, P; Blay, JY; Ray-Coquard, I, 2001)
"The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas."4.81Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001)
"Ifosfamide is one of the three most active agents in the treatment of soft tissue sarcomas."4.79Ifosfamide in the treatment of soft tissue sarcomas. ( Budd, GT; Connelly, EF, 1996)
"Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease."4.79High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. ( Demetri, GD, 1996)
"This article gives highlights of ongoing pediatric solid tumor and leukemia trials in the United States that use ifosfamide in combination with mesna."4.79Ongoing clinical studies of ifosfamide for pediatric cancer in the United States. ( Pratt, CB, 1996)
"We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985."4.78Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. ( Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993)
"Doxorubicin and ifosfamide are currently the two main drugs for the treatment of soft tissue sarcomas in adults."4.78Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. ( Azzarelli, A; Bertulli, R; Casali, P; Devizzi, L; Pastorino, U; Santoro, A; Zucchinelli, P, 1993)
" The most active single agents against osteosarcoma are doxorubicin (overall response rate, 21%), methotrexate (30% to 40%), cisplatin (25%), and ifosfamide (28%)."4.78Chemotherapy of advanced sarcomas of bone and soft tissue. ( Antman, KH, 1992)
"Ifosfamide is an analogue of cyclophosphamide that has been extensively investigated in sarcomas."4.78The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. ( Dirix, LY; Van Oosterom, AT, 1990)
"The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas."4.77The role of ifosfamide in the treatment of sarcomas. ( Dirix, LY; Van Oosterom, AT, 1989)
"The most active single agents in soft-tissue sarcomas are doxorubicin (Adriamycin) and ifosfamide, with response rates of 20-35%."4.77Chemotherapy of advanced soft-tissue sarcomas. ( Antman, KH; Elias, AD, 1988)
"The alkylating agent ifosfamide, an analog of cyclophosphamide, has demonstrated significant activity in soft tissue sarcoma and testicular carcinoma."4.77Ifosfamide. ( Baker, LH; Zalupski, M, 1988)
"We conducted a multi-institutional retrospective study, identifying sarcoma patients who received anthracyclines and/or ifosfamide during pregnancy."4.12Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. ( Agulnik, M; Davis, LE; Godbole, S; Hirbe, AC; Livingston, JA; Miller, D; Park, Y; Parkes, A; Posey, K; Robinson, SI; Skubitz, K; Van Tine, BA, 2022)
"To investigate the value of contrast-enhanced computed tomography (CECT) radiomics features in predicting the efficacy of epirubicin combined with ifosfamide in patients with pulmonary metastases from soft tissue sarcoma."4.12Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features. ( Jiang, X; Li, M; Ma, ST; Miao, L; Wang, YM; Zhang, HH, 2022)
"To compare long-term outcomes of high-grade, primary soft-tissue-sarcoma (STS), using Ifosfamide-Doxorubicin vs local therapy alone, in histology-specific sarcomas."4.02The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience. ( Burchette, RJ; Goy, BW; Helmstedter, CS; Padmanabhan, A; Syed, S, 2021)
"For Ewing sarcoma, interval-compressed vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide administered every 2 weeks rather than every 3 weeks has been shown to improve event-free survival in pediatric patients."3.96Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide. ( Bassale, S; Davis, LE; Lim, JY; Lu, E; Ryan, CW, 2020)
"We compared the outcomes in soft tissue sarcoma (STS) treated with olaratumab and doxorubicin (OD) versus doxorubicin, ifosfamide, and mesna (AIM) to assess whether OD could supersede AIM in STS therapy."3.96Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas. ( Copeland, VC; Cranmer, LD; Hammer, KJ; Loggers, ET; Pollack, SM; Wagner, MJ, 2020)
"The objective of this study was to analyze outcomes for patients with soft tissue sarcoma of the extremities using neoadjuvant ifosfamide-based chemotherapy and hypofractionated reduced dose radiotherapy, followed by limb-sparing surgery."3.88Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. ( Bernthal, NM; Bukata, SV; Chmielowski, B; Dry, SM; Eckardt, JJ; Eilber, FC; Eilber, FR; Federman, N; Kalbasi, A; Kamrava, M; Luu, M; Nelson, SD; Pennington, JD; Reed, JP; Selch, MT; Singh, AS; Steinberg, ML; Wang, PC, 2018)
"A retrospective search of the Royal Marsden Sarcoma Unit Database was performed to identify patients initially treated with ifosfamide (as single agent or in combination) and who were subsequently rechallenged with single-agent ifosfamide."3.88Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. ( Benson, C; Constantinidou, A; Jones, RL; Judson, I; Messiou, C; Miah, A; Noujaim, J; Thway, K, 2018)
"This study was designed to assess patterns of recurrence and long-term outcomes of patients undergoing surgery for localized retroperitoneal sarcoma (RPS) after neoadjuvant high dose long-infusion ifosfamide (HLI) and radiotherapy (RT)."3.85Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303. ( Basso, S; Bertola, G; Bertuzzi, A; Buonadonna, A; Casali, PG; Colombo, C; De Paoli, A; De Sanctis, R; Fiore, M; Giordano, L; Gronchi, A; Marrari, A; Navarria, F; Navarria, P; Quagliuolo, V; Sanfilippo, R; Sangalli, C; Santoro, A, 2017)
"Anthracycline and ifosfamide-based chemotherapy represents a widely used regimen both in early and advanced settings in soft tissue sarcoma (STS)."3.85Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). ( Amadori, D; Bongiovanni, A; De Vita, A; Di Iorio, V; Foca, F; Ibrahim, T; Liverani, C; Mercatali, L; Miserocchi, G; Monti, M; Recine, F; Riva, N, 2017)
"We retrospectively reviewed outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma (STS)."3.85VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. ( Baek, SW; Choi, YS; Jo, DY; Kim, S; Lee, HJ; Moon, JY; Ryu, H; Song, IC; Yun, HJ, 2017)
" Finally, the approach is demonstrated in a phase II trial studying two dose levels of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor in soft tissue sarcoma patients over four cycles."3.83Multivariate Markov models for the conditional probability of toxicity in phase II trials. ( Fernandes, LL; Murray, S; Taylor, JM, 2016)
"5%) nonmetastatic soft tissue sarcoma received neoadjuvant chemoradiotherapy with ifosfamide (1."3.83Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience. ( Agaimy, A; Croner, R; Fietkau, R; Hohenberger, W; Lettmaier, S; Ott, O; Semrau, S; Stubbe, F; Vassos, N, 2016)
"A retrospective study of sarcoma and lymphoma patients receiving ifosfamide chemotherapy was performed at the participating institutions."3.81An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. ( Butrynski, J; Cirrone, F; Feng, Y; Fisher, DC; Harris, C; McDonnell, AM; Neuberg, D; Szabatura, AH; Voit, D, 2015)
"A 67-year-old male patient developed progressive renal failure following successful treatment of a soft tissue sarcoma that comprised surgical resection after neoadjuvant radiochemotherapy with the application of doxorubicin (cumulative dose 180 mg/m²) and ifosfamide (cumulative dose 33 g/m²)."3.80[End-stage renal disease after sarcoma therapy - case 3/2014]. ( Amann, K; Artunc, F; Bakos, G; Baumann, D; Bunz, H; Ciarimboli, G; Kluba, T; Kopp, HG; Müller, M; Schlatter, E; Steinke, I; Weyrich, P, 2014)
"For high-risk soft tissue sarcoma (HR-STS) of adults new treatment strategies are needed to improve outcome with regard to local control and overall survival."3.80Current trials and new aspects in soft tissue sarcoma of adults. ( Issels, RD; Schlemmer, M, 2002)
"Our data suggest that multimodal treatment with ifosfamide and/or locoregional hyperthermia in combination with neoadjuvant radiotherapy might improve outcome in high-risk soft tissue sarcomas."3.79Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas. ( Bamberg, M; Eckert, F; Gani, C; Kluba, T; Kopp, HG; Mayer, F; Müller, AC; Zips, D, 2013)
"Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9."3.79Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma. ( Badalamenti, G; Bronte, G; Fulfaro, F; Incorvaia, L; Leto, G; Maltese, G; Provenzano, S, 2013)
"Ifosfamide is an alkylating agent, frequently used in the treatment of sarcoma."3.77Ifosfamide nephropathy in patients with sarcoma. ( Keikhaei, M; Mashhadi, MA; Sanadgol, H, 2011)
"We retrospectively examined the incidence, severity, and risk factors of ifosfamide encephalopathy in 61 Japanese patients with bone and soft tissue sarcomas at our institution."3.76Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. ( Kikuchi, S; Konno, S; Tajino, T; Takeda, A; Yamada, H, 2010)
"We evaluated the feasibility and toxicity of bevacizumab in combination with sequential high-dose (HD) ifosfamide, carboplatin and etoposide refractory to standard chemotherapy in patients with sarcoma and germ cell cancer (GCC)."3.76Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study. ( Arnold, D; Behlendorf, T; Jordan, K; Kegel, T; Mueller, LP; Schmoll, HJ; Sippel, C; Voigt, W; Wolf, HH, 2010)
"To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management."3.76Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010)
"Ifosfamide is currently used to treat pediatric sarcomas and increasing its dosage may be associated with a better response rate."3.76Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma. ( Casanova, M; Cefalo, G; Favini, F; Ferrari, A; Luksch, R; Massimino, M; Meazza, C; Podda, M, 2010)
" Doxorubicin should be administered preferably as 3-weekly bolus injections at doses higher than 60 mg/m2 because of its dose-response relationship."3.76The treatment of soft tissue sarcomas with focus on chemotherapy: a review. ( Pinedo, HM; Verweij, J, 1986)
"A retrospective study of inpatients with sarcoma who received a two or four-day regimen of MAI (mesna, doxorubicin, and ifosfamide) between January 1, 2004 and December 31, 2006 was conducted."3.74Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. ( Hatfield Seung, A; Howell, JE; Nesbit, SA; Szabatura, AH, 2008)
"Our data suggest a potential role for anthracycline- and ifosfamide-containing chemotherapy in the adjuvant setting for early-stage uterine sarcomas."3.74Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience. ( Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Markaki, S; Papadimitriou, CA; Rodolakis, A; Voulgaris, Z; Zorzou, MP, 2007)
"Patients treated on sarcoma protocols containing ifosfamide as the only potential gonadotoxic agent, were evaluated, assessing pubertal development, menstrual history in the females and semen analysis in males."3.74Does ifosfamide affect gonadal function? ( Crofton, PM; Levitt, G; Williams, D, 2008)
"To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas."3.73Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. ( Piura, B; Rabinovich, A, 2005)
"Medical records of adults and children diagnosed with sarcoma whom received ifosfamide with a cumulative dose >20 g/m(2) were evaluated."3.72Influence of age upon Ifosfamide-induced nephrotoxicity. ( Blough, D; Friedman, DL; Hawkins, DS; Magbulos, M; McCune, JS; Schuetze, S, 2004)
"To assess the impact of different factors on response rate (RR), time to tumor progression (TTP), and overall survival time (OS) in patients with locally advanced or metastatic soft tissue sarcoma (ASTS), included in three protocols with high-dose ifosfamide (HDIF)."3.72Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS). ( Balañá, C; Buesa, J; Casado, A; de Las Peñas, R; del Muro, XG; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Quintana, MJ, 2004)
"Twenty-three children and adolescents with metastatic sarcomas received vincristine, doxorubicin, cyclophosphamide, ifosfamide, sodium mercaptoethanesulfonate (mensa), and etoposide (VACIME) chemotherapy, consisting of 8 courses of vincristine 2 mg/m(2) on Day 0, doxorubicin 37."3.71Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. ( Douglas, J; Felgenhauer, J; Gooley, T; Hawkins, DS; Kreissman, S; Park, J; Pendergrass, TW; Rowley, SD; Sanders, JE; Thomson, B, 2002)
"Adriamycin, dacarbazine and ifosfamide are three effective chemotherapy drugs in treating progressive soft tissue sarcoma."3.71[Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma]. ( Chen, LK; Liang, Y; Liu, JL; Teng, XY; Xu, GC; Zhou, XM, 2002)
"The aim of this study was to investigate the severity and time-course of alterations in gastroduodenal and intestinal permeability in relation to nausea/emesis following administration of the highly emetogenic polydrug regimen IFADIC (ifosfamide, Adriamycin, dacarbazine) using a differential lactulose/mannitol absorption (SLM) test."3.71Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine). ( Brodowicz, T; Fazeny-Dörner, B; Marosi, C; Muhm, M; Veitl, M; Vogelsang, H; Wenzel, C; Zielinski, C, 2002)
"Ifosfamide is a leading drug in soft tissue sarcoma therapy."3.70Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998)
"In three new approved indications (non Hodgkin's lymphoma, Hodgkin's lymphoma and acute lymphoblastic leukaemia) and in three previously existing indications (ovarian cancer, soft tissue sarcomas and osteogenic sarcomas), non comparative trials show that ifosfamide can induce tumour regression in patients who relapse after a first course of chemotherapy (sometimes containing cyclophosphamide)."3.70Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness. ( , 1998)
"Accelerated split-course radiation with 60 to 64 Gy and concurrent chemotherapy using adriamycin/ifosfamide is a safe and effective treatment for soft tissue sarcoma."3.70[Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control]. ( Fietkau, R; Grabenbauer, GG; Hohenberger, W; Papadopoulos, T; Sauer, R; Schuchardt, U; Wittekind, C, 1999)
"Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas."3.70Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy. ( Altundağ, K; Baltali, E; Barişta, I; Celik, I; Firat, D; Güler, N; Güllü, I; Kars, A; Ozişik, Y; Tekuzman, G; Türker, A; Uner, A; Yalçin, S; Zengin, N, 2000)
" This study compares the kidney toxicity to the kidney of ifosfamide, carboplatin and etoposide (ICE) chemotherapy alone, and ICE chemotherapy combined with either extracorporeal (e-WBH) or radiant-heat-induced hyperthermia (r-WBH) in 43 patients with refractory sarcoma."3.70Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia. ( Filejski, W; Gerke, P; Robins, HI; Steinhoff, J; Wiedemann, GJ, 2000)
"Between 1992 and 1999, 13 consecutive patients with completely resected moderate- to high-grade uterine sarcoma received three cycles of adjuvant ifosfamide (1."3.70Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000)
"A total of 33 patients (median age, 44 years) with high-grade, adult soft-tissue sarcoma were treated with etoposide given at 600 mg/m2 in a 72-h continuous infusion and ifosfamide given at 1500 mg/m2 per day for 3 days every 3 weeks."3.69Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. ( Saeter, G; Solheim, OP; Talle, K, 1995)
"Four patients with metastatic ovarian mixed Müllerian sarcoma (2 homologous, 2 heterologous) were treated with mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy."3.69Mesna, doxorubicin, ifosfamide, and dacarbazine chemotherapy for ovarian mixed müllerian sarcoma: report of four cases. ( Greenberg, S; Patsner, B, 1995)
"The renal function of newly diagnosed children and young adults with high risk sarcomas was followed during therapy with a high dose ifosfamide-containing regimen."3.69A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. ( Balis, FM; Blaney, S; Ho, PT; Izraeli, S; Jarosinski, P; Weaver-McClure, L; Wexler, LH; Zimmerman, K, 1995)
"Twenty patients with advanced sarcomas entered a pilot study with ifosfamide (IF) and mercaptoethane sulfonate sodium (Mesna) as a second-line treatment for six planned cycles."3.69High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas. ( Alkiş, N; Baltali, E; Barişta, I; Celik, I; Güler, N; Güllü, I; Kars, A; Tekuzman, G; Yalçin, S; Zengin, N, 1996)
"High-dose ifosfamide (HD-IFX) has shown significant antitumor activity in advanced sarcoma and breast carcinoma."3.69Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. ( Albanell, J; Baselga, J; Bellmunt, J; Casado, S; Eres, N; Ribas, A, 1997)
"From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)."3.69[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997)
"This study was designed to test the feasibility of administering doxorubicin at an optimal dose-intensity (> 70 mg/m2 per 21 days) in combination with ifosfamide under recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) cover in patients with metastatic soft tissue sarcomas."3.68Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Grou ( Clavel, M; Crowther, D; Kerbrat, P; Rouesse, J; Somers, R; Spooner, D; Steward, WP; Tueni, E; Tursz, T; Verweij, J, 1993)
"A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects."3.68[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993)
"Between 1982 and 1986, 38 patients with soft-tissue sarcomas were treated with the combination doxorubicin/dacarbazine (group A); between 1986 and 1990, another 46 patients received doxorubicin/ifosfamide (group B); and between 1990 and 1991, 11 patients received an alternating regimen of doxorubicin and ifosfamide (group C)."3.68Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide. ( Agarwal, K; Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Zornig, C, 1993)
"Two trials using ifosfamide-based combination chemotherapy for advanced soft-tissue sarcoma have been completed."3.68Ifosfamide combination regimens for soft-tissue sarcoma. ( Bell, DR; Dalley, D; Levi, J; Simes, RJ; Stuart-Harris, R; Wiltshaw, E, 1993)
"The response of ifosfamide-based chemotherapeutic regimens was retrospectively analyzed in adult patients with advanced soft-tissue sarcoma who were treated at the West German Tumor Center, Essen, between 1978 and 1990."3.68Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. ( Kellner, R; Schütte, J; Seeber, S, 1993)
"Currently, anthracyclines and ifosfamide are the most effective drugs for the treatment of disseminated soft-tissue sarcoma."3.68A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. ( Anagnou, J; Bokemeyer, C; Harstrick, A; Knipp, H; Köhne-Wömpner, CH; Neumann, S; Poliwoda, H; Schmoll, HJ; Schöffski, P; Wipperman, B, 1993)
"A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)."3.68Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993)
"We gave the "optimal" dose of doxorubicin (75 mg/m2) with ifosfamide (5 g/m2), the two most active agents against metastatic soft-tissue sarcomas, in an attempt to determine the feasibility of administration of these doses in combination."3.68The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. ( Clavel, M; Crowther, D; Kerbrat, P; Rouesse, J; Somers, R; Spooner, D; Steward, WP; Tueni, E; Tursz, T; Verweij, J, 1993)
"Twenty-eight patients with non-pretreated metastatic soft tissue sarcomas were entered on a treatment protocol of rapidly alternating epirubicin/dacarbazine and ifosfamide: Epirubicin 100 mg/m2 d1, dacarbazine 500 mg/m2 d1 + d2, ifosfamide 6000 mg/m2 24-h infusion d15; repeated d29."3.68Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. ( Bokemeyer, C; Harstrick, A; Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöffski, P, 1992)
"The pharmacokinetics of ifosfamide were studied in 20 patients with soft tissue and bone sarcomas."3.68Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteine. ( Ayele, W; Benvenuto, JA; Legha, SS; Newman, RA; Nicaise, C; Raber, MN, 1992)
"From July 1986 to 1990, 65 patients with deep-seated, advanced sarcomas (43 soft-tissue sarcomas, 12 Ewing's sarcomas, 7 chondrosarcomas and 3 osteosarcomas) were entered in a protocol involving regional hyperthermia (RHT) combined with systemic ifosfamide and etoposide."3.68Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients. ( Denzlinger, C; Gerl, A; Issels, RD; Mittermüller, J; Ortmaier, A; Sauer, H; Simon, W; Wilmanns, W, 1991)
"The mesna, doxorubicin, ifosfamide, dacarbazine regimen produced a 47% response rate (including 10% complete responses) in 105 eligible adults with advanced sarcoma."3.68Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. ( Aisner, J; Antman, KH; Elias, A; Ryan, L, 1990)
"From July 1986 to July 1989, 40 patients (92% pretreated) with deep-seated, advanced soft tissue sarcomas (STS, 25 patients), Ewing's sarcomas (ES, eight patients), osteosarcomas (OS, three patients) and chondrosarcomas (ChS, four patients) were treated at the University of Munich in a protocol involving regional hyperthermia (RHT) combined with ifosfamide plus etoposide."3.68Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. ( Berger, H; Boehm, E; Denecke, H; Issels, RD; Jauch, KW; Nagele, A; Peter, K; Prenninger, SW; Sauer, H; Wilmanns, W, 1990)
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma."3.68Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990)
"The combination of ifosfamide (IFO) and epirubicin (EPI) has been found to be an effective regimen in the treatment of metastatic tumours and shows remarkable activity in heavily pretreated breast cancer patients."3.68Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. ( Hoffmann, W; Könner, J; Migeod, F; Seeber, S; Weidmann, B, 1990)
"Forty-three adult patients with locally advanced or metastatic soft tissue sarcoma entered a pilot study of combination chemotherapy comprising 50 mg of doxorubicin/m2 by intravenous bolus, 850 mg of dacarbazine/m2 by 1-hour infusion, and 5 g of ifosfamide/m2 by 24-hour infusion with mesna uroprotection."3.67Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group. ( Bramwell, V; Eisenhauer, E; Knowling, M; Quirt, I; Verma, S; Warr, D; Young, V, 1989)
"Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients."3.67Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986)
"One hundred twenty-four children and young adults with recurrent tumors, predominantly sarcomas, were treated with the combination of ifosfamide, etoposide, and the uroprotector, mesna (2-mercaptoethane sulphonate), in a phase II trial."3.67Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. ( Forquer, R; Jarosinski, P; Kinsella, TJ; Magrath, I; Miser, JS; Triche, TJ; Tsokos, M; Wesley, R, 1987)
"Fifty-four patients with advanced soft tissue sarcoma were treated with a combination of ifosfamide (5 g/m2) and adriamycin (40-60 mg/m2) at 3 weekly intervals."3.67A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. ( Fisher, C; King, M; MacMillan, S; Mansi, JL; Stuart-Harris, R; Wiltshaw, E, 1988)
"We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors."3.67A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986)
" Hemorrhagic cystitis was not observed in patients treated with 400-500 mg of mesna iv every 4 hours during ifosfamide treatment."3.67Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. ( Antman, KH; Montella, D; Rosenbaum, C; Schwen, M, 1985)
"In a phase II study, 42 patients with advanced soft-tissue sarcoma were treated with ifosfamide by 24-h infusion and mesna by 4-h IV bolus, repeated every 3 weeks."3.66High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. ( Gowing, NF; Harper, PG; Kaye, SB; Mooney, CA; Parsons, CA; Stuart-Harris, RC; Wiltshaw, E, 1983)
"The efficacy of ifosfamide combination chemotherapy was studied in 164 patients, 94 with advanced testicular carcinoma and 70 with metastatic sarcoma."3.66Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. ( Cremer, M; Niederle, N; Scheulen, ME; Schmidt, CG; Schütte, J; Seeber, S, 1983)
"The value of neoadjuvant chemotherapy in soft tissue sarcoma (STS) is not completely understood."3.11Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. ( Bagué, S; Bianchi, G; Blay, JY; Braglia, L; Brunello, A; Bruzzi, P; Casali, PG; Coindre, JM; Dei Tos, AP; Diaz-Beveridge, R; Donati, DM; Ferraresi, V; Fontana, V; Grignani, G; Gronchi, A; Infante, G; Lopez-Pousa, A; Lugowska, I; Marchesi, E; Marrari, A; Martin-Broto, J; Merlo, DF; Miceli, R; Morosi, C; Palassini, E; Palmerini, E; Pasquali, S; Picci, P; Quagliuolo, V; Stacchiotti, S; Tendero, O, 2022)
"The therapy of high-risk soft tissue sarcomas (STS) remains an interdisciplinary challenge."3.01Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review. ( Ademaj, A; Corradini, S; Eckert, F; Flörcken, A; Ghadjar, P; Issels, R; Kaul, D; Lindner, LH; Oberacker, E; Ott, OJ; Pink, D; Potkrajcic, V; Reichardt, P; Riesterer, O; Roohani, S; Spalek, MJ; Veltsista, PD; Zips, D, 2023)
"The value of chemotherapy in soft tissue sarcoma (STS) remains controversial."2.94Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial. ( Cabarrou, B; Chevreau, C; Chibon, F; Filleron, T; Le Guellec, S; Lesluyes, T; Lodin, S; Massoubre, A; Mounier, M; Poublanc, M; Valentin, T, 2020)
"Patients with soft tissue sarcoma are at risk for local recurrence and distant metastases despite optimal local treatment."2.87Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. ( Abdel-Rahman, S; Angele, M; Belka, C; Daugaard, S; Dürr, HR; Ghadjar, P; Gronchi, A; Hiddemann, W; Hohenberger, P; Issels, RD; Jauch, KW; Knösel, T; Lindner, LH; Mansmann, U; Mella, O; Reichardt, P; Salat, C; Schmidt, M; Verweij, J; Vujaskovic, Z; Wessalowski, R; Wust, P, 2018)
"Patients with Stage III non-round cell soft tissue sarcomas in the extremities were eligible."2.80Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). ( Araki, N; Chuman, H; Fukuda, H; Hatano, H; Hiruma, T; Iwamoto, Y; Mizusawa, J; Morioka, H; Ozaki, T; Takahashi, M; Tanaka, K; Tsuchiya, H, 2015)
"Metastatic soft tissue sarcoma (STS) prognosis remains poor and few cytotoxic agents offer proven efficacy."2.77High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. ( Bay, JO; Blay, JY; Bonichon, F; Bui-Nguyen, B; Chevreau, C; Coindre, JM; Cupissol, D; Italiano, A; Jimenez, M; Lotz, JP; Mathoulin-Pélissier, S; Penel, N; Ray-Coquard, I; Thyss, A, 2012)
"The role of chemotherapy in high-risk soft tissue sarcoma is controversial."2.76A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. ( Bischof, M; Dietrich, S; Dimitrakopoulou-Strauss, A; Egerer, G; Ho, AD; Kasper, B; Lehner, B; Mechtersheimer, G; Roeder, F; Schmitt, T; Strauss, LG; Wuchter, P, 2011)
"Prognosis of patients with metastatic soft tissue sarcoma remains poor."2.75Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study. ( Dietrich, S; Egerer, G; Ho, AD; Kasper, B; Scharrenbroich, I; Schmitt, T; Wuchter, P, 2010)
" Fifty-nine patients underwent primary surgery by wide or marginal excision and were subsequently randomized to receive radiotherapy alone or in combination with six courses of chemotherapy consisting of ifosfamide, DTIC, and doxorubicin administered in 14-day intervals supported by G-CSF on days 5-13."2.75Intensified adjuvant IFADIC chemotherapy in combination with radiotherapy versus radiotherapy alone for soft tissue sarcoma: long-term follow-up of a prospective randomized feasibility trial. ( Abdolvahab, F; Brodowicz, T; Dominkus, M; Ebm, C; Fakhrai, N; Jantsch, M; Kauer-Dorner, D; Kostler, WJ; Pokrajac, B; Zielinski, CC, 2010)
" A novel five-drug combination of etoposide, vincristine, dactinomycin, ifosfamide, and doxorubicin (EVAIA) was evaluated for high-risk patients, but cumulative chemotherapy dosage and treatment duration were reduced for the remaining individuals as compared with that of the previous trial CWS-86."2.74Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. ( Bielack, SS; Brecht, I; Dantonello, TM; Dickerhoff, R; Gadner, H; Greiner, J; Greulich, M; Harms, D; Herbst, M; Int-Veen, C; Juergens, H; Kirsch, S; Klingebiel, T; Koscielniak, E; Leuschner, I; Marky, I; Scheel-Walter, HG; Schmelzle, R; Schmidt, BF; Treuner, J, 2009)
"To compare the radiological criteria RECIST, WHO, and tumor volume for evaluation of tumor response in patients with soft tissue sarcomas (STS) showing either good or poor pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia, and to examine the dependence of the findings on the applied thermal dose."2.74Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS). ( Abdel-Rahman, S; Issels, RD; Lindner, LH; Reiser, MF; Santl, M; Stahl, R; Wang, T, 2009)
"Ifosfamide is a chemotherapeutic agent that requires cytochrome P450 3A (CYP3A) for bioactivation and metabolism."2.73Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. ( Baker, LH; Chugh, R; Griffith, KA; Leu, KM; Taylor, JM; Thomas, DG; Wagner, T; Worden, FP; Zalupski, MM, 2007)
"Six patients experienced early disease progression, and four patients died while on treatment."2.73Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. ( Daniels, S; McTiernan, A; Roylance, R; Seddon, B; Sykes, K; Whelan, J, 2007)
"Eligibility included a high-grade soft tissue sarcoma > or = 8 cm in diameter of the extremities and body wall."2.72Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. ( Blum, RH; DeLaney, TF; Eisenberg, B; Ettinger, DS; Harmon, DC; Harris, J; Kraybill, WG; Letson, GD; Lucas, DR; Spiro, IJ, 2006)
" Samples for pharmacokinetic analysis were obtained after the MTD was reached."2.72Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas. ( Beaulieu, BB; Kristal, O; Lewis, LD; Moore, AS; Northrup, NC; Page, RL; Rassnick, KM, 2006)
"Uterine sarcomas are rare tumors."2.72Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus. ( Fietkau, R; Gerber, B; Klautke, G; Kortmann, B; Reimer, T, 2006)
"Noninvasive MR thermography of soft tissue sarcoma was feasible and suitable for validating the quality of heating during RHT."2.72Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry. ( Budach, V; Felix, R; Ganter, H; Gellermann, J; Hildebrandt, B; Issels, R; Reichardt, P; Tunn, PU; Wlodarczyk, W; Wust, P, 2006)
"Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy."2.72Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. ( Abdel-Rahman, S; Baumert, J; Falk, M; Hentrich, M; Hiddemann, W; Issels, RD; Licht, T; Salat, C; Schlemmer, M; Straka, C; Wendtner, CM, 2006)
"To determine the efficacy of neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for local tumor control and overall survival (OS) in adult patients with retroperitoneal or visceral (RP/V) high-risk soft tissue sarcomas (HR-STS)."2.70Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. ( Abdel-Rahman, S; Baumert, J; Baur, A; Hiddemann, W; Issels, RD; Krych, M; Lindner, LH; Wendtner, CM, 2002)
"Adjuvant chemotherapy for soft tissue sarcoma is controversial because previous trials reported conflicting results."2.70Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. ( Apice, G; Azzarelli, A; Barbieri, E; Bonetti, M; Buonadonna, A; Comandone, A; De Paoli, A; Frustaci, S; Gherlinzoni, F; Olmi, P; Picci, P; Pignatti, G; Serraino, D; Zmerly, H, 2001)
"In this phase II study, activity and safety of neoadjuvant regional hyperthermia (RHT) combined with chemotherapy was investigated in 59 patients with primary advanced or recurrent high-risk soft-tissue sarcoma (STS)."2.70Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. ( Abdel-Rahman, S; Aydemir, U; Falk, MH; Hiddemann, W; Issels, RD; Kurze, V; Sauer, H; Wendtner, C, 2001)
" 54 patients were prospectively treated with four cycles of etoposide, ifosfamide and doxorubicin (EIA) combined with regional hyperthermia (RHT) followed by surgery, another four cycles of EIA without RHT and external beam radiation."2.70Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. ( Abdel-Rahman, S; Baumert, J; Falk, MH; Hiddemann, W; Issels, RD; Krych, M; Santl, M; Wendtner, C, 2001)
" These results indicate that there is no identifiable pharmacokinetic basis for insistence on either bolus or infusional methods of IFOS administration."2.69The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study. ( Brennan, C; Hartley, JM; Nicholson, PW; Singer, JM; Souhami, RL, 1998)
"The goal of the second German Soft Tissue Sarcoma Study CWS-86 (1985 to 1990) was to improve the prognosis in children and adolescents with soft tissue sarcoma by means of a clinical trial comprising intensive chemotherapy and risk-adapted local therapy."2.69Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. ( Gadner, H; Harms, D; Henze, G; Herbst, M; Jürgens, H; Klingebiel, T; Knietig, R; Koscielniak, E; Morgan, M; Schmidt, BF; Treuner, J, 1999)
"Etoposide monotherapy was successful in 8%; the effectiveness of cisplatin was 5-23%."2.69The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. ( Bodoky, G; Eckhardt, S; Láng, I; Pápai, Z; Poller, I; Rahóty, P; Szántó, J; Szendroi, M, 2000)
"Gemcitabine was administered as a 360 min infusion on days 1, 8 and 15 of a 28 day cycle."2.69Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. ( Dietzmann, A; Genvresse, I; Grunewald, R; Koschuth, A; Possinger, K; Späth-Schwalbe, E, 2000)
"Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation."2.69Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. ( Bejkos, D; Bischof-Delaloye, A; Chassot, PG; Chiolero, R; Genton, A; Guillou, L; Landry, M; Lejeune, FJ; Leyvraz, PF; Leyvraz, S; Liénard, D; Mirimanoff, RO; Mosimann, F; Pujol, N; Raffoul, W, 2000)
"More effective high-dose combination regimens are needed which have broad cytotoxic activity, steep dose-response relations and non-overlapping non-hematologic toxicities (to allow administration of full doses of each agent)."2.68Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. ( Ayash, LJ; Elias, AD; Frei, E; Gonin, R; Mazanet, R; McCauley, M; Schnipper, L; Schwartz, G; Tepler, I; Wheeler, C, 1995)
"In advanced soft tissue sarcomas of adults, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared."2.68Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. ( Buesa, J; Casali, P; Mouridsen, H; Rankin, E; Santoro, A; Somers, R; Spooner, D; Steward, W; Tursz, T; Verweij, J, 1995)
" No clinical evidence of renal failure was attributed to the high dosage of the drug in the course of assays of biochemical components of the blood, blood- and urine-beta-2-microglobulins, N-acetyl-D-hexoaminidase (NAG) level in urine, creatinine clearance and complex renoscintigraphy data."2.68[High-dose ifosfamide in the treatment of patients with soft tissue sarcoma]. ( Averinova, SG; Garin, AM; Kashkadaeva, AV; Liubimova, NV; Romanova, LF; Shiriaev, SV; Sidorova, NI; Tiuliandin, SA, 1996)
"Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1."2.67Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Bramwell, VH; Dombernowsky, P; Mouridsen, HT; Onsrud, M; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Verweij, J, 1993)
"Ifosfamide dosage was not increased."2.67Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study. ( Chevallier, B; Facchini, T; Fargeot, P; Leyvraz, S; Olivier, JP; Vo Van, ML, 1993)
"Patients with localized high-risk soft tissue sarcoma are at high risk for both local recurrence and distant metastases despite optimal surgical treatment."2.61[Multimodal treatment of sarcomas: standards and new aspects in pharmacological and radio-oncological treatment]. ( Lindner, LH, 2019)
"Localized soft tissue sarcoma may be cured with complete tumor excision, but overall, outcomes are sub-optimal."2.58Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy. ( Charlson, J, 2018)
"Proximal epithelioid sarcoma (PES) originating from the pleura is a clinical entity rarely reported in the literature."2.53[Pleural epithelioid sarcoma: about a case and review of the literature]. ( Akasbi, Y; Amara, B; Arifi, S; Chatar, A; Fatemi, H; Lemrabet, FZ; Mellas, N; Ouahbi, H; Oualla, K; Tizniti, S, 2016)
"Sarcomas are a group of rare solid tumours arising from mesenchymal or connective tissue."2.50Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease. ( Cornillie, J; Hompes, D; Li, H; Schöffski, P; Wozniak, A, 2014)
"Soft tissue sarcomas are rare tumours in adults and therefore require a multidisciplinary approach for optimal management."2.47Systemic management strategies for metastatic soft tissue sarcoma. ( Movva, S; Verschraegen, C, 2011)
"Soft tissue sarcomas are a heterogeneous group of connective tissue tumors, with more than 50 different subtypes."2.44Chemotherapeutic management of soft tissue sarcoma. ( Thornton, K, 2008)
"Soft tissue sarcomas are rare cancers of mesenchymal origin."2.44Emerging drugs for the treatment of soft tissue sarcomas. ( Alberti, L; Blay, JY; Cassier, PA; Dufresne, A; Fayette, J; Ranchere, D; Ray-Coquard, I, 2007)
"In advanced epithelial ovarian cancer, it has been tested in association with cisplatin, achieving results equal, if not better than cyclophosphamide, with acceptable toxicity."2.42Ifosfamide in the treatment of malignant epithelial ovarian tumors. ( Fei, F; Fruscio, R; Lissoni, AA; Rossi, R; Villa, A; Zani, G, 2003)
"For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival."2.42Ifosfamide with regional hyperthermia in soft-tissue sarcomas. ( Issels, RD; Schlemmer, M; Wendtner, CM, 2003)
"Soft tissue sarcomas are a heterogeneous group of malignancies arising from mesenchymal tissues."2.42Emerging treatments for soft tissue sarcoma of adults. ( Fahn, W; Issels, RD, 2004)
"Primary soft tissue sarcoma (STS) of the breast is a rare and heterogeneous disease."2.41Primary soft tissue sarcoma of the breast. ( Benjamin, RS; Trent II, JC; Valero, V, 2001)
" Such simultaneous administration enabled us to substantially increase the dosage intensity of both, thereby increasing the effectiveness of each drug."2.40Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations. ( Lackman, RD; Weiss, AJ, 1997)
"The first chemotherapy study of soft tissue sarcoma (STS) by the Scandinavian Sarcoma Group was started in 1981 (SSG I)."2.40Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience. ( Alvegård, TA; Fernberg, JO; Hall, KS; Monge, O; Saeter, G; Strander, H; Wiklund, T, 1999)
"The groups active in the treatment of osteosarcomas and Ewing's sarcomas should be encouraged to investigate the new active drugs in the relapsing patients."2.39New drugs for the treatment of sarcomas. ( van Oosterom, AT; Verweij, J, 1995)
"Osteosarcoma is a clinically heterogeneous disease which continues to resist biologic diagnosis, classification, or staging."2.39Problems and controversies in the management of childhood sarcomas. ( Womer, RB, 1996)
"The role of chemotherapy for soft tissue sarcoma with the exception of rhabdomyosarcoma remains controversial."2.38[Chemotherapy for soft tissue sarcoma--current concepts and review]. ( Hatakeyama, K; Ishii, T; Umeda, T; Wakita, H, 1993)
"Sarcomas are a relatively rare and heterogeneous group of malignant tumors of principally mesenchymal origin."2.38The clinical management of soft tissue sarcomas. ( Elias, AD, 1992)
"In epithelial ovarian cancer, responses were observed in eight (20%) of 41 evaluable patients, with three (7%) complete responses."2.38Gynecologic Oncology Group studies with ifosfamide. ( Blessing, JA; Homesley, H; Manetta, A; McGuire, W; Sutton, GP, 1992)
"Thoracic sarcomas are rare malignancies, with limited data for unresectable/advanced scenarios."1.91Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas. ( Alatorre-Alexander, JA; Carrasco-CaraChards, S; Cruz-Zermeño, M; de Jesús Rodríguez-Zea, I; Godina-Flores, A; Green-Renner, D; Guzmán-Casta, J; Guzmán-Huesca, J; Imaz-Olguin, V; Juarez-Vignon Whaley, JJ; Martínez-Barrera, LM; Riera-Sala, R; Rodriguez-Cid, JR; Sánchez-Domínguez, G; Sánchez-Ríos, CP; Santillán-Doherty, PJ; Seidman-Sorsby, A; Sosa-Sánchez, R, 2023)
"A population pharmacokinetic approach was applied to analyze data obtained in 42 patients at cycle 1 (without aprepitant) and cycle 2 (with aprepitant for 34 of them)."1.91Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide. ( Allal, B; Chaltiel, L; Chatelut, E; Chevreau, C; Filleron, T; Firmin, N; Lambert, M; Mseddi, M; Toulmonde, M; Valentin, T; Yakoubi, M, 2023)
"Treatment of highly malignant soft tissue sarcomas (STSs) requires multicomponent therapy including surgery, radiotherapy, and chemotherapy."1.91Perspectives of Cell Sensitivity/Resistance Assay in Soft Tissue Sarcomas Chemotherapy. ( Anastasia, TA; Belitsky, GA; Bokhyan, BY; Fetisov, TI; Khazanova, SA; Kirsanov, KI; Lovenger, AA; Marshall, VI; Rogozhin, DV; Shtompel, PA; Trapeznikova, ES; Yakubovskaya, MG; Zinovieva, VY, 2023)
"However, because sarcoma is very rare, there is little evidence regarding the management of elderly patients with sarcoma."1.72Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. ( Ozaki, T; Tanaka, K, 2022)
"Pancreatic Ewing's sarcoma is not reported commonly, with inconsistent clinical manifestations."1.72Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report. ( Chan, WT; Hou, JY; Jiang, CB; Lee, HC; Liu, HC; Liu, YC; Sheu, JC; Wu, PS; Yeh, TC; Yeung, CY, 2022)
"Soft tissue sarcomas are a group of tumors derived from the mesenchymal origin."1.56Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion. ( Al-Rohil, RN; Bentley, RC; Cardona, DM; Feng, X; Jour, G; Shen, G; Underwood, CIM, 2020)
"Uterine sarcomas are very rare tumours with different histotypes, molecular features and clinical outcomes; therefore, it is difficult to carry out prospective clinical trials, and this often results in heterogeneous management of patients in the clinical practice."1.56Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). ( Aristei, C; Biondetti, PR; Cananzi, FCM; Casali, P; Ciccarone, F; Colombo, N; Comandone, A; Corvo', R; De Iaco, P; Dei Tos, AP; Donato, V; Ferrandina, G; Fiore, M; Gadducci, A; Gronchi, A; Guerriero, S; Infante, A; Lorusso, D; Odicino, F; Pirronti, T; Quagliuolo, V; Sanfilippo, R; Scambia, G; Testa, AC; Zannoni, GF, 2020)
"Although 40% of cases of soft tissue sarcoma (STS) are diagnosed in patients aged ≥65 years, this group is largely excluded from or under-represented in clinical trials and receives disproportionately less treatment than younger patients."1.51Sarcomas and old age: few options for such a large patient population. ( Jones, RL, 2019)
"Treatment goals for advanced soft tissue sarcoma (STS) vary according to disease stage and treatment line."1.51Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma? ( Hindi, N; Martin-Broto, J; Moura, DS, 2019)
"Olaratumab (OLA), a monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), has recently been used against soft-tissue sarcoma (STS) combined with doxorubicin (DOX), with limited efficacy."1.51Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model. ( Bouvet, M; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Razmjooei, S; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N; Zhang, Z, 2019)
"Eighteen patients (35."1.48Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. ( Armento, G; Badalamenti, G; Catania, G; Incorvaia, L; Maltese, G; Napolitano, A; Santini, D; Silletta, M; Spalato Ceruso, M; Tonini, G; Valeri, S; Vincenzi, B, 2018)
"On multivariate analysis, positive surgical margins negatively impacted LRC, DFS, and OS (hazard ratio [HR]=10."1.43The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome. ( Benedetto, P; Conway, S; Dosch, A; Fernandez, G; Kwon, D; Mahmoud, O; Pitcher, JD; Temple, HT; Trent, J; Wolfson, AH, 2016)
"OBJECT Primary CNS sarcomas are very rare pediatric tumors with no defined standard of care."1.43Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children. ( Bartels, U; Bouffet, E; Hader, W; Hawkins, C; Lafay-Cousin, L; Laperriere, N; Laughlin, S; Lindzon, G; Nordal, R; Taylor, MD, 2016)
"Malignant meningioma has a bad prognosis."1.43A successful case of an anaplastic meningioma treated with chemotherapy for soft tissue sarcomas. ( Buccoliero, AM; Farina, S; Favre, C; Fonte, C; Genitori, L; Guidi, M; Lucchesi, M; Sardi, I; Scoccianti, S, 2016)
"Soft tissue sarcomas are a heterogeneous group of malignant tumors."1.40Chemotherapy influences the pseudocapsule composition in soft tissue sarcomas. ( Cheng, EY; Clohisy, DR; Manivel, JC; O'Donnell, PW, 2014)
"As adjuvant chemotherapy (AC) for soft tissue sarcomas is controversial, we performed a retrospective analysis of patients seen at Washington University in St."1.40Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy. ( Adkins, DR; Luo, J; Montgomery, L; Morgensztern, D; Schenone, AD; Van Tine, BA, 2014)
"No significant dose-response effect of adjuvant RT was demonstrated."1.39Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall. ( Bauer, HC; Bruland, OS; Eide, GE; Engellau, J; Engström, K; Jebsen, NL; Monge, OR; Muren, LP; Trovik, CS, 2013)
"The spindle cell rhabdomyosarcoma is a rare variant of the embryonal rhabdomyosarcoma, mostly occurring in childhood."1.39Spindle cell rhabdomyosarcoma of the prostate. ( Ellinger, J; Fechner, G; Goltz, D; Latz, S; Leuschner, I; Marx, C; Müller, SC, 2013)
"Epithelioid sarcoma is a rare soft tissue sarcoma subtype."1.38Role of palliative chemotherapy in advanced epithelioid sarcoma. ( Al-Muderis, O; Constantinidou, A; Fisher, C; Jones, RL; Judson, IR; Olmos, D; Scurr, M; Thway, K, 2012)
"High-risk soft tissue sarcoma was defined as high-grade malignancy and at least two of the following criteria: size≥8 cm, vascular invasion, or necrosis."1.37Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall. ( Bruland, ØS; Engellau, J; Eriksson, M; Folin, A; Hall, KS; Jebsen, NL; Trovik, CS; Turesson, I, 2011)
"Grade 3 toxic events were observed in 18 patients (30%) and Grade 4 events in 6 patients (10%)."1.37Determinants of toxicity, patterns of failure, and outcome among adult patients with soft tissue sarcomas of the extremity and superficial trunk treated with greater than conventional doses of perioperative high-dose-rate brachytherapy and external beam r ( Cambeiro, M; Fernández Sanmamed, M; Gaztañaga, M; Martín-Algarra, S; Martinez-Monge, R; Pagola, M; San Julián, M; San Miguel, I; Vázquez-García, B, 2011)
"Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity."1.37High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011)
"Breast stromal sarcoma is very rare, accounting for less than 1% of mammary neoplasms, and the treatment strategy is not well established, especially regarding chemotherapy."1.37Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case. ( Inoue, K; Iwase, H; Kuriwaki, K; Sueta, A; Yamamoto, Y, 2011)
"The resulting treatment-induced necrosis rates are predictive of subsequent metastatic risk, and this information may provide an opportunity to guide postoperative systemic therapies."1.36Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. ( Connell, PP; Haydon, RC; Luu, HH; MacDermed, DM; Miller, LL; Montag, AG; Peabody, TD; Simon, MA; Undevia, SD, 2010)
"Extraskeletal Ewing's sarcoma (EES) is a rare form of soft tissue sarcoma."1.36Extraskeletal Ewing's sarcoma family of tumours in adults: analysis of 57 patients from a single institution. ( Ajarim, D; Al Dayel, F; Allam, A; Bazarbashi, S; El Weshi, A; Memon, M; Pant, R, 2010)
"Soft tissue sarcoma is a malignant connective tissue tumor that may arise anywhere in the body and from diverse mesenchymal elements."1.35Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy? ( Patel, S; Schuetze, SM, 2009)
"The response of adult soft tissue sarcoma (STS) to chemotherapy is uncertain."1.34[Responses of 109 adult soft tissue sarcoma patients to chemotherapy]. ( Guan, ZZ; Huang, HQ; Jiang, WQ; Li, FH; Lin, TY; Luo, HY; Qiu, MZ; Sun, XF; Wang, F; Wang, SS; Xu, F; Xu, GC; Xu, RH, 2007)
"Although FDC sarcoma is considered a low-grade tumor, the tumor in the present case not only developed at an unusual location with bone metastasis but also involved bone marrow."1.33Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature. ( Admirand, JH; Bueso-Ramos, CE; Ford, RJ; Jiang, L; Moran, C, 2006)
"Numerous studies on extremity soft tissue sarcomas have consistently shown that presentation with locally recurrent disease is associated with the development of subsequent local recurrences and that large tumor size and high histologic grade are significant factors associated with decreased survival."1.32High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. ( Dorey, F; Eckardt, J; Eilber, FC; Eilber, FR; Nelson, SD; Rosen, G; Selch, M, 2003)
"Congenital mesoblastic nephroma was originally considered to be a benign neoplasm."1.32Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases. ( Hitchcock, RJ; Mitchell, CD; Patel, Y, 2003)
"Thirty-seven patients had distant metastases at presentation."1.32Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. ( Hatano, H; Hotta, T; Kawashima, H; Morita, T; Ogose, A; Ueda, T; Yazawa, Y, 2003)
"Patients had Ewing's sarcoma/primitive neuroectodermal tumour (PNET), rhabdomyosarcoma, non-rhabdo soft tissue sarcomas or other advanced soft tissue tumours."1.31Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. ( Daller, RT; Fenton, JG; Miser, JS; Womer, RB, 2000)
"Prospective, multicenter study in 44 soft tissue sarcoma (STS) patients with first relapse."1.30Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. ( Hess, CF; Jürgens, H; Klingebiel, T; Koscielniak, E; Pertl, U; Pötter, R; Rossi, R; Schött, C; Spaar, HJ; Treuner, J; van Heek-Romanowski, R; Willnow, U, 1998)
" So we compared VAC protocol and ifosfamiide for toxic effects."1.30Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide). ( Erman, O; Simşek, T; Trak, B; Uner, M; Zorlu, GC, 1998)
"The role and value of chemotherapy for soft tissue sarcomas remain unclear."1.30[Chemotherapy for pulmonary metastases of soft tissue sarcoma]. ( Kito, M; Umeda, T, 1998)
"The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17-78 months for the four AMLs, 96 months for the MDS and 82-136 months for the three sarcomas."1.30Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. ( Ahrens, S; Dunst, J; Harms, D; Jürgens, H; Paulussen, M; Rübe, C; Winkelmann, W; Zoubek, A, 1998)
" A critical question in comparing an experimental treatment to a standard is how much increase in an adverse event rate is an acceptable trade-off for achieving a targeted improvement in efficacy, or vice versa."1.30Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials. ( Cheng, SC; Thall, PF, 1999)
"Ifosfamide was administered at the daily dose of 1200 mg/m2/24 h."1.29[Peri-operative chemotherapy during resection of pulmonary metastases of sarcoma]. ( Azorin, JF; Delepine, G; Delepine, N; Destable, MD; Pocard, M; Tremblay, B, 1994)
"Ifosfamide was escalated from 5 to 10 g/m2 with a fixed carboplatin dose of 480 mg/m2."1.29Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. ( Bucsky, P; d'Oleire, F; Eleftheriadis, S; Feddersen, S; Geisler, J; Klouche, M; Knop, E; Mentzel, M; Schmucker, P; Wiedemann, GJ, 1994)
"Ifosfamide was infused into 14 patients with advanced sarcoma for 5 days at a dose of 2."1.29Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. ( Cerny, T; Hartmann, B; Junker, E; Küpfer, A; Lauterburg, BH; Nguyen, T, 1994)
"The OHS osteosarcoma tumors caused sclerotic lesions with high and uniform isotope uptake, and the MHMX unclassified sarcoma showed a mixed pattern with both sclerotic and lytic areas, whereas the LOX melanoma caused lytic bone lesions with low uptake of the radionuclide."1.29Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. ( Bruland, O; Fodstad, O; Kjønniksen, I; Winderen, M, 1994)
" Estimated pharmacokinetic parameters (clearance, volume of distribution, and half-life) were dependent on body size and age but not any other patient variable."1.29Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. ( Boddy, AV; Idle, JR; Pearson, AD; Price, L; Wyllie, R; Yule, SM, 1993)
"From November 1990 to September 1991, 23 adults with high-risk, nonmetastatic sarcomas (20 soft-tissue sarcomas and 3 chondrosarcomas) were entered in a pilot protocol (RHT-91) involving regional hyperthermia combined with systemic chemotherapy followed by surgery."1.29Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study. ( Abdel-Rahman, S; Berger, H; Bosse, D; Issels, RD; Jauch, KW; Panzer, M; Peter, K; Sauer, H; Starck, M; Stiegler, H, 1993)
"Paclitaxel was given at a dose of 120 mg/m2 to five patients, 135 mg/m2 to five patients, 150 mg/m2 to three patients, and 175 mg/m2 to 11 patients."1.29Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. ( Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L, 1996)
"Ifosfamide is a newly available analog of cyclophosphamide in the oxazaphosphorine drug class."1.28Ifosfamide vs cyclophosphamide in cancer therapy. ( Weiss, RB, 1991)
"The model systems were human breast carcinoma (MX1/3) and human sarcoma (S117) grown in nude mice."1.28Local hyperthermia enhances cyclophosphamide, ifosfamide and cis-diamminedichloroplatinum cytotoxicity on human-derived breast carcinoma and sarcoma xenografts in nude mice. ( Biersack, A; Roszinski, S; Wagner, T; Weiss, C; Wiedemann, G, 1992)
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies."1.28Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990)
" We have studied in patients with advanced cancer the feasibility and bioavailability of a subcutaneously administered isotonic and neutral (pH 7) IFO solution given continuously over 10 h for up to 5 days."1.28Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients. ( Brunner, KW; Cerny, T; Küpfer, A; Zeugin, T, 1990)
"Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990."1.28Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. ( Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M, 1990)

Research

Studies (496)

TimeframeStudies, this research(%)All Research%
pre-199039 (7.86)18.7374
1990's153 (30.85)18.2507
2000's140 (28.23)29.6817
2010's126 (25.40)24.3611
2020's38 (7.66)2.80

Authors

AuthorsStudies
Kim, JH1
Kim, SH1
Jeon, MK1
Kim, JE1
Kim, KH1
Yun, KH1
Jeung, HC1
Rha, SY2
Ahn, JH2
Kim, HS1
Benjamin, RS9
Pasquali, S2
Palmerini, E3
Quagliuolo, V9
Martin-Broto, J5
Lopez-Pousa, A11
Grignani, G5
Brunello, A3
Blay, JY18
Tendero, O2
Diaz-Beveridge, R1
Ferraresi, V1
Lugowska, I1
Infante, G1
Braglia, L1
Merlo, DF2
Fontana, V1
Marchesi, E1
Donati, DM1
Palassini, E3
Bianchi, G1
Marrari, A4
Morosi, C1
Stacchiotti, S8
Bagué, S1
Coindre, JM5
Dei Tos, AP7
Picci, P5
Bruzzi, P2
Miceli, R2
Casali, PG8
Gronchi, A14
Goy, BW1
Syed, S1
Padmanabhan, A1
Burchette, RJ1
Helmstedter, CS1
Kinoshita, H1
Hagiwara, Y1
Ishii, T6
Kamoda, H1
Tsukanishi, T1
Ohtori, S1
Yonemoto, T3
Oda, Y2
Tanaka, K6
Hirose, T1
Hasegawa, T2
Hiruta, N1
Hisaoka, M1
Yoshimoto, M1
Otsuka, H1
Bekki, H1
Endo, M1
Kunisada, T2
Hiruma, T3
Tsuchiya, H3
Katagiri, H2
Matsumoto, Y2
Kawai, A4
Nakayama, R2
Kawashima, H3
Takenaka, S2
Emori, M2
Watanuki, M2
Yoshida, Y1
Okamoto, T1
Mizusawa, J3
Fukuda, H5
Ozaki, T6
Iwamoto, Y5
Nojima, T1
Moreau-Bachelard, C1
Campion, L1
Toulmonde, M5
Le Cesne, A9
Brahmi, M2
Italiano, A5
Mir, O3
Piperno-Neumann, S4
Laurence, V1
Firmin, N2
Penel, N6
Duffaud, F3
Chevreau, C8
Bertucci, F2
Narciso, B1
Dubray-Longeras, P1
Delcambre, C2
Saada-Bouzid, E2
Boudou-Rouquette, P1
Soulie, P1
Perrin, C1
Bompas, E3
Acem, I1
van Houdt, WJ2
Grünhagen, DJ1
van der Graaf, WTA2
Rueten-Budde, AJ1
Gelderblom, H7
Verhoef, C1
van de Sande, MAJ1
Miller, D1
Livingston, JA1
Park, Y1
Posey, K1
Godbole, S1
Skubitz, K1
Robinson, SI1
Agulnik, M1
Davis, LE2
Van Tine, BA2
Hirbe, AC1
Parkes, A1
Sanfilippo, RG1
Marreaud, SI1
Judson, IR3
Litiere, S8
Kasper, B12
Schöffski, P6
Schoot, RA1
Chisholm, JC1
Casanova, M4
Minard-Colin, V1
Geoerger, B1
Cameron, AL1
Coppadoro, B1
Zanetti, I3
Orbach, D5
Kelsey, A3
Rogers, T1
Guizani, C1
Elze, M1
Ben-Arush, M1
McHugh, K1
van Rijn, RR1
Ferman, S1
Gallego, S1
Ferrari, A6
Jenney, M1
Bisogno, G4
Merks, JHM1
Machida, R1
Tsukushi, S1
Asanuma, K1
Hiraga, H2
Hiraoka, K1
Abe, S2
Nishida, Y1
Nagano, A1
Suehara, Y1
Kawano, M1
Morii, T1
Hatano, H3
Toguchida, J1
Okuma, T2
Takeyama, M1
Akisue, T1
Furuta, T1
Outani, H1
Yamamoto, T1
Kataoka, T1
Miao, L1
Ma, ST1
Jiang, X1
Zhang, HH1
Wang, YM1
Li, M1
Liu, X1
Jiang, S1
Wang, H1
Wu, X1
Yan, W1
Chen, Y1
Xu, Y2
Wang, C1
Yao, W1
Wang, J1
Yu, L1
Miao, J1
Chen, H1
Xia, J1
Huang, M1
Zhang, X1
Luo, Z1
Liu, YC3
Yeh, TC3
Wu, PS3
Sheu, JC3
Lee, HC3
Yeung, CY3
Jiang, CB3
Liu, HC3
Hou, JY3
Chan, WT3
Rodriguez-Cid, JR3
Juarez-Vignon Whaley, JJ3
Sánchez-Domínguez, G3
Guzmán-Casta, J3
Carrasco-CaraChards, S3
Guzmán-Huesca, J3
Riera-Sala, R3
Sánchez-Ríos, CP3
Cruz-Zermeño, M3
Seidman-Sorsby, A3
de Jesús Rodríguez-Zea, I3
Alatorre-Alexander, JA3
Martínez-Barrera, LM3
Santillán-Doherty, PJ3
Godina-Flores, A3
Imaz-Olguin, V3
Sosa-Sánchez, R3
Green-Renner, D3
Merjaneh, N1
Kim, H1
Escoto, H1
Metts, J1
Ray, A1
Bukowinski, A1
LeBlanc, Z1
Fair, D1
Watanbe, M1
Alva, E1
Todd, K1
Daley, J1
Hartt, D1
Cramer, SL1
Szabo, S1
Pressey, JG1
Valentin, T2
Lambert, M1
Chaltiel, L1
Allal, B1
Mseddi, M1
Yakoubi, M1
Filleron, T2
Chatelut, E1
Gutierrez-Sainz, L1
Martinez-Fdez, S1
Pedregosa-Barbas, J1
Peña, J1
Alameda, M1
Viñal, D1
Villamayor, J1
Martinez-Recio, S1
Perez-Wert, P1
Pertejo-Fernandez, A1
Gallego, A1
Martinez-Marin, V1
Zamora, P1
Espinosa, E1
Mendiola, M1
Feliu, J1
Redondo, A1
Veltsista, PD1
Oberacker, E1
Ademaj, A1
Corradini, S1
Eckert, F3
Flörcken, A1
Kaul, D1
Lindner, LH7
Issels, R2
Ott, OJ1
Pink, D2
Potkrajcic, V1
Reichardt, P9
Roohani, S1
Spalek, MJ1
Riesterer, O1
Zips, D2
Ghadjar, P2
Fetisov, TI1
Khazanova, SA1
Shtompel, PA1
Trapeznikova, ES1
Zinovieva, VY1
Marshall, VI1
Lovenger, AA1
Rogozhin, DV1
Anastasia, TA1
Bokhyan, BY1
Belitsky, GA1
Yakubovskaya, MG1
Kirsanov, KI1
Jones, RL4
Hindi, N2
Moura, DS1
Lu, E2
Ryan, CW3
Bassale, S1
Lim, JY1
D'Ambrosio, L2
Touati, N2
Flippot, R1
Czarnecka, AM1
Sanfilippo, R4
Katz, D1
Vincenzi, B2
Stark, DP1
Mazzeo, F1
Tuchscherer, A1
Sherriff, J1
Estival, A2
Sents, W1
Ray-Coquard, I7
Tolomeo, F1
Rutkowski, P1
Hammer, KJ1
Copeland, VC1
Loggers, ET1
Pollack, SM1
Wagner, MJ1
Cranmer, LD1
Findlay, BL1
Gargollo, PC1
Granberg, CF1
Le Guellec, S1
Cabarrou, B1
Lesluyes, T1
Lodin, S1
Massoubre, A1
Mounier, M1
Poublanc, M1
Chibon, F1
Ryckewaert, T1
Pannier, D1
Underwood, CIM1
Cardona, DM1
Bentley, RC1
Shen, G1
Feng, X1
Jour, G1
Al-Rohil, RN1
Ferrandina, G1
Aristei, C1
Biondetti, PR1
Cananzi, FCM1
Casali, P5
Ciccarone, F1
Colombo, N1
Comandone, A9
Corvo', R1
De Iaco, P1
Donato, V1
Fiore, M4
Gadducci, A1
Guerriero, S1
Infante, A1
Odicino, F1
Pirronti, T1
Testa, AC1
Zannoni, GF1
Scambia, G1
Lorusso, D1
Byun, DJ1
Katz, LM1
Xiao, J1
Rapp, TB1
Paoluzzi, L1
Rosen, G5
Schiff, PB1
Modi, JN1
Cimino, SK1
Schmoll, HJ5
Heißner, K1
Kopp, HG3
Kessler, T1
Mayer-Steinacker, R1
Rüssel, J1
Egerer, G8
Crysandt, M1
Niederwieser, D1
Kunitz, A1
Eigendorff, E1
Petersen, I2
Steighardt, J1
Cygon, F1
Meinert, F1
Stein, A1
Hua, Q1
Xu, G1
Zhao, L2
Zhang, T1
Marquina, G1
Dudzisz-Śledź, M1
Steeghs, N1
Karavasilis, V1
de Haan, J1
Wozniak, A2
Cousin, S1
Domènech, M1
Bovée, JVMG1
Charon-Barra, C1
Marreaud, S5
De Meulemeester, L1
Olungu, C1
Young, RJ1
Lia, M1
Hogendoorn, PCW1
Fisher, C5
Mechtersheimer, G4
Daugaard, S4
Sciot, R1
Collin, F1
Messiou, C2
Grünwald, V1
van der Graaf, W1
Wardelmann, E1
Judson, I9
Teepen, JC1
van Leeuwen, FE1
Tissing, WJ1
van Dulmen-den Broeder, E1
van den Heuvel-Eibrink, MM1
van der Pal, HJ1
Loonen, JJ1
Bresters, D1
Versluys, B1
Neggers, SJCMM1
Jaspers, MWM1
Hauptmann, M1
van der Heiden-van der Loo, M1
Visser, O1
Kremer, LCM1
Ronckers, CM1
De Sanctis, R5
Giordano, L2
Colombo, C1
De Paoli, A9
Navarria, P2
Sangalli, C3
Buonadonna, A6
Bertola, G2
Navarria, F1
Bertuzzi, A3
Basso, S1
Santoro, A18
Issels, RD15
Verweij, J26
Wessalowski, R2
Wust, P3
Hohenberger, P6
Angele, M1
Salat, C3
Vujaskovic, Z2
Mella, O1
Mansmann, U2
Dürr, HR2
Knösel, T1
Abdel-Rahman, S9
Schmidt, M1
Hiddemann, W6
Jauch, KW4
Belka, C2
Badalamenti, G2
Armento, G1
Silletta, M1
Spalato Ceruso, M1
Catania, G1
Napolitano, A1
Maltese, G2
Valeri, S1
Incorvaia, L2
Santini, D1
Tonini, G1
García Del Muro, X2
Maurel, J5
Martínez Trufero, J1
Lavernia, J1
López Pousa, A1
de Las Peñas, R4
Cubedo, R3
Berros, JP1
Casado Herráez, A1
de Juan, A1
Martín Broto, J2
Pennington, JD1
Eilber, FC6
Eilber, FR5
Singh, AS1
Reed, JP1
Chmielowski, B1
Eckardt, JJ4
Bukata, SV1
Bernthal, NM1
Federman, N1
Nelson, SD5
Dry, SM2
Wang, PC1
Luu, M1
Selch, MT1
Steinberg, ML1
Kalbasi, A1
Kamrava, M1
Chowdhary, M1
Sen, N1
Jeans, EB1
Miller, L1
Batus, M1
Gitelis, S1
Wang, D1
Abrams, RA1
Lee, J3
Jung, HA1
Kim, Y1
Choi, S1
Han, J1
Choi, YL1
Lee, SH2
Ahn, JS1
Park, K1
Sun, JM1
Schiavetti, A1
Pedetti, V1
Varrasso, G1
Marrucci, O1
Celani, C1
Andreoli, G1
Bonci, E1
Charlson, J1
Pizzamiglio, S2
Verderio, P4
Woll, PJ2
Higuchi, T1
Miyake, K1
Sugisawa, N1
Oshiro, H1
Zhang, Z1
Razmjooei, S1
Yamamoto, N1
Hayashi, K1
Kimura, H1
Miwa, S1
Igarashi, K1
Bouvet, M1
Singh, SR1
Hoffman, RM1
Spunt, SL2
Francotte, N1
De Salvo, GL1
Chi, YY1
Hayes-Jordan, A1
Kao, SC1
Brennan, B1
Weiss, AR1
van Noesel, MM1
Million, L1
Alaggio, R2
Parham, DM1
Randall, RL1
McCarville, MB1
Hawkins, DS4
Nevala, R1
Tukiainen, E1
Tarkkanen, M1
Böhling, T1
Blomqvist, C1
Sampo, M1
Chawla, SP4
Staddon, A1
Hendifar, A2
Messam, CA1
Patwardhan, R1
Kamel, YM1
Gani, C1
Kluba, T2
Mayer, F1
Bamberg, M1
Müller, AC1
O'Donnell, PW1
Manivel, JC1
Cheng, EY1
Clohisy, DR1
Johnson, K1
Notrica, DM1
Carpentieri, D1
Jaroszewski, D1
Henry, MM1
Jebsen, NL2
Engellau, J2
Engström, K1
Bauer, HC1
Monge, OR2
Muren, LP1
Eide, GE1
Trovik, CS2
Bruland, OS1
Martín-Liberal, J1
Broto, JM1
Gallego, O2
Brendel, E1
Tirado, OM1
del Muro, XG3
Chocarro, G1
Amesty, MV1
Hernández, F1
Chenu, BG1
Ortíz, R1
Hernández, S1
Sánchez, A1
Gámez, M1
Santamaría, ML1
Tovar, JA1
Yoo, C1
Park, KH1
Kim, TM1
Kim, YJ1
Lee, HJ2
Lee, KH1
Dani, C1
Giorello, L1
Cao, J1
Huang, XE1
Liu, J1
Wu, XY1
Lu, YY1
Okuno, S1
Shives, T1
Mahoney, M1
Haddock, M1
Sim, F1
O'Connor, MI2
Markovic, SN1
Maples, W1
Leahy, MG2
Nguyen, BB1
Patel, SR8
Staddon, AP2
Lardelli, P1
Nieto, A1
Alfaro, V1
Dutour, A1
Josserand, V1
Jury, D1
Guillermet, S1
Decouvelaere, AV1
Chotel, F1
Pointecouteau, T1
Rizo, P1
Coll, JL1
Schenone, AD1
Luo, J1
Montgomery, L1
Morgensztern, D1
Adkins, DR1
Hartmann, JT3
Kerst, JM1
Sufliarsky, J1
Whelan, J3
Krarup-Hansen, A2
Alcindor, T1
Hermans, C5
Hogendoorn, PC4
van der Graaf, WT1
Dincbas, FO1
Oksuz, DC1
Yetmen, O1
Hiz, M1
Dervisoglu, S1
Turna, H1
Kantarci, F1
Mandel, NM1
Koca, S1
Szabatura, AH2
Cirrone, F1
Harris, C1
McDonnell, AM1
Feng, Y1
Voit, D1
Neuberg, D1
Butrynski, J1
Fisher, DC1
Baumann, D1
Amann, K1
Schlatter, E1
Ciarimboli, G1
Müller, M1
Bakos, G1
Steinke, I1
Bunz, H1
Weyrich, P1
Artunc, F1
Mahmoud, O1
Dosch, A1
Kwon, D1
Pitcher, JD1
Conway, S1
Benedetto, P1
Fernandez, G1
Trent, J1
Temple, HT1
Wolfson, AH1
Roeder, F2
Lehner, B3
Schmitt, T6
Sedlaczek, O1
Grüllich, C1
Wuchter, P4
Hensley, FW1
Huber, PE1
Debus, J1
Bischof, M2
Cornillie, J1
Li, H1
Hompes, D1
Kataoka, K1
Kimura, A1
Matsunobu, T2
Matsumine, A1
Araki, N3
Siurala, M1
Bramante, S1
Vassilev, L1
Hirvinen, M1
Parviainen, S1
Tähtinen, S1
Guse, K1
Cerullo, V1
Kanerva, A1
Kipar, A1
Vähä-Koskela, M1
Hemminki, A1
Salman, D1
Swinden, J1
Barton, S1
Peron, JM1
Nabhani-Gebara, S1
De Niro, JE1
Cham, EM1
Silkiss, RZ1
Basso, U3
Marchetti, S1
Colombo, P1
Lutman, RF2
Chuman, H2
Takahashi, M1
Morioka, H1
Pápai, Z3
Tolcher, AW1
Cupissol, D4
Babovic, N1
Isambert, N2
Franke, FA1
Cohen, P1
Le-Guennec, S1
Demetri, GD4
Schuler, M1
Davis, EJ1
Chugh, R3
Lucas, DR3
Biermann, JS3
Zalupski, MM4
Feng, M1
Wong, SL1
Jacobson, J1
Zyczynski, L1
Reinke, D1
Metko, G1
Baker, LH7
Schuetze, SM3
Semenova, AI1
Protsenko, SA1
Komarov, YI1
Teletaeva, GM1
Latipova, DH1
Novik, AV1
Fernandes, LL1
Murray, S1
Taylor, JM3
Ferrari, S3
Bottelli, S1
Libertini, M1
Mulder, RL3
Paulides, M7
Langer, T8
Kremer, LC3
van Dalen, EC3
Noujaim, J1
Constantinidou, A2
Thway, K2
Miah, A1
Benson, C1
Rizzato, MD1
Rastrelli, M1
Roma, A1
Maruzzo, M1
Fiduccia, P1
Buzzaccarini, MS1
Scarzello, G1
Rossi, CR1
Zagonel, V1
Lafay-Cousin, L1
Lindzon, G1
Taylor, MD1
Hader, W1
Hawkins, C1
Nordal, R1
Laperriere, N1
Laughlin, S1
Bouffet, E2
Bartels, U1
Stubbe, F1
Agaimy, A1
Ott, O1
Lettmaier, S1
Vassos, N1
Croner, R1
Hohenberger, W2
Fietkau, R3
Semrau, S1
Tsukamoto, S1
Kurematsu, Y1
Honoki, K1
Kido, A1
Somekawa, S1
Kaya, D1
Sadamitsu, T1
Fukui, H1
Tanaka, Y1
Wang, B1
Yu, X1
Xu, S1
Xu, M1
Saha, D1
Basu, A1
Maiti, A1
Rodriguez, E1
Matsuo, K1
Takazawa, Y1
Ross, MS1
Elishaev, E1
Podzielinski, I1
Yunokawa, M1
Sheridan, TB1
Bush, SH1
Klobocista, MM1
Blake, EA1
Takano, T1
Matsuzaki, S1
Baba, T1
Satoh, S1
Shida, M1
Nishikawa, T1
Ikeda, Y1
Adachi, S1
Yokoyama, T1
Takekuma, M1
Fujiwara, K2
Hazama, Y1
Kadogami, D1
Moffitt, MN1
Takeuchi, S1
Nishimura, M1
Iwasaki, K1
Ushioda, N1
Johnson, MS1
Yoshida, M1
Hakam, A1
Li, SW1
Richmond, AM1
Machida, H1
Mhawech-Fauceglia, P1
Ueda, Y1
Yoshino, K1
Yamaguchi, K1
Oishi, T1
Kajiwara, H1
Hasegawa, K1
Yasuda, M1
Kawana, K1
Suda, K1
Miyake, TM1
Moriya, T1
Yuba, Y1
Morgan, T1
Fukagawa, T1
Wakatsuki, A1
Sugiyama, T1
Pejovic, T1
Nagano, T1
Shimoya, K1
Andoh, M1
Shiki, Y1
Enomoto, T1
Sasaki, T1
Mikami, M1
Shimada, M1
Konishi, I1
Kimura, T1
Post, MD1
Shahzad, MM1
Im, DD1
Yoshida, H1
Omatsu, K1
Ueland, FR1
Kelley, JL1
Karabakhtsian, RG1
Roman, LD1
Seddon, B2
Lucchesi, M1
Buccoliero, AM1
Scoccianti, S1
Guidi, M1
Farina, S1
Fonte, C1
Favre, C1
Genitori, L1
Sardi, I1
Bongiovanni, A1
Monti, M1
Foca, F1
Recine, F1
Riva, N1
Di Iorio, V1
Liverani, C1
De Vita, A1
Miserocchi, G1
Mercatali, L1
Amadori, D1
Ibrahim, T1
Kusaba, H1
Kumagai, H1
Inadomi, K1
Harimaya, K1
Takayoshi, K1
Arita, S1
Ariyama, H1
Akashi, K1
Baba, E1
Watanabe, T1
Kurata, T1
Sano, K1
Suzuki, S1
Kaneko, T1
Motobayashi, M1
Shigemura, T1
Sumi, T1
Koike, K1
Nakazawa, Y1
Fresneau, B1
Hackshaw, A1
Paulussen, M3
Anderson, JR2
Dirksen, U1
Lewis, I1
van den Berg, H1
Gaspar, N1
Boddy, AV6
Wheatley, K1
Pignon, JP1
De Vathaire, F3
Le Deley, MC1
Le Teuff, G1
Moon, JY1
Baek, SW1
Ryu, H1
Choi, YS1
Song, IC1
Yun, HJ1
Jo, DY1
Kim, S1
Stoeckle, E1
Michot, A1
Rigal, L1
Babre, F1
Sargos, P1
Henriques de Figueiredo, B1
Brouste, V1
Le Loarer, F1
Kind, M2
Ouahbi, H1
Akasbi, Y1
Oualla, K1
Amara, B1
Chatar, A1
Tizniti, S1
Fatemi, H1
Lemrabet, FZ1
Arifi, S1
Mellas, N1
Thornton, K2
Pesce, CE1
Choti, MA1
Hosokawa, S1
Takebayashi, S1
Mineta, H1
Suzuki, K1
Baba, S1
Howell, JE1
Hatfield Seung, A1
Nesbit, SA1
Sweiss, KI1
Beri, R1
Shord, SS1
Wei, ZG1
Tang, LF1
Chen, ZM1
Tang, HF1
Li, MJ1
Fayette, J2
Thyss, A3
Guillemet, C2
Rios, M1
Rolland, F1
Fargeot, P3
Bay, JO2
Mathoulin-Pelissier, S2
Bui-Nguyen, B3
Kawamoto, H1
Saito, I1
Yoshimura, K1
Ridola, V2
Fawaz, O2
Aubier, F1
Bergeron, C4
Pichon, F2
Gentet, JC2
Schmitt, C2
Dufour, C1
Oberlin, O4
Dantonello, TM1
Int-Veen, C2
Harms, D3
Leuschner, I2
Schmidt, BF2
Herbst, M2
Juergens, H1
Scheel-Walter, HG1
Bielack, SS1
Klingebiel, T5
Dickerhoff, R1
Kirsch, S1
Brecht, I1
Schmelzle, R1
Greulich, M1
Gadner, H3
Greiner, J1
Marky, I2
Treuner, J6
Koscielniak, E6
Fra, J4
Martín, J7
Cruz, J1
Casado, A5
Poveda, A4
Martínez-Trufero, J3
Balañá, C3
Gómez, MA1
Rubio-Viqueira, B1
Rubió, J1
Andrés, R1
Sevilla, I1
de la Cruz, JJ1
Buesa, JM5
Benz, MR1
Czernin, J1
Allen-Auerbach, MS1
Tap, WD2
Elashoff, D1
Chow, K1
Evilevitch, V1
Phelps, ME1
Weber, WA1
MacDermed, DM1
Miller, LL1
Peabody, TD2
Simon, MA1
Luu, HH1
Haydon, RC1
Montag, AG2
Undevia, SD1
Connell, PP1
Stroppa, E1
Di Comite, G1
Mussi, C1
Barbato, A1
Coriat, R1
Camps, S1
Ropert, S1
Billemont, B1
Leconte, M1
Larousserie, F1
Anract, P1
Alexandre, J1
Goldwasser, F1
Lashkari, A1
Chow, WA1
Valdes, F1
Leong, L1
Phan, V1
Twardowski, P1
Kapoor, N1
Molina, A1
Al-Kadhimi, Z1
Frankel, P1
Somlo, G1
Stahl, R1
Wang, T1
Santl, M2
Reiser, MF1
Peeters, J1
Meitert, J1
Beck, JD5
Yuen, C1
Ho, AD4
Patel, S2
Rey, A4
Niaudet, P2
Defachelles, AS1
Rubie, H1
Munzer, M1
Plantaz, D1
Deville, A1
Minard, V1
Corradini, N1
Leverger, G1
Sleijfer, S2
Ouali, M2
van Glabbeke, M9
Rodenhuis, S4
Scharrenbroich, I1
Dietrich, S3
Jung, S1
Shimizu, H1
Tanibuchi, A1
Akaishi, M1
Mikami, S1
Mukai, M1
Takahashi, T1
Yozu, R1
Postovsky, S1
Vlodavsky, E1
Kuten, A2
Shendler, Y1
Doweck, I1
Ben Arush, MW2
Tajino, T1
Kikuchi, S1
Yamada, H1
Takeda, A1
Konno, S1
Jordan, K1
Wolf, HH1
Voigt, W1
Kegel, T1
Mueller, LP1
Behlendorf, T1
Sippel, C1
Arnold, D1
Dimitrakopoulou-Strauss, A4
Strauss, LG4
Vasamiliette, J2
Haberkorn, U3
Stroebel, P1
Schem, BC1
Wendtner, CM5
Ploner, F1
Baur-Melnyk, A1
Barnoud, R1
Collardeau-Frachon, S1
de la Roche, E1
Vasiljevic, A1
Thomson, V1
Ranchère, D2
Devouassoux, G1
Devouassoux-Shisheboran, M1
El Weshi, A1
Allam, A1
Ajarim, D1
Al Dayel, F1
Pant, R1
Bazarbashi, S1
Memon, M1
Liu, YL1
Tsai, SH1
Chang, FW1
Yu, MH1
Matuschek, C1
Mueller, AC1
Weinmann, M1
Budach, W2
Meazza, C2
Luksch, R1
Podda, M1
Favini, F1
Cefalo, G2
Massimino, M2
Anderson, P1
Hirota, M1
Ishikawa, N1
Oi, M1
Tedoriya, T1
Fehr, M1
von Moos, R1
Furrer, M1
Cathomas, R1
Bruland, ØS1
Eriksson, M1
Turesson, I2
Folin, A1
Hall, KS2
Fakhrai, N1
Ebm, C1
Kostler, WJ3
Jantsch, M1
Abdolvahab, F1
Dominkus, M1
Pokrajac, B1
Kauer-Dorner, D1
Zielinski, CC3
Brodowicz, T4
Olmos, D1
Al-Muderis, O1
Scurr, M1
De Pas, T5
Rosati, G1
Spitaleri, G1
Boni, C2
Tucci, A3
Frustaci, S8
Scalamogna, R1
Radice, D1
Boselli, S1
Toffalorio, F1
Catania, C2
Noberasco, C1
Delmonte, A1
Vecchio, F1
de Braud, F4
Bonichon, F2
Lotz, JP1
Jimenez, M1
San Miguel, I1
San Julián, M1
Cambeiro, M1
Fernández Sanmamed, M1
Vázquez-García, B1
Pagola, M1
Gaztañaga, M1
Martín-Algarra, S1
Martinez-Monge, R1
Reed, D1
Altiok, S1
Mashhadi, MA1
Sanadgol, H1
Keikhaei, M1
Chang, MH1
Baek, KK1
Han, B1
Lim, T1
Park, JO1
Berrada, N1
Domont, J1
Cioffi, A1
Boulet, B1
Terrier, P1
Bonvalot, S2
Trichot, C1
Lokiec, F2
Sueta, A1
Yamamoto, Y1
Inoue, K1
Kuriwaki, K1
Iwase, H1
Rosenberg, P1
Carinelli, S1
Peiretti, M1
Zanagnolo, V1
Maggioni, A1
Brandts, CH1
Schulz, C1
Willich, N2
Steffen, B1
Hardes, J1
Gosheger, G1
Winkelmann, W2
Serve, H1
Heinecke, A1
Berdel, WE1
Thomas, M1
Movva, S1
Verschraegen, C1
Wang, K1
Geng, Y1
Shao, Y1
Yin, Y1
Ogura, K1
Goto, T2
Imanishi, J1
Shinoda, Y1
Tsuda, Y1
Kobayashi, H2
Akiyama, T1
Hirata, M1
Yamamoto, A1
Kawano, H1
Mullen, JT2
Kobayashi, W1
Wang, JJ1
Harmon, DC4
Choy, E2
Hornicek, FJ3
Rosenberg, AE1
Chen, YL2
Spiro, IJ3
DeLaney, TF4
Tschoep-Lechner, K1
Drexler, I1
Hammer, D1
Neumann, D1
Pohla, H1
Sutter, G1
Noessner, E1
Mercuri, M1
Mariani, L1
Valagussa, P1
Longhi, A1
Sanchez de Toledo, J2
Martelli, H1
Jenney, ME1
Scopinaro, M1
Merks, JH1
Bouvet, N1
Ellershaw, C1
Spooner, D5
Stevens, MC2
Burnside, N1
MacGowan, SW1
Azzarelli, A6
Hoekstra, HJ1
Leahy, M1
Van Coevorden, F2
Bramwell, VH5
Look Hong, NJ1
Yoon, SS1
Nielsen, GP1
Szymonifka, J1
Yeap, BY1
Ferraro, A1
Majò, J1
Pautier, P1
Floquet, A1
Gladieff, L1
Selle, F1
Weber, B1
Largillier, R1
Opinel, P1
Reynaud-Bougnoux, A1
Kerbrat, P3
Netter-Pinon, G1
Pinto, N1
Duvillard, P1
Haie-Meder, C1
Lhommé, C1
Latz, S1
Ellinger, J1
Goltz, D1
Marx, C1
Müller, SC1
Fechner, G1
Provenzano, S1
Bronte, G1
Leto, G1
Fulfaro, F1
Krych, M2
Baumert, J3
Baur, A1
Serrone, L3
Nardoni, C2
Gelibter, A1
Felici, A1
Cognetti, F3
Blot, E1
Decaudin, D1
Veyradier, A1
Bardier, A1
Zagame, OL1
Pouillart, P1
Felgenhauer, J2
Park, J1
Kreissman, S1
Thomson, B1
Douglas, J1
Rowley, SD1
Gooley, T1
Sanders, JE1
Pendergrass, TW1
Petrioli, R1
Coratti, A1
Correale, P1
D'Aniello, C1
Grimaldi, L1
Tanzini, G1
Civitelli, S1
Marsili, S1
Messinese, S1
Marzocca, G1
Pirtoli, L1
Francini, G1
van Oosterom, AT10
Mouridsen, HT6
Nielsen, OS5
Dombernowsky, P7
Krzemieniecki, K1
Svancarova, L2
Chen, LK1
Xu, GC2
Teng, XY1
Liang, Y1
Liu, JL1
Zhou, XM1
Huang, YH1
Wen, XP1
Hu, L1
Selch, M4
Dorey, F2
Eckardt, J3
Toma, S6
Romanini, A2
Massidda, B1
Labianca, R1
Massacesi, C1
Antimi, M2
Biasco, G1
Aglietta, M1
Apice, G2
Grier, HE3
Krailo, MD1
Tarbell, NJ1
Link, MP1
Fryer, CJ1
Pritchard, DJ2
Gebhardt, MC2
Dickman, PS1
Perlman, EJ1
Meyers, PA1
Donaldson, SS2
Moore, S1
Rausen, AR1
Vietti, TJ1
Miser, JS5
Wall, N1
Starkhammar, H1
Westermann, AM1
Wiedemann, GJ5
Jager, E1
Jager, D1
Katschinski, DM3
Knuth, A1
Vörde Sive Vörding, PZ1
Van Dijk, JD1
Finet, J1
Neumann, A1
Longo, W1
Bakhshandeh, A1
Tiggelaar, CL1
Gillis, W1
Bailey, H1
Peters, SO1
Robins, HI4
Patel, Y1
Mitchell, CD1
Hitchcock, RJ1
O'Sullivan, B1
Bell, RS1
Suit, HD1
Mankin, HJ1
Rosenberg, AL1
Rosenthal, DI1
Miryousefi, F1
Ancukiewicz, M1
Ogose, A1
Yazawa, Y1
Ueda, T1
Hotta, T1
Morita, T1
Vadhan-Raj, S3
Bueso-Ramos, C1
Folloder, J1
Papadopolous, N3
Burgess, A1
Broemeling, LD1
Broxmeyer, HE1
Lissoni, AA1
Fei, F1
Rossi, R4
Fruscio, R1
Villa, A1
Zani, G1
Schlemmer, M4
Bidoli, E1
La Mura, N1
Berretta, M1
Boz, G1
Gherlinzoni, F2
Mace, JR1
Keohan, ML1
Bernardy, H1
Junge, K1
Niebch, G1
Romeis, P1
Thoma, A1
Wagner, T4
Mueller, U1
Demetri, G1
Stöhr, W4
Bielack, S4
Ohata, N1
Morimoto, Y1
Tanaka, M1
Inoue, H1
McCune, JS1
Friedman, DL1
Schuetze, S1
Blough, D1
Magbulos, M1
Fiegl, M1
Fahn, W2
Buesa, J4
Quintana, MJ1
Kosaku, H1
Hozumi, T1
Kondo, T1
Van Winkle, P1
Angiolillo, A1
Krailo, M1
Cheung, YK1
Anderson, B1
Davenport, V1
Reaman, G1
Cairo, MS2
Grobmyer, SR1
Maki, RG1
Mazumdar, M1
Riedel, E1
Brennan, MF1
Singer, S1
Worden, FP2
Sondak, VK1
Leu, KM2
McGinn, CJ1
Yalcin, B2
Pamir, A2
Buyukcelik, A1
Utkan, G1
Akbulut, H2
Demirkazik, A2
Icli, F2
Rapidis, AD1
Gakiopoulou, H1
Stavrianos, SD1
Vilos, GA1
Faratzis, G1
Douzinas, EE1
Givalos, N1
Patsouris, E1
Scagnellato, A1
Prete, A1
D'Angelo, P1
Di Cataldo, A1
Carli, M2
Pappo, AS4
Devidas, M1
Jenkins, J2
Rao, B1
Marcus, R1
Thomas, P1
Gebhardt, M1
Pratt, C1
Dusenbery, KE1
Potish, RA1
Argenta, PA1
Judson, PL1
Umeda, T5
Wada, T1
Ihara, K1
Isu, K1
Sugiura, H1
Yabe, H1
Tsugane, S1
Beppu, Y1
Siehl, JM1
Thiel, E1
Schmittel, A1
Hütter, G1
Deckert, PM1
Szelényi, H1
Keilholz, U1
Uchida, A1
Tabata, M1
Kiura, K1
Tanimoto, Y1
Kanehiro, A1
Aoe, M1
Ohohara, N1
Ueoka, H1
Tanimoto, M1
Piura, B1
Rabinovich, A1
Terrier-Lacombe, MJ1
van Unnik, A1
Quintana, E1
Fan, SK1
Wang, YG1
Jeon, IS1
Lee, SM1
Pisters, PW3
Kraybill, WG1
Harris, J1
Ettinger, DS1
Blum, RH3
Letson, GD1
Eisenberg, B1
Ferringer, T1
Banks, PM1
Metcalf, JS1
Leyvraz, S6
Zweifel, M1
Jundt, G1
Lissoni, A2
Cerny, T6
Sessa, C4
Fey, M1
Dietrich, D2
Honegger, HP2
Rassnick, KM2
Moore, AS1
Northrup, NC1
Kristal, O2
Beaulieu, BB1
Lewis, LD1
Page, RL2
Rodriguez, CO1
Khanna, C1
Rosenberg, MP1
Chaffin, K1
Navid, F1
Santana, VM1
Billups, CA1
Merchant, TE1
Furman, WL2
Cain, AM1
Rao, BN2
Hale, GA1
Jürgens, H6
Kortmann, B1
Reimer, T1
Gerber, B1
Klautke, G1
Losa, R1
Sierra, M1
Goitia, A1
Uña, E1
Nadal, R1
Del Muro, JG1
Gión, M1
Escudero, P3
Esteban, E1
Suppiah, R1
Wood, L1
Elson, P1
Budd, GT3
Christensen, TB1
Blay, J1
Gellermann, J1
Hildebrandt, B1
Ganter, H1
Wlodarczyk, W1
Budach, V2
Felix, R1
Tunn, PU1
Herrmann, R1
Guillou, L2
Christinat, A1
Fey, MF1
Wernli, M1
Pestalozzi, B1
Jiang, L1
Admirand, JH1
Moran, C1
Ford, RJ1
Bueso-Ramos, CE1
Falk, M1
Licht, T1
Straka, C1
Hentrich, M1
Cassier, PA1
Dufresne, A1
Alberti, L1
Kim, KT1
Han, SY1
Park, EH1
Jang, JS1
Roh, MH1
Lee, SW1
Jeong, JS1
Dörr, HG1
Bölling, T1
Sauer, R2
Griffith, KA1
Thomas, DG2
Papadimitriou, CA1
Zorzou, MP1
Markaki, S1
Rodolakis, A1
Voulgaris, Z1
Bozas, G1
Kastritis, E1
Bamias, A1
Gika, D1
Dimopoulos, MA1
Roylance, R1
McTiernan, A1
Sykes, K1
Daniels, S1
Lorigan, P1
Radford, JA2
Van Glabbeke, MM1
Kirkpatrick, A2
Bertoni, F1
Bacci, G1
Rossi, E1
Stefani, M1
Ghiotto, C1
Marino, D1
Crivellari, G1
Monfardini, S3
Williams, D1
Crofton, PM1
Levitt, G1
Tascilar, M1
Loos, WJ1
Seynaeve, C1
Qiu, MZ1
Xu, F1
Wang, SS1
Luo, HY1
Wang, F1
Li, FH1
Sun, XF1
Lin, TY1
Huang, HQ1
Jiang, WQ1
Guan, ZZ1
Xu, RH1
Iagaru, A1
Masamed, R1
Menendez, LR1
Fedenko, A1
Conti, PS1
Chandra, P1
Schmidt, RM1
Madan, P1
Topkara, VK1
Boos, J1
Beske, F1
Hallmen, E1
Dantonello, T1
Kazanowska, B1
Verma, S2
Younus, J1
Stys-Norman, D1
Haynes, AE1
Blackstein, M1
Hosenpud, JR1
Samuels, B1
Hayden, JB1
Hung, AY1
Mansoor, A1
Mundt, AJ2
Undevia, S1
Kshirsagar, MP1
Hamre, MR1
Seeber, S5
Dimitriadis, K1
Schütte, J7
Schmidt, CG3
Stuart-Harris, R3
Harper, PG2
Kaye, SB2
Wiltshaw, E5
Stuart-Harris, RC1
Parsons, CA1
Mooney, CA1
Gowing, NF1
Niederle, N2
Scheulen, ME2
Cremer, M1
Burkert, H1
Utracka-Hutka, B1
Czownicki, Z1
Bierbaum, W1
Bremer, K1
Firusian, N1
Higi, M1
Elias, AD6
Eilber, F1
Forscher, C2
Fu, YS1
Saeter, G3
Talle, K1
Solheim, OP2
Antoine, E1
Spielmann, M1
Le Chevalier, T1
Brain, E1
Toussaint, C1
Janin, N1
Kayitalire, L1
Fontaine, F1
Genin, J1
Palumbo, R5
Ruymann, FB1
Vietti, T1
Gehan, E1
Wiener, E2
Wharam, M2
Newton, WA1
Maurer, H2
Bui, BN2
Chevallier, B3
Krakowski, I2
Peny, AM1
Maugard-Louboutin, C1
Ayash, LJ2
Wheeler, C2
Schwartz, G1
Tepler, I1
Gonin, R1
McCauley, M1
Mazanet, R1
Schnipper, L2
Frei, E1
Tursz, T5
Mouridsen, H4
Steward, W3
Somers, R10
Rankin, E1
Boros, L2
Garrow, GC2
Asbury, RF2
Chang, AY2
Yule, SM3
Wyllie, R2
Price, L2
Pearson, AD5
Idle, JR4
Patsner, B1
Greenberg, S1
Cole, M1
Fields, KK1
Elfenbein, GJ1
Lazarus, HM1
Cooper, BW1
Perkins, JB1
Creger, RJ1
Ballester, OF1
Hiemenz, JH1
Janssen, WE1
Zorsky, PE1
Pocard, M1
Azorin, JF1
Delepine, N1
Delepine, G1
Tremblay, B1
Destable, MD1
d'Oleire, F1
Knop, E1
Eleftheriadis, S2
Bucsky, P1
Feddersen, S1
Klouche, M1
Geisler, J1
Mentzel, M3
Schmucker, P1
Blair, SC1
Raney, B1
Ensign, LG1
Foreman, J1
Khan, F1
Newton, W1
Ortega, J1
Ragab, A1
Lauterburg, BH1
Nguyen, T1
Hartmann, B1
Junker, E1
Küpfer, A3
Arndt, C1
Morgenstern, B1
Wilson, D1
Liedtke, R1
Miser, J2
Stuschke, M1
Kjønniksen, I1
Winderen, M1
Bruland, O1
Fodstad, O1
Hatakeyama, K1
Wakita, H1
Skubitz, KM1
Hamdan, H1
Thompson, RC1
Foladore, S1
Crivellari, D1
Carbone, A1
Sorio, R2
Morassut, S1
Craft, AW1
Edmonson, JH4
Ryan, LM1
Brooks, JS1
Shiraki, M1
Frytak, S1
Parkinson, DR1
Antman, K1
Crowley, J1
Balcerzak, SP3
Rivkin, SE1
Weiss, GR1
Elias, A6
Natale, RB1
Cooper, RM1
Barlogie, B1
Trump, DL1
González-Manzano, R1
Vieitez, JM1
Tangco, E1
Fernandez de Alava, E1
Herranz, P1
Garcia-Foncillas, J1
Hibi, S1
Naya, M1
Takaya, K1
Morimoto, M1
Kataoka, Y1
Todo, S1
Imashuku, S1
Steward, WP5
Clavel, M4
Crowther, D3
Rouesse, J3
Tueni, E2
Gilard, V2
Malet-Martino, MC2
de Forni, M2
Niemeyer, U2
Ader, JC1
Martino, R2
Kitoh, M2
Tatezaki, S2
Satoh, T2
Legha, SS2
Nicaise, C3
Blackledge, G8
Onsrud, M2
Thomas, D7
Sylvester, R3
Weh, HJ2
Agarwal, K1
Zornig, C2
Schwarz, R2
Dietel, M2
Hossfeld, DK2
Dalley, D1
Bell, DR1
Levi, J1
Simes, RJ1
Kellner, R1
Fissi, S1
Montalto, F1
Metch, B1
Weiss, SA1
Weick, JK1
Fabian, C1
Stephens, RL1
Harstrick, A2
Bokemeyer, C3
Köhne-Wömpner, CH2
Knipp, H1
Anagnou, J1
Wipperman, B1
Neumann, S1
Poliwoda, H2
Pastorino, U2
Bertulli, R1
Zucchinelli, P2
Devizzi, L2
Canavese, G1
Albanese, E1
Cantoni, E1
Barisone, A1
Reggiardo, G1
Rosso, R1
Santi, L2
Bosse, D1
Starck, M1
Panzer, M1
Stiegler, H1
Berger, H2
Sauer, H4
Peter, K2
Edmonson, J1
Ryan, L5
Pelletier, L1
Olivier, JP1
Facchini, T1
Vo Van, ML1
Vantongelen, K1
Michelotti, A1
Giannessi, P1
Bengala, C1
Conte, P1
Ho, PT1
Zimmerman, K1
Wexler, LH1
Blaney, S1
Jarosinski, P2
Weaver-McClure, L1
Izraeli, S1
Balis, FM1
Güllü, I3
Yalçin, S5
Tekuzman, G3
Barişta, I3
Alkiş, N1
Celik, I3
Zengin, N2
Güler, N2
Kars, A3
Baltali, E2
Connelly, EF1
Hui, L1
Pratt, CB3
Bui, NB1
Stöckle, E1
Kantor, G1
Thomas, L1
English, M1
Skinner, R1
Roguin, A1
Higasi, A1
Psikakos, G1
Papanicolaou, A1
Boutis, L1
Goutzioulis, M1
Makedos, G1
Papanicolaou, N1
Hicks, LG1
Zalupski, M2
Santoni, J1
Weill, S1
Tubiana-Hulin, M1
Weiss, AJ1
Lackman, RD1
Womer, RB2
Gutsche, S1
Deeken, M1
Crahé, R1
Weiss, C2
Storer, B1
Tiuliandin, SA1
Liubimova, NV1
Sidorova, NI1
Averinova, SG1
Kashkadaeva, AV1
Romanova, LF1
Shiriaev, SV1
Garin, AM1
Mulkerin, DL1
Touhidi, R1
Baranzelli, MC1
Gourmel, B1
N'Guyen, M1
Deligny, N1
Demaille, MC1
Galligioni, E1
Favaro, D1
Lo Re, G1
Tumolo, S1
Plager, C3
Burgess, MA4
Hays, C1
Bellmunt, J2
Eres, N1
Ribas, A1
Casado, S1
Albanell, J1
Baselga, J1
Long, HJ2
Kvols, LK1
Mann, BS1
Grill, JP1
Franzke, A1
Schöber, C1
Arseniev, L1
Metzner, B1
Link, H1
Kanz, L1
Tesoro-Tess, JD1
Gianni, MC1
Fossati-Bellani, F1
Lombardi, F1
Therasse, P1
Alvegård, TA2
Strander, H2
Klepp, R1
Söderberg, M1
Wist, E1
Raabe, N1
Erlanson, M1
Hannisdal, E1
Palmeri, S1
Gatti, C1
Raffo, P2
Villani, G2
Walter, AW1
Shearer, PD1
Greenwald, CA1
Bowman, LC1
Gajjar, A1
Jenkins, JJ1
Theis, JG2
Chan, HS2
Greenberg, ML2
Malkin, D2
Karaskov, V2
Moncica, I2
Koren, G2
Doyle, J2
Singer, JM1
Hartley, JM1
Brennan, C1
Nicholson, PW1
Souhami, RL1
Pertl, U1
Hess, CF1
Pötter, R1
van Heek-Romanowski, R1
Schött, C1
Spaar, HJ1
Willnow, U1
Tilgner, J1
Dörken, B1
Pronzato, P1
Losardo, P1
Pensa, F1
Tognoni, A1
Lévy, E1
Thirion, P1
Piedbois, P1
Ozişik, Y2
Antón, A2
García del Muro, J2
Simşek, T1
Uner, M1
Trak, B1
Erman, O1
Zorlu, GC1
Kito, M1
Dunst, J1
Ahrens, S1
Rübe, C1
Zoubek, A1
Arranz, F1
Valentí, V1
Menéndez, D1
Bacchi, M1
Bressoud, A1
Hermann, R1
Orlando, L1
Nolè, F1
Munzone, E1
Zampino, MG1
Fazio, N1
Aapro, MS1
Goldhirsch, A1
Leone, L1
Oliva, C1
Monteleone, M1
Colussi, AM1
Dal Canton, O1
Bergnolo, P1
Boglione, A1
Bumma, C1
Arndt, CA1
Nascimento, AG1
Schroeder, G1
Schomberg, PJ1
Neglia, JP1
Sencer, SF1
Silberman, TL1
Moertel, CL1
Tillisch, JK1
Neumaier, C1
Cosso, M1
Bertero, G1
Spadini, N1
Valente, S1
Pastorino, M1
Czyzewski, EA1
Goldman, S1
Nachman, J1
Rubin, C1
Hallahan, DE1
Maugard, C1
Mihura, J1
Gil, B1
Cour-Chabernaud, V1
Schuchardt, U1
Wittekind, C1
Papadopoulos, T1
Grabenbauer, GG1
Fernberg, JO1
Wiklund, T1
Monge, O1
Sawyer, M1
Bramwell, V3
Wiltschke, C1
von Briel, T1
Schaad, R1
Schmitz, SF1
Honegger, P1
Brunner, J1
Huuhtanen, RL1
Wiklund, TA2
Blomqvist, CP2
Böhling, TO1
Virolainen, MJ1
Tribukait, B1
Andersson, LC1
Henze, G1
Morgan, M1
Knietig, R1
Hawkins, D1
Pendergrass, T1
Lindsley, K1
Conrad, EU1
Türker, A1
Altundağ, K1
Uner, A1
Firat, D1
van Hoesel, Q2
Keizer, HJ4
van Oosterom, A4
Krzemienlecki, K1
Oosterhuis, JW2
Daller, RT1
Fenton, JG1
Gerke, P1
Filejski, W1
Steinhoff, J1
Dinçol, D1
Samur, M1
Sencan, O1
Onur, H1
Senler, FC1
Kerbusch, T2
Huitema, AD1
Ouwerkerk, J2
Mathôt, RA1
Schellens, JH2
Beijnen, JH2
Frisch, J1
Bodoky, G1
Szántó, J1
Poller, I1
Rahóty, P1
Eckhardt, S1
Láng, I1
Szendroi, M1
Späth-Schwalbe, E1
Genvresse, I1
Koschuth, A1
Dietzmann, A1
Grunewald, R1
Possinger, K1
Kushner, DM1
Webster, KD1
Belinson, JL1
Rybicki, LA1
Kennedy, AW1
Markman, M1
Gwyther, SJ1
Meric, F1
Milas, M1
Hunt, KK2
Hess, KR1
Hildebrandt, G1
Papadopolous, NE1
Pollock, RE1
Feig, BW2
Bouhour, D1
Dumontet, C2
Philip, T2
Biron, P3
Lejeune, FJ1
Pujol, N1
Liénard, D1
Mosimann, F1
Raffoul, W1
Genton, A1
Landry, M1
Chassot, PG1
Chiolero, R1
Bischof-Delaloye, A1
Mirimanoff, RO1
Bejkos, D1
Leyvraz, PF1
Lopez, AM1
Ketchum, M1
Nichols, H1
Xu, MJ1
Peng, YM1
Dorr, R1
Alberts, DS1
Bonetti, M1
Olmi, P1
Pignatti, G1
Barbieri, E1
Zmerly, H1
Serraino, D1
Bangalore, N1
Bhargava, P2
Hawkins, MJ1
Thall, PF1
Cheng, SC1
Zeuli, M2
Gamucci, T1
Nardi, M1
Gortzak, E1
van Geel, AN1
Ezzat, A1
Wendtner, C2
Falk, MH2
Kurze, V1
Aydemir, U1
Papaldo, P1
Pacetti, U1
Attems, Y1
Hejna, M1
Tomek, S1
Amann, G1
Fiebiger, WC1
Wiltschke, CH1
Krainer, M1
Mathĵt, RA1
Cormier, JN1
Herzog, CE1
Ballo, MT1
Raney, RB2
Zagars, GK1
Peterson, AC1
Porter, M1
Porter, J1
Barr, FG1
Qualman, SJ1
Wiener, ES1
Maurer, HM1
Crist, WM1
Petersen, IA1
Shives, TC1
Mahoney, MR1
Rock, MG1
Haddock, MG1
Sim, FH1
Maples, WJ1
Gunderson, LL1
Foo, ML1
Buckner, JC2
Stafford, SL1
Curigliano, G1
Masci, G1
Pagani, O1
Marrocco, E1
Fazeny-Dörner, B1
Veitl, M1
Wenzel, C1
Zielinski, C1
Muhm, M1
Vogelsang, H1
Marosi, C1
Trent II, JC1
Valero, V1
Ritter, S1
Schröder, HJ1
Mitrou, PS1
Fischer, M1
Mitrou, G1
Röttger, P1
Van Glabekke, M1
Meckenstock, R1
Chauvin, F1
Philip, I1
Brunat-Mentigny, M1
Antman, KH9
Sutton, GP2
Blessing, JA2
Manetta, A1
Homesley, H1
McGuire, W1
Crasnier, F1
Chouini-Lalanne, N1
Vierhout, ME1
Chadha-Ajwani, S1
Wijnen, JA1
Splinter, TA1
Zondervan, PE1
Ras, JH1
Drogendijk, AC1
Virolainen, M1
Elomaa, I1
Sogno, G1
Venturino, A1
Bignami, P1
Bonadonna, G1
Benvenuto, JA1
Ayele, W1
Raber, MN1
Newman, RA1
Weiss, RB2
Pinkerton, CR1
Suarez, A1
McDowell, H1
Comoy, E1
Flamant, F1
Wiedemann, G1
Roszinski, S1
Biersack, A1
Mittermüller, J1
Gerl, A1
Simon, W1
Ortmaier, A1
Denzlinger, C1
Wilmanns, W2
Greifenberg, B1
Soedirman, J1
Eder, JP1
Deary, J1
Weissman, L1
Schryber, S1
Hunt, M1
Critchlow, J1
Shaw, PJ1
Eden, T1
Aisner, J2
Baker, WJ1
Fistel, SJ1
Jones, RV1
Photopulos, G1
Berman, ML1
Homesley, HD1
Prenninger, SW1
Nagele, A1
Boehm, E1
Denecke, H1
Zaidi, SH1
Iqbal, Z1
Mallick, JA1
Zeugin, T1
Brunner, KW1
Zügel, M1
Wingberg, D1
Stewart, W2
Dirix, LY2
Hoffmann, W1
Weidmann, B1
Migeod, F1
Könner, J1
Scheulen, M1
Czeglarski, G1
Sherman, D1
Douglass, EC1
Etcubanas, E1
Goren, MP1
Green, AA1
Hayes, FA1
Horowitz, ME1
Meyer, WH1
Thompson, EI1
Wilimas, JA1
Willemse, PH1
de Vries, EG1
Loprinzi, CL1
Schaid, DJ1
Sulkes, A1
Collins, J1
Boven, E1
Calame, JJ1
Molthoff, CF1
Pinedo, HM3
Loehrer, PJ1
Sledge, GW1
Usakewicz, J1
Hainsworth, JD1
Martelo, OJ1
Omura, G1
Braun, TJ1
Quirt, I1
Warr, D1
Young, V1
Knowling, M1
Eisenhauer, E1
Cantwell, BM2
Harris, AL2
Westbury, G1
Harmer, C1
McKinna, A1
Kinsella, TJ1
Triche, TJ1
Tsokos, M1
Forquer, R1
Wesley, R1
Magrath, I2
Carmichael, J1
Ghani, S1
Mansi, JL1
MacMillan, S1
King, M1
Zamboglou, N1
Fürst, G1
Pape, H1
Bannach, B1
Molls, M1
Schmitt, G1
Cavalli, F1
Verwey, J1
von Oosterom, A1
Hartlapp, JH2
Münch, HJ2
Illiger, HJ2
Wolter, H2
Jensen, JC2
de Kraker, J1
Voûte, PA1
Sandlund, J1
Raynor, A1
Rosenberg, S1
Arasi, V1
Brade, WP1
Herdrich, K1
Varini, M1
Montella, D1
Rosenbaum, C1
Schwen, M1

Clinical Trials (39)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma[NCT03809637]Phase 237 participants (Actual)Interventional2017-01-10Active, not recruiting
An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tiss[NCT00643565]Phase 2154 participants (Actual)Interventional2008-07-29Completed
A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005][NCT00379457]Phase 3600 participants (Anticipated)Interventional2006-06-30Recruiting
Pegylated-liposome Doxorubicin Combined With Ifosfamide As First-line Treatment for Patients With Advanced or Metastatic Soft Tissue Sarcoma[NCT03268772]Phase 240 participants (Actual)Interventional2015-04-01Active, not recruiting
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma[NCT04307277]Phase 3600 participants (Anticipated)Interventional2020-10-09Recruiting
"A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxaz[NCT02808247]Phase 280 participants (Actual)Interventional2017-07-07Terminated (stopped due to Exceed of pre-specified number of failures in the experimental arm)
Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults[NCT00003052]Phase 3340 participants (Anticipated)Interventional1997-07-31Completed
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age[NCT00346164]Phase 3588 participants (Actual)Interventional2007-02-05Completed
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen[NCT00358540]Phase 118 participants (Actual)Interventional2006-06-01Completed
An Evaluation of PET/CT Imaging as a Predictor of Disease Free Survival Following Neo-Adjuvant Chemotherapy for Soft Tissue Sarcoma[NCT00346125]70 participants (Actual)Interventional2006-04-10Completed
A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas[NCT01830153]Phase 241 participants (Actual)Interventional2010-04-30Completed
A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007]Phase 2/Phase 337 participants (Actual)Interventional2016-03-31Completed
A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS)[NCT00796120]Phase 3121 participants (Actual)Interventional2008-11-30Completed
Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma[NCT00061984]Phase 3455 participants (Actual)Interventional2003-04-30Completed
Trabectedin in Soft Tissue Sarcomas. A Retrospective Observational Analysis (TrObs)[NCT02793050]510 participants (Actual)Observational2016-06-15Completed
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.[NCT03375437]376 participants (Actual)Interventional2018-02-15Active, not recruiting
A Phase II Study Evaluating Neo-/Adjuvant EIA Chemotherapy, Surgical Resection and Radiotherapy in High-risk Soft Tissue Sarcoma[NCT01382030]Phase 250 participants (Actual)Interventional2005-06-30Completed
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemother[NCT00699517]Phase 3355 participants (Actual)Interventional2008-06-30Completed
Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy[NCT01710176]Phase 3550 participants (Actual)Interventional2011-06-01Active, not recruiting
A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults[NCT00876031]Phase 3195 participants (Actual)Interventional2009-07-01Completed
The Use of Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Treatment of High-grade Extremity Soft Tissue and Non-metastatic Sarcomas[NCT02812654]Phase 270 participants (Anticipated)Interventional2015-03-31Recruiting
Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405]97 participants (Actual)Interventional2016-10-31Terminated (stopped due to Withdrawal of analysis study Partner.)
First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (FZD10) in Patients With Relapsed or Refractory Non Resectable Synovial Sarcomas[NCT01469975]Phase 120 participants (Actual)Interventional2011-12-31Terminated (stopped due to Too slow accrual.)
Multicentric, Randomized Phase II Trial for the Treatment of Patients With Relapsed Osteosarcoma[NCT02718482]Phase 27 participants (Actual)Interventional2016-04-06Terminated (stopped due to Not adequate enrollment (sample size not possible to reach))
MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood[NCT00002898]Phase 3400 participants (Anticipated)Interventional1995-01-31Completed
RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA[NCT00002641]Phase 3350 participants (Anticipated)Interventional1995-02-28Completed
A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595]Phase 20 participants (Actual)Interventional2009-02-28Withdrawn (stopped due to No patients accrued since study opened)
Prospective Evaluation of the Prognostic Relevance of PCR Positivity in Blood and Bone Marrow in Non-Metastatic Ewings Sarcoma[NCT00339898]414 participants (Actual)Observational2004-03-12Completed
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY AND RADIATION THERAPY IN THE MANAGEMENT OF HIGH-RISK, HIGH-GRADE, SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND BODY WALL[NCT00002791]Phase 20 participants Interventional1997-02-28Completed
Continuous 5 Days Infusion of High Dose Ifosfamide and Adriamycin in Patients With Advanced Sarcoma[NCT00002526]Phase 220 participants (Actual)Interventional1993-01-31Completed
Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma[NCT00003212]Phase 3780 participants (Anticipated)Interventional1998-01-31Completed
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499]Phase 253 participants (Actual)Interventional2010-01-31Completed
Phase II Prospective Study With BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas, After Anthracycline-based Therapy[NCT00406601]Phase 269 participants (Actual)Interventional2006-11-30Completed
Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus[NCT03342300]Phase 2/Phase 30 participants (Actual)Interventional2017-11-06Withdrawn (stopped due to No participants enrolled)
A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma[NCT01755195]Phase 255 participants (Actual)Interventional2013-01-15Active, not recruiting
Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma[NCT00802880]Phase 280 participants (Actual)Interventional2009-03-31Completed
A Phase II Study on Preoperative Administration of Gleevec in Patients With Initially Non-Resectable Gastrointestinal Stromal Tumor[NCT00290485]Phase 250 participants Interventional2005-08-31Recruiting
Breast Sarcomas: A Retrospective Analysis of Clinical Features and Outcomes[NCT04749446]300 participants (Anticipated)Observational2021-04-02Recruiting
Late Effects of Treatment in Survivors of Pediatric Sarcomas[NCT00006515]39 participants (Actual)Observational2000-11-16Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Area Under the Curve at Steady State (AUCss) of Bevacizumab

AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. AUCss is expressed in milligrams times days per milliliter (mg*day/mL). (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase

Interventionmg*day/mL (Mean)
Bevacizumab + Chemotherapy1010

Clearance of Bevacizumab

CL is a quantitative measure of the rate at which a drug substance is removed from the body. CL is expressed in milliliters per day (mL/day). (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase (1 cycle = 3 weeks)

InterventionmL/day (Mean)
Bevacizumab + Chemotherapy167

Duration of Response

Duration of Response was defined as time between first objective response and the occurrence of an EFS event (described in Outcome Measure 1). Objective response was defined in Outcome Measure 3. Median duration of response was estimated using Kaplan-Meier estimates and 95% CI for median was computed using the method of Brookmeyer and Crowley. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years

Interventionmonths (Median)
ChemotherapyNA
Bevacizumab + Chemotherapy17.48

EFS Duration as Per IRC Assessment

EFS was defined as the time between randomization and occurrence of EFS event. EFS events are described in Outcome Measure 1. Median EFS was estimated using Kaplan-Meier estimates and 95% confidence intervals (CI) for median was computed using the method of Brookmeyer and Crowley. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years)

Interventionmonths (Median)
Chemotherapy14.85
Bevacizumab + Chemotherapy20.63

Half-Life of Bevacizumab

Half-life is the time measured for the plasma concentration to decrease by one half. (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase (1 cycle = 3 weeks)

Interventiondays (Mean)
Bevacizumab + Chemotherapy20.8

Overall Survival Duration

Overall survival was defined as the time between randomization and death due to any cause. Participants without an event were censored at the last time they were known to be alive. Median overall survival was estimated using Kaplan-Meier estimates and 95% CI for median was computed using the method of Brookmeyer and Crowley. (NCT00643565)
Timeframe: Screening up to approximately 10.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years)

Interventionmonths (Median)
Chemotherapy24.02
Bevacizumab + Chemotherapy32.79

Percentage of Participants Who Died

(NCT00643565)
Timeframe: Screening up to approximately 10.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years.

Interventionpercentage of participants (Number)
Chemotherapy50
Bevacizumab + Chemotherapy51.4

Percentage of Participants Who Experienced EFS Events Among Participants Who Had Objective Response

EFS events was described in Outcome Measure 1 and Outcome Measure 3. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years

Interventionpercentage of participants (Number)
Chemotherapy40.7
Bevacizumab + Chemotherapy76.5

Percentage of Participants Who Experienced Event-Free Survival (EFS) Events as Per Independent Review Committee (IRC) Assessment

EFS events included tumor progression (IRC assessed), no evidence of response after 3 cycles of induction (derived from IRC assessment), second primary cancer, or death due to any cause. Data for participants who had not experienced an event by the time of clinical cut-off were censored at the date of the last disease assessment prior to the clinical cut-off date. Data for participants who did not have any post-baseline disease assessments were censored at the time of randomization. Tumor progression was defined using Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST v1.0) as at least a 20% increase in the disease measurement, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions, or evidence of clinical progression and unequivocal progression of existing non-target lesions. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years)

Interventionpercentage of participants (Number)
Chemotherapy52.5
Bevacizumab + Chemotherapy68.9

Percentage of Participants With Objective Response Prior to First Local Therapy Assessed by RECIST v1.0 Criteria

Objective response prior to first local therapy (surgery and/or radiotherapy) was defined as complete response (CR) or partial response (PR) determined on two consecutive occasions >/=4 weeks apart. Tumor response was assessed as per IRC using RECIST v1.0. CR was defined as disappearance of all target and non-target lesions. If immunocytology was available, no disease was to be detected by that methodology. PR was defined as at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study entry. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years

Interventionpercentage of participants (Number)
Chemotherapy36.0
Bevacizumab + Chemotherapy54.0

Volume of Distribution of Bevacizumab

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state. (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase (1 cycle = 3 weeks)

InterventionmL (Mean)
Bevacizumab + Chemotherapy2070

Complete or Partial Response Rate

Tumor response by imaging. Complete Response (CR): Complete disappearance of the tumor. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment. Overall Response (OR)=CR+PR. (NCT00346164)
Timeframe: 13 weeks

Interventionpercentage of patients (Number)
Arm D33.1

Event Free Survival Probability Disease Extent

Probability of no relapse, secondary malignancy or death after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years

InterventionProbability (Number)
Non-metastatic0.7758
Metastatic0.1960

Event Free Survival Probability Histologic Grade

Probability of no relapse, secondary malignancy or death after 5 years since enrollment (NCT00346164)
Timeframe: 5 years

InterventionProbability (Number)
Histologic Grade 10.9636
Histologic Grade 20.8505
Histologic Grade 30.6136

Incidence of Distant Metastasis

Percent of patients who had distant metastasis. (NCT00346164)
Timeframe: Up to 10 years

InterventionPercentage of participants (Number)
Non-metastatic10.59
Metastatic60.87
Histologic Grade 10.00
Histologic Grade 25.06
Histologic Grade 323.38

Overall Survival Probability Disease Extent

Probability of survival after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years

InterventionProbability (Number)
Non-metastatic0.8752
Metastatic0.3153

Overall Survival Probability Extent of Resection of the Primary Tumor

Probability of survival after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years

InterventionProbability (Number)
Less Than Total Resection0.5975
Negative Margins0.9353
Positive Margins0.7764

Percent Tumor Necrosis

Percent tumor necrosis by pathology review. (NCT00346164)
Timeframe: 13 weeks

Interventionpercentage of tumor necrosis (Mean)
Arm D59.4

Probability for Event Free Survival.

Probability of no relapse, secondary malignancy or death after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years

InterventionProbability of EFS at 5 years (Number)
Arm A: No Adjuvant Treatment0.8984
Arm B: Low Risk; Adjuvant Radiotherapy0.7647
Arm C: Intermediate & High Risk; Adjuvant Chemoradiotherapy0.6079
Arm D: Intermediate & High Risk; Neoadjuvant Chemoradiotherapy0.4873

Toxicity Rate

Percentage of Arm D patients experiencing grade 4+ adverse events. (NCT00346164)
Timeframe: 13 weeks

Interventionpercentage of participants (Number)
Arm D3.06

Degree of Agreement in Histologic Grade Between Pediatric Oncology Group (POG) and Fédération Nationale Des Centres de Lutte Contre le Cancer (FNCLCC) Pathologic Grading Systems

POG and FNCLCC grades were determined by pathologists based on published standards. A higher grade is associated with a more severe disease. (NCT00346164)
Timeframe: At diagnosis

,,
InterventionParticipants (Count of Participants)
Histologic grade 1 by POGHistologic grade 2 by POGHistologic grade 3 by POG
Histologic Grade 1 by FNCLCC46249
Histologic Grade 2 by FNCLCC869145
Histologic Grade 3 by FNCLCC10240

Degree of Agreement in Histologic Grade Determined by the Enrolling Institution Versus by Central Pathology Reviewers

Histologic grades were determined by the central pathology reviewers and institutional pathologists based on published standards. A higher grade is associated with a more severe disease. (NCT00346164)
Timeframe: At Diagnosis

,,
InterventionParticipants (Number)
Histologic grade 1 by central pathology reviewersHistologic grade 2 by central pathology reviewersHistologic grade 3 by central pathology reviewers
Histologic Grade 1 by Enrolling Institution3843
Histologic Grade 2 by Enrolling Institution55610
Histologic Grade 3 by Enrolling Institution19268

6-month Progression - Free Survival

Percentage of participants survived for 6 months from the start of study treatment without progression of disease. Progression of the disease was associated with increasing symptoms, including pain from new or progressing lesions. Delay in disease progression generally represents a clinical benefit to the participant. (NCT00796120)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Trabectedin66.7
Doxorubicin Plus Ifosfamide78.3

Duration of Response (DOR)

The DOR is defined as the time from date of first documentation of response (CR or PR, whichever comes first) to the date of documented PD or death. PR=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, CR =Disappearance of all non-target lesions. (NCT00796120)
Timeframe: Up to 20 months

Interventiondays (Median)
TrabectedinNA
Doxorubicin Plus IfosfamideNA

Overall Survival

Overall survival defined as time from the date of randomization to the date of death. For participants who were alive at the time of analysis, overall survival was censored at the last contact date. (NCT00796120)
Timeframe: Baseline up to End of Study (an average of 4 years)

Interventionmonths (Median)
Trabectedin46.6
Doxorubicin Plus Ifosfamide33.5

Percentage of Participants With Objective Response

Tumor response was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Partial Response (PR)=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, Complete Response (CR) =Disappearance of all non-target lesions. Percentage of participants with objective tumor response was determined by the number of participants with PR or CR divided by the total number of response-evaluable participants. (NCT00796120)
Timeframe: Every 6 weeks during first 9 months of the study and thereafter every 9 weeks up to 20 months

Interventionpercentage of participants (Number)
Trabectedin5.9
Doxorubicin Plus Ifosfamide27.0

Progression - Free Survival (PFS)

The PFS was assessed as median number of days from the date of randomization until the first documented sign of disease progression (increase in disease; radiographic, clinical, or both) or death due to any cause, whichever occurred earlier. (NCT00796120)
Timeframe: Every 6 weeks from randomization during the first 9 months and thereafter, every 9 weeks up to 20 months

Interventionmonths (Median)
Trabectedin19.6
Doxorubicin Plus Ifosfamide8.3

Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.

InterventionParticipants (Count of Participants)
Cabozantinib53

Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas

Objective response was assessed by the Response Evaluation Criteria in Solid Tumors RECIST) v1.1. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.

Interventionpercentage of particpants (Number)
Cabozantinib11.1

Percentage of Participants With 6 Month Progression Free Survival (PFS)

Progression in participants with soft tissue sarcomas treated with cabozantinib was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions. (NCT01755195)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Cabozantinib49.3

Mean Change From Baseline in Levels of Circulating Hepatocyte Growth Factor (HGF)

Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of HGF. HGF protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1

Interventionpg/mL (Mean)
Baseline to Cycle 1 Day 1Baseline to Cycle 2 Day 1
Cabozantinib-51.3344.8

Mean Change From Baseline in Levels of Circulating Soluble Mesenchymal Epithelial Transition Factor (sMET)

Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble MET (sMET). sMET protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1

Interventionng/mL (Mean)
Baseline to Cycle 1 Day 1Baseline to Cycle 2 Day1
Cabozantinib-6.116.4

Mean Change From Baseline in Levels of Circulating Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR-2)

Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble VEGFR2 (sVEGFR-2). sVEGFR-2 protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1

Interventionng/mL (Mean)
Baseline to Cycle 1 Day 1Baseline to Cycle 2 Day 1
Cabozantinib-1.0-10.9

Mean Change From Baseline in Levels of Circulating Vascular Endothelial Growth Factor A (VEGF-A)

Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of VEGF-A. VEGF-A protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1

Interventionpg/mL (Mean)
Baseline to Cycle 1 Day 1Baseline to Cycle 2 Day 1
Cabozantinib5.632.5

Overall Survival

(NCT00802880)
Timeframe: Until completion of follow-up or patient death (estimated to be 1 year)

Interventionmonths (Median)
Dacarbazine8.09

Rate of Nausea/Emesis (Any Grade)

Approximately 18 weeks (NCT00802880)
Timeframe: Completion of 6 cycles of treatment (18 weeks)

Interventionpercentage of participants (Number)
Dacarbazine22.5

Rate of Neutropenia (Grade 3/4)

"Grade 3 neutropenia = absolute neutrophil count of <1000 - 500/mm^3~Grade 4 neutropenia = absolute neutrophil count of <500/mm^3" (NCT00802880)
Timeframe: Completion of 6 cycles of treatment (18 weeks)

Interventionpercentage of participants (Number)
Dacarbazine7.5

Time to Progression (TTP)

-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Until completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Dacarbazine2.07

Best Anatomical Tumor Response

"Complete response (CR): disappearance of all target lesions, disappearance of all non-target lesions, normalization of tumor level marker~Partial response (PR): at least 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the upper limits of normal~Stable disease (SD): neither sufficient shrinkage in target lesions to qualify for PR nor sufficient increase to qualify for progressive disease taking as references the smallest sum LD since the treatment started, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the normal limits of normal~Progressive disease (PD): at least 20% increase in the sum of the LD of target lesions and/or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions" (NCT00802880)
Timeframe: After completion of 3 cycles

Interventionparticipants (Number)
Complete responsePartial responseStable diseaseProgressive disease
Dacarbazine022230

Comparison of the SUV at up to 3 Tumor Sites

(NCT00802880)
Timeframe: Baseline and after every three cycles of treatment (up to 1 year)

Interventionstandard uptake value (Mean)
BaselineEnd of cycle 3End of cycle 6End of cycle 9End of cycle 12
Dacarbazine7.427.577.76.897.48

Correlate Overall Survival With Best Anatomic Response

(NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Partial responseStable diseaseProgressive disease
Dacarbazine18.1614.777.96

Correlate Overall Survival With Best Metabolic Response

(NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Partial metabolic responseStable metabolic diseaseProgressive metabolic disease
Dacarbazine18.1618.598.75

Correlate the Time to Progression With Best Anatomic Response

-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Partial responseStable diseaseProgressive disease
DacarbazineNA4.141.97

Correlate the Tumor Metabolic Response Rate With the Tumor Anatomic Response Rate

(NCT00802880)
Timeframe: After completion of 3 cycles

,,,
Interventionparticipants (Number)
PRSDPDTotal
Partial Metabolic Response1214
Progressive Metabolic Disease182433
Stable Metabolic Disease010212
Total2202749

Correlate Time to Progression With Best Metabolic Response

-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Partial metabolic responseStable metabolic diseaseProgressive metabolic disease
Dacarbazine3.955.302.07

Overall Disease Control Rate

(NCT00802880)
Timeframe: 12 months

Interventionparticipants (Number)
Complete responsePartial responseStable diseaseProgressive disease
Dacarbazine0051

Overall Tumor Metabolic Response

"Complete metabolic response (CMR)-complete resolution of all metabolically active target and non-target lesions, and no interval development of new lesions.~Partial metabolic response (PMR)~Target lesions: 20% or greater decrease in maximum SUV from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions.~Non-target lesions: decrease in total number of non-target lesions, without complete resolution of metabolically active disease, or unequivocal decrease in degree of FDG activity within >50% of the lesions. No unequivocal new lesions.~Stable metabolic disease (SMD): does not qualify for CMR, PMR, or PMD.~Progressive metabolic disease (PMD):~Unequivocal development of one more new metabolically active lesions~Target lesion: 20% or greater increase in maximum SUV from baseline.~Non-target lesions: unequivocal increase in FDG activity" (NCT00802880)
Timeframe: After completion of 3 cycles

Interventionparticipants (Number)
CMRPMRSMDPMD
Dacarbazine041334

Reviews

73 reviews available for ifosfamide and Sarcoma, Epithelioid

ArticleYear
Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
    Oncology research and treatment, 2022, Volume: 45, Issue:9

    Topics: Doxorubicin; Humans; Ifosfamide; Liposarcoma; Sarcoma; Trabectedin

2022
Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2023, Volume: 40, Issue:1

    Topics: Combined Modality Therapy; Humans; Hyperthermia, Induced; Ifosfamide; Sarcoma; Soft Tissue Neoplasms

2023
Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis.
    Journal of chemotherapy (Florence, Italy), 2021, Volume: 33, Issue:5

    Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem

2021
What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?
    Current opinion in oncology, 2021, 07-01, Volume: 33, Issue:4

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Tri

2021
Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy.
    Current treatment options in oncology, 2018, 10-25, Volume: 19, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D

2018
[Multimodal treatment of sarcomas: standards and new aspects in pharmacological and radio-oncological treatment].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2019, Volume: 90, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; H

2019
Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease.
    Oncology research and treatment, 2014, Volume: 37, Issue:6

    Topics: Antineoplastic Agents; Dioxoles; Doxorubicin; Evidence-Based Medicine; Humans; Ifosfamide; Indazoles

2014
Evaluation of the stability profile of anticancer drugs: A review of Ifosfamide and Mesna regimen for the treatment of metastatic soft tissue sarcoma.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:1

    Topics: Antineoplastic Agents; Drug Stability; Humans; Ifosfamide; Mesna; Sarcoma

2016
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    The Cochrane database of systematic reviews, 2015, Sep-30, Issue:9

    Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamid

2015
First-line treatment in advanced or metastatic disease: one size fits all or adapted to specific histiotypes?
    Current opinion in oncology, 2016, Volume: 28, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials,

2016
Trabectedin for the treatment of soft tissue sarcomas.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:11

    Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials a

2016
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).
    Pediatric blood & cancer, 2017, Volume: 64, Issue:8

    Topics: Alkylating Agents; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Ifosfamide; Male; Random

2017
[Pleural epithelioid sarcoma: about a case and review of the literature].
    The Pan African medical journal, 2016, Volume: 25

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fatal Outcome; Female; Humans; I

2016
Chemotherapeutic management of soft tissue sarcoma.
    The Surgical clinics of North America, 2008, Volume: 88, Issue:3

    Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Chemotherap

2008
Multidisciplinary management of metastatic sarcoma.
    The Surgical clinics of North America, 2008, Volume: 88, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality

2008
Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.
    Drug safety, 2008, Volume: 31, Issue:11

    Topics: Adult; Albumins; Antineoplastic Agents, Alkylating; Bilirubin; Brain Diseases; Cohort Studies; Enzym

2008
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid

2010
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid

2010
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid

2010
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid

2010
Palifosfamide, a bifunctional alkylator for the treatment of sarcomas.
    IDrugs : the investigational drugs journal, 2010, Volume: 13, Issue:1

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinic

2010
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    The Cochrane database of systematic reviews, 2010, Feb-17, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamide; Sarc

2010
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
    Bulletin du cancer, 2010, Volume: 97, Issue:6

    Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Hu

2010
Spontaneous pneumothorax during chemotherapy: a case report.
    Onkologie, 2010, Volume: 33, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drainage; Humans; Ifosfamide; Mal

2010
Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.
    Cancer control : journal of the Moffitt Cancer Center, 2011, Volume: 18, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Doxorubici

2011
Cervical sarcoma botryoides and ovarian Sertoli-Leydig cell tumor: a case report and review of literature.
    Archives of gynecology and obstetrics, 2012, Volume: 285, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; I

2012
Systemic management strategies for metastatic soft tissue sarcoma.
    Drugs, 2011, Nov-12, Volume: 71, Issue:16

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dioxoles; Doxo

2011
Malignant primary cardiac tumours.
    Interactive cardiovascular and thoracic surgery, 2012, Volume: 15, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardiac Surgical Procedures;

2012
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    The Cochrane database of systematic reviews, 2012, Dec-12, Volume: 12

    Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamid

2012
Ifosfamide in the treatment of malignant epithelial ovarian tumors.
    Oncology, 2003, Volume: 65 Suppl 2

    Topics: Antineoplastic Agents, Alkylating; Carcinoma; Female; Humans; Ifosfamide; Ovarian Neoplasms; Sarcoma

2003
Ifosfamide with regional hyperthermia in soft-tissue sarcomas.
    Oncology, 2003, Volume: 65 Suppl 2

    Topics: Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Humans; Hyperthermia, Induced; Ifosfamide

2003
Ifosfamide in the adjuvant therapy of soft tissue sarcomas.
    Oncology, 2003, Volume: 65 Suppl 2

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj

2003
[Soft tissue sarcoma: postoperative chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos

2004
[Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Carboplatin; Cisplatin;

2004
Emerging treatments for soft tissue sarcoma of adults.
    Expert opinion on emerging drugs, 2004, Volume: 9, Issue:2

    Topics: Adult; Antineoplastic Agents; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Ther

2004
On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Abdominal Neoplasms; Antineoplastic Agents; Brachytherapy; Chemotherapy, Adjuvant; Combined Modality

2005
Advances in chemotherapy for patients with extremity soft tissue sarcoma.
    The Orthopedic clinics of North America, 2006, Volume: 37, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Dose-Response Rela

2006
Emerging drugs for the treatment of soft tissue sarcomas.
    Expert opinion on emerging drugs, 2007, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Dacarbazine; Doxorubicin; Gastrointestinal Stromal Tumors; Humans

2007
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
    The oncologist, 2007, Volume: 12, Issue:11

    Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Doxorubicin; Drug Thera

2007
Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
    Cancer treatment reviews, 2008, Volume: 34, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Humans; Ifosfam

2008
Ifosfamide: European perspective.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat

1982
Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.
    Hematology/oncology clinics of North America, 1995, Volume: 9, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini

1995
Preoperative therapy for soft tissue sarcoma.
    Hematology/oncology clinics of North America, 1995, Volume: 9, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials a

1995
New drugs for the treatment of sarcomas.
    Hematology/oncology clinics of North America, 1995, Volume: 9, Issue:4

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, A

1995
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
    Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; L

1995
[Chemotherapy for soft tissue sarcoma--current concepts and review].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Humans; Ifosfam

1993
Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Acetylcysteine; Bone Neoplasms; Fluid Therapy; Humans; Ifosfamide; Mesna; Randomized Controlled Tria

1993
Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase

1993
Ifosfamide in the treatment of soft tissue sarcomas.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials,

1996
High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C

1996
Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto

1996
[Locally developed sarcoma of the thoracic wall].
    Bulletin du cancer, 1996, Volume: 83, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Back; Chemotherapy, Adjuvant; Combined Modality Ther

1996
Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations.
    American journal of clinical oncology, 1997, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Doxorubicin; Dr

1997
Problems and controversies in the management of childhood sarcomas.
    British medical bulletin, 1996, Volume: 52, Issue:4

    Topics: Amputation, Surgical; Antineoplastic Agents; Child; Child, Preschool; Doxorubicin; Humans; Ifosfamid

1996
[Adjuvant chemotherapy of soft tissue sarcoma].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 1997, Volume: 1, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Fo

1997
Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.
    Acta orthopaedica Scandinavica. Supplementum, 1999, Volume: 285

    Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic;

1999
The treatment of distant metastases in soft tissue sarcoma.
    Seminars in radiation oncology, 1999, Volume: 9, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality

1999
Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Dacarbazine; Doxorubicin; Hum

2001
[High-dose chemotherapy in soft tissue sarcomas of adults].
    Bulletin du cancer, 2001, Volume: 88, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as

2001
Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.
    Cancer, 2001, Sep-15, Volume: 92, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Combined Mo

2001
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
    Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Clin

2001
Current trials and new aspects in soft tissue sarcoma of adults.
    Cancer chemotherapy and pharmacology, 2002, Volume: 49 Suppl 1

    Topics: Adult; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Europe;

2002
Primary soft tissue sarcoma of the breast.
    Current treatment options in oncology, 2001, Volume: 2, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Doxorub

2001
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Europe; Humans; Ifosfamide; Sarcoma;

1992
The clinical management of soft tissue sarcomas.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Humans; Ifosfam

1992
Chemotherapy of advanced sarcomas of bone and soft tissue.
    Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Dacarbazin

1992
Gynecologic Oncology Group studies with ifosfamide.
    Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 12

    Topics: Adenocarcinoma; Carcinoma; Clinical Trials, Phase II as Topic; Endometrial Neoplasms; Female; Genita

1992
Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Humans; Ifosfamide; Sarcoma

1992
Megatherapy for soft tissue sarcomas. EBMT experience.
    Bone marrow transplantation, 1991, Volume: 7 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Dacti

1991
Ifosfamide in paediatric oncology: tried but not tested?
    Lancet (London, England), 1990, Apr-28, Volume: 335, Issue:8696

    Topics: Child; Cyclophosphamide; Evaluation Studies as Topic; Humans; Ifosfamide; Neoplasms; Prognosis; Sarc

1990
The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review.
    Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Osteosarcoma; Sarcoma; Sarcoma,

1990
The role of ifosfamide in the treatment of sarcomas.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Osteosarcoma; Sarcoma; Sa

1989
Chemotherapy of advanced soft-tissue sarcomas.
    Seminars in surgical oncology, 1988, Volume: 4, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Dru

1988
Ifosfamide.
    Journal of the National Cancer Institute, 1988, Jun-15, Volume: 80, Issue:8

    Topics: Breast Neoplasms; Drug Evaluation, Preclinical; Female; Humans; Ifosfamide; Lung Neoplasms; Lymphoma

1988
The treatment of soft tissue sarcomas with focus on chemotherapy: a review.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1986, Volume: 5, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy;

1986
Ifosfamide--pharmacology, safety and therapeutic potential.
    Cancer treatment reviews, 1985, Volume: 12, Issue:1

    Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu

1985

Trials

187 trials available for ifosfamide and Sarcoma, Epithelioid

ArticleYear
Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial.
    ESMO open, 2021, Volume: 6, Issue:5

    Topics: Cisplatin; Humans; Ifosfamide; Pemetrexed; Sarcoma; Soft Tissue Neoplasms

2021
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
    Cancer, 2022, Jan-01, Volume: 128, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Humans; Ifosfamide; N

2022
Metastatic Rhabdomyosarcoma: Results of the European
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 11-10, Volume: 40, Issue:32

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free

2022
Metastatic Rhabdomyosarcoma: Results of the European
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 11-10, Volume: 40, Issue:32

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free

2022
Metastatic Rhabdomyosarcoma: Results of the European
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 11-10, Volume: 40, Issue:32

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free

2022
Metastatic Rhabdomyosarcoma: Results of the European
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 11-10, Volume: 40, Issue:32

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free

2022
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306.
    British journal of cancer, 2022, Volume: 127, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Febrile Neutr

2022
Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 12-15, Volume: 28, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Neoplasms, Second P

2022
Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.
    BMC cancer, 2020, Jul-31, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Doxorubicin; Hum

2020
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.
    JAMA oncology, 2021, Feb-01, Volume: 7, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deox

2021
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 152

    Topics: Adult; Aged; Female; Humans; Ifosfamide; Indoles; Male; Medical Futility; Middle Aged; Neoplasm Stag

2021
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
    Acta oncologica (Stockholm, Sweden), 2017, Volume: 56, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Female; Follow-U

2017
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
    JAMA oncology, 2018, Apr-01, Volume: 4, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy;

2018
Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
    Investigational new drugs, 2018, Volume: 36, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fema

2018
Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity.
    American journal of clinical oncology, 2019, Volume: 42, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Chemoradiotherapy; Doxorubicin; Fe

2019
Long-term renal function and hypertension in adult survivors of childhood sarcoma: Single center experience.
    Pediatric hematology and oncology, 2018, Volume: 35, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Body Mass Index; Child; Child, Preschool; Cros

2018
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 109

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dox

2019
Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 112

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined

2019
Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.
    BMC cancer, 2013, Mar-16, Volume: 13

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Dose-

2013
Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Cell Prol

2014
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E

2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E

2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E

2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E

2013
Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:4

    Topics: Aged; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Feasibility Studies; Humans; Ifosfamid

2014
Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively.
    American journal of clinical oncology, 2016, Volume: 39, Issue:2

    Topics: Administration, Inhalation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2016
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:6

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Adm

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.
    BMC cancer, 2014, May-20, Volume: 14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe

2014
A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; D

2014
Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial.
    Anticancer research, 2015, Volume: 35, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Dru

2015
Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304).
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Dr

2015
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Cisplatin; Disease-Free Survival; Double-Blind Metho

2015
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine;

2015
Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Fiv
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy;

2015
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
    Investigational new drugs, 2009, Volume: 27, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship

2009
Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Extremiti

2009
Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-20, Volume: 27, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined

2009
Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-10, Volume: 27, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dise

2009
Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas.
    Investigational new drugs, 2010, Volume: 28, Issue:6

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; H

2010
Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration S

2010
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
    Anticancer research, 2009, Volume: 29, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality

2009
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2009, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com

2009
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2009, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com

2009
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2009, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com

2009
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2009, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com

2009
Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study.
    Bone marrow transplantation, 2010, Volume: 45, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Hemat

2010
Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis.
    European journal of nuclear medicine and molecular imaging, 2010, Volume: 37, Issue:8

    Topics: Discriminant Analysis; Doxorubicin; Drug Therapy, Combination; Fluorodeoxyglucose F18; Follow-Up Stu

2010
Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Volume: 51, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Discriminant Analysis; Doxorubicin; Etoposide; Feasi

2010
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.
    The Lancet. Oncology, 2010, Volume: 11, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy;

2010
Intensified adjuvant IFADIC chemotherapy in combination with radiotherapy versus radiotherapy alone for soft tissue sarcoma: long-term follow-up of a prospective randomized feasibility trial.
    Wiener klinische Wochenschrift, 2010, Volume: 122, Issue:21-22

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Doxorubi

2010
Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.
    Chemotherapy, 2011, Volume: 57, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu

2011
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modal

2012
Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sc

2012
Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemoradiotherapy, Adjuvant; D

2012
A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma.
    BMC cancer, 2011, Dec-07, Volume: 11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali

2011
Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas.
    Cancer, 2012, Aug-01, Volume: 118, Issue:15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva

2012
Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-10, Volume: 30, Issue:8

    Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas

2012
Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatr
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-10, Volume: 30, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Dactinomycin;

2012
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dox

2012
Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemothe

2013
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4

    Topics: Adult; Aged; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Do

2013
Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jul-15, Volume: 20, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Et

2002
Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma.
    American journal of clinical oncology, 2002, Volume: 25, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2002
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:18

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Disease Progression; Dose-Response Relationship, Dru

2002
[Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
    Ai zheng = Aizheng = Chinese journal of cancer, 2002, Volume: 21, Issue:8

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Fem

2002
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
    The New England journal of medicine, 2003, Feb-20, Volume: 348, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp

2003
A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma.
    Oncology, 2003, Volume: 64, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Th

2003
Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.
    International journal of radiation oncology, biology, physics, 2003, Jul-15, Volume: 56, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Dox

2003
Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-15, Volume: 21, Issue:16

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies

2003
Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-01, Volume: 9, Issue:16 Pt 1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Cross-Over Studies; Female; Hu

2003
Late effects surveillance system for sarcoma patients.
    Pediatric blood & cancer, 2004, Volume: 42, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Cisplatin; Doxorubicin; Feasibili

2004
Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Cancer, 2004, Apr-01, Volume: 100, Issue:7

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined

2004
Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2004, Volume: 20, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Th

2004
Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
    Pediatric blood & cancer, 2005, Volume: 44, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch

2005
Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe

2004
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-01, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Ant

2005
High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
    Experimental oncology, 2004, Volume: 26, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Disease-Free Survival;

2004
The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.
    Cancer, 2005, Apr-15, Volume: 103, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dactinom

2005
Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-20, Volume: 23, Issue:18

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Doxoru

2005
Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas.
    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2005, Volume: 10, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female;

2005
Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study.
    Cancer, 2005, Aug-01, Volume: 104, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Disease Progression; Drug

2005
Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jul-01, Volume: 23, Issue:19

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphami

2005
Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-01, Volume: 24, Issue:4

    Topics: Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj

2006
Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-01, Volume: 24, Issue:4

    Topics: Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj

2006
Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-01, Volume: 24, Issue:4

    Topics: Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj

2006
Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-01, Volume: 24, Issue:4

    Topics: Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj

2006
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Femal

2006
Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas.
    American journal of veterinary research, 2006, Volume: 67, Issue:3

    Topics: Animals; Antineoplastic Agents, Alkylating; Area Under Curve; Cat Diseases; Cats; Dose-Response Rela

2006
Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas.
    American journal of veterinary research, 2006, Volume: 67, Issue:3

    Topics: Animals; Antineoplastic Agents, Alkylating; Cat Diseases; Cats; Drug Administration Schedule; Female

2006
Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Cancer, 2006, Apr-15, Volume: 106, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined M

2006
Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2006, Volume: 182, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Respons

2006
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2

    Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve;

2007
Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
    Investigational new drugs, 2006, Volume: 24, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doce

2006
Full-dose ifosfamide can be safely administered to outpatients.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:2

    Topics: Adolescent; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool

2008
Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:14

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship,

2006
Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry.
    Cancer, 2006, Sep-15, Volume: 107, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Temperature; Chemotherapy, Adjuvant; Combined M

2006
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
    British journal of cancer, 2006, Nov-20, Volume: 95, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship,

2006
Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
    Oncology, 2006, Volume: 71, Issue:1-2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etopo

2006
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
    Cancer, 2007, Jun-01, Volume: 109, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Breath Tests; Cytochrome P-450 CYP3A; Cytochrom

2007
Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2007, Volume: 19, Issue:8

    Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression;

2007
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-20, Volume: 25, Issue:21

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dose-Respon

2007
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphami

2008
Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography.
    Onkologie, 2008, Volume: 31, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; Fluorodeoxygl

2008
Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.
    Cancer, 2008, Volume: 112, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose Fractio

2008
Ifosfamide: European perspective.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat

1982
[Preliminary evaluation of the effectiveness of holoxan in the treatment of malignant soft tissue and bone neoplasms].
    Nowotwory, 1981, Volume: 31, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Clinical Trials a

1981
[Chemotherapy in advanced sarcomas (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1981, Sep-11, Volume: 106, Issue:37

    Topics: Cisplatin; Doxorubicin; Drug Therapy, Combination; Humans; Ifosfamide; Lung Neoplasms; Sarcoma; Vinc

1981
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Dacarbazine; Doxorubici

1995
Feasibility and compliance of epirubicin plus ambulatory continuous infusion ifosfamide at escalating doses in advanced soft tissue sarcomas: a phase I study.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Feasibility Studies; Humans; Ifosfamide;

1995
Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
    Journal of pediatric hematology/oncology, 1995, Volume: 17, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Dact

1995
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:10

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Double-Blind Met

1995
Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Bone marrow transplantation, 1995, Volume: 15, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Digesti

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Phase I study of escalating doses of paclitaxel (Taxol) with fixed doses of ifosfamide, carboplatin, and etoposide.
    Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinom

1995
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl

1995
Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas.
    American journal of clinical oncology, 1994, Volume: 17, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Gastrointestinal Neo

1994
Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
    The American journal of pediatric hematology/oncology, 1994, Volume: 16, Issue:4

    Topics: Acute Kidney Injury; Adolescent; Adult; Chemotherapy, Adjuvant; Child; Child, Preschool; Creatinine;

1994
[Value of neoadjuvant radiochemotherapy in undifferentiated soft tissue sarcomas].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1994, Volume: 170, Issue:8

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemothe

1994
Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
    Cancer, 1993, Nov-15, Volume: 72, Issue:10

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols;

1993
Epirubicin and ifosfamide in advanced soft tissue sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Feasibility Stu

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1993
Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study.
    American journal of clinical oncology, 1993, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxo

1993
Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Chi-Square Distribution; Cyclophosphamide; Female; Humans; Ifosfamide; Leuk

1993
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administr

1993
Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Ch

1993
Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cispl

1993
Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration S

1993
Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study.
    Cancer investigation, 1993, Volume: 11, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubici

1993
Chemotherapy administration and data collection in an EORTC collaborative group--can we trust the results?
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Data Collection; Doxorubicin; Granulocyte-Mac

1993
Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas.
    American journal of clinical oncology, 1996, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response

1996
High-dose ifosfamide in the treatment of advanced soft tissue sarcomas.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 7

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Female; Humans; If

1996
Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:7

    Topics: Acute Disease; Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Chronic Disea

1996
GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial. A Southwest Oncology Group study.
    Cancer investigation, 1996, Volume: 14, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; Doxorubicin; Granulocyte-M

1996
Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.
    Anti-cancer drugs, 1996, Volume: 7, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Chromatography, High Pressur

1996
Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Th

1996
[High-dose ifosfamide in the treatment of patients with soft tissue sarcoma].
    Voprosy onkologii, 1996, Volume: 42, Issue:6

    Topics: Adult; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Humans; Ifosfamide;

1996
Optimization of chemotherapy administration for clinical 41.8 degrees C whole body hyperthermia.
    Cancer letters, 1997, May-19, Volume: 115, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Temperature; Breast Neoplasms; Carboplatin; Car

1997
[High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
    Bulletin du cancer, 1997, Volume: 84, Issue:2

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Clonazepam; Dose-Response Relations

1997
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dose-Response Relationsh

1997
Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:7

    Topics: Adult; Antineoplastic Agents; Cisplatin; Doxorubicin; Drug Synergism; Granulocyte-Macrophage Colony-

1997
A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas.
    Cancer, 1997, Oct-01, Volume: 80, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Granu

1997
Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th

1997
Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Granulocyte Co

1997
A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas.
    Medical and pediatric oncology, 1998, Volume: 30, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Child, Pr

1998
Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin.
    International journal of clinical pharmacology and therapeutics, 1998, Volume: 36, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe

1998
The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.
    British journal of cancer, 1998, Volume: 77, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Biotransformation; Cross-Over Studies; Cyclophosphamide; Dexamet

1998
Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Filgras

1998
High-dose-intensity combination chemotherapy for advanced sarcomas: a pilot study.
    Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; Doxorubicin;

1998
Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas.
    American journal of clinical oncology, 1998, Volume: 21, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxo

1998
Treatment of advanced refractory sarcomas with ifosfamide and etoposide combination chemotherapy.
    Cancer investigation, 1998, Volume: 16, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide;

1998
Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: a study of the Spanish Group for Research on Sarcomas (GEIS).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide

1998
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Granulocyte-Macrophage Colony-Stimulating Fa

1998
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dose-Respon

1998
High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasib

1998
Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study.
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubici

1999
Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS).
    American journal of clinical oncology, 1999, Volume: 22, Issue:3

    Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Do

1999
Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dose-Response Relationship, Drug;

1999
Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:12

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali

1999
Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas.
    Medical and pediatric oncology, 2000, Volume: 34, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Child; Child, Preschool; Cyc

2000
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Follow-Up Studies; Humans

2000
Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
    Cancer, 2000, May-01, Volume: 88, Issue:9

    Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chi-Square Distribu

2000
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
    British journal of clinical pharmacology, 2000, Volume: 49, Issue:6

    Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Area Under Curve; Computer Simulation; F

2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu

2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu

2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu

2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu

2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu

2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu

2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu

2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu

2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu

2000
The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma.
    Cancer, 2000, Jul-01, Volume: 89, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule

2000
Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
    Anti-cancer drugs, 2000, Volume: 11, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Doxorubicin; Drug Therapy, Combination;

2000
Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group.
    Anti-cancer drugs, 2000, Volume: 11, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Middle Aged; Peer Re

2000
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Nov-01, Volume: 18, Issue:21

    Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combin

2000
Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2000, Volume: 26, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, C

2000
A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies.
    Cancer chemotherapy and pharmacology, 2000, Volume: 46, Issue:5

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating;

2000
Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dis

2001
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:3

    Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot

2001
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com

2001
Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies;

2001
Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies;

2001
Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules.
    Onkologie, 2001, Volume: 24, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship,

2001
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:9

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Pro

2001
Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
    European journal of clinical pharmacology, 2001, Volume: 57, Issue:6-7

    Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Cyclophosphamide; Female; Humans; Ifosfa

2001
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
    Cancer, 2002, Feb-01, Volume: 94, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined

2002
Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Rela

2002
Current trials and new aspects in soft tissue sarcoma of adults.
    Cancer chemotherapy and pharmacology, 2002, Volume: 49 Suppl 1

    Topics: Adult; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Europe;

2002
[Clinical experience with the cytostatic drug ifosfamide].
    Die Medizinische Welt, 1977, Sep-02, Volume: 28, Issue:35

    Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; Drug Ther

1977
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Europe; Humans; Ifosfamide; Sarcoma;

1992
Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.
    Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Drug Administ

1992
Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Humans; Ifosfamide; Sarcoma

1992
Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
    Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Female; G

1991
A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com

1991
Dana-Farber Cancer Institute studies in advanced sarcoma.
    Seminars in oncology, 1990, Volume: 17, Issue:1 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation

1990
Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Child; Chil

1990
Ifosfamide in soft tissue sarcoma.
    JPMA. The Journal of the Pakistan Medical Association, 1990, Volume: 40, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Dactinomycin; Doxorubicin; Etoposide;

1990
Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:1

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Female; Hematuria; Human

1989
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:9

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bra

1989
Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Hematopoiesis; Humans; Ifosfamide; Mult

1989
Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.
    Cancer treatment reports, 1986, Volume: 70, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Doxorubic

1986
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Infections;

1986
The treatment of soft tissue sarcomas with focus on chemotherapy: a review.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1986, Volume: 5, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy;

1986
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas.
    European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Middle

1987
Ifosfamide--pharmacology, safety and therapeutic potential.
    Cancer treatment reviews, 1985, Volume: 12, Issue:1

    Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu

1985

Other Studies

242 other studies available for ifosfamide and Sarcoma, Epithelioid

ArticleYear
There is more to soft tissue sarcomas than just grade and size.
    Cancer, 2022, Jan-01, Volume: 128, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms

2022
The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2021, Volume: 165

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Retrospectiv

2021
Doxorubicin Combined With Ifosfamide for Sarcoma Induces Muscle Atrophy and Sleep Disruption.
    Anticancer research, 2021, Volume: 41, Issue:12

    Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Doxorubicin

2021
Standardization of evaluation method and prognostic significance of histological response to preoperative chemotherapy in high-grade non-round cell soft tissue sarcomas.
    BMC cancer, 2022, Jan-21, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Dr

2022
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).
    ESMO open, 2022, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Doxorubicin; Humans; Ifosf

2022
The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 165

    Topics: Antineoplastic Combined Chemotherapy Protocols; Extremities; Humans; Ifosfamide; Retrospective Studi

2022
Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group.
    Japanese journal of clinical oncology, 2022, May-31, Volume: 52, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Humans; Ifosfamid

2022
Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy.
    Cancer medicine, 2022, Volume: 11, Issue:18

    Topics: Adolescent; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

2022
First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.
    Cancer, 2022, 08-01, Volume: 128, Issue:15

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms;

2022
Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features.
    BMC medical imaging, 2022, 07-26, Volume: 22, Issue:1

    Topics: Epirubicin; Humans; Ifosfamide; Lung Neoplasms; Retrospective Studies; Sarcoma; Soft Tissue Neoplasm

2022
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
    Medicine, 2022, Nov-25, Volume: 101, Issue:47

    Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male;

2022
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
    Medicine, 2022, Nov-25, Volume: 101, Issue:47

    Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male;

2022
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
    Medicine, 2022, Nov-25, Volume: 101, Issue:47

    Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male;

2022
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
    Medicine, 2022, Nov-25, Volume: 101, Issue:47

    Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male;

2022
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti

2023
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti

2023
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti

2023
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti

2023
Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations.
    Journal of pediatric hematology/oncology, 2023, 08-01, Volume: 45, Issue:6

    Topics: Biomarkers, Tumor; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant

2023
Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2023, Jun-01, Volume: 185

    Topics: Antiemetics; Aprepitant; Humans; Ifosfamide; Retrospective Studies; Sarcoma

2023
Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023, Volume: 25, Issue:12

    Topics: Dacarbazine; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Retrospective Studies; Sarcoma; Soft Ti

2023
Perspectives of Cell Sensitivity/Resistance Assay in Soft Tissue Sarcomas Chemotherapy.
    International journal of molecular sciences, 2023, Jul-31, Volume: 24, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Sarcoma; Soft Tissu

2023
Sarcomas and old age: few options for such a large patient population.
    Future oncology (London, England), 2019, Volume: 15, Issue:26s

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycy

2019
Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?
    Future oncology (London, England), 2019, Volume: 15, Issue:26s

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin

2019
Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide.
    The oncologist, 2020, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp

2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and
    Cancer, 2020, 06-01, Volume: 126, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide

2020
Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.
    American journal of clinical oncology, 2020, Volume: 43, Issue:6

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Combined Chemothera

2020
Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Pediatric Sarcoma for Maximal Oncologic Control.
    Urology, 2020, Volume: 141

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Cystectomy; Cytoreducti

2020
Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals.
    Cancer, 2020, 10-15, Volume: 126, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Leiomy

2020
Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals.
    Cancer, 2020, 10-15, Volume: 126, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Leiomy

2020
Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion.
    American journal of clinical pathology, 2020, 11-04, Volume: 154, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Cyclop

2020
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia).
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 139

    Topics: Adenosarcoma; Anthracyclines; Antineoplastic Agents; Chemotherapy, Adjuvant; Consensus; Dacarbazine;

2020
Modern Management of High-risk Soft Tissue Sarcoma With Neoadjuvant Chemoradiation: A Single-center Experience.
    American journal of clinical oncology, 2021, 01-01, Volume: 44, Issue:1

    Topics: Adolescent; Adult; Aged; Disease-Free Survival; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; M

2021
Incidence of ifosfamide induced encephalopathy in patients receiving concomitant fosaprepitant.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:8

    Topics: Adult; Brain Diseases; Humans; Ifosfamide; Incidence; Morpholines; Retrospective Studies; Sarcoma

2021
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Jul-10, Volume: 35, Issue:20

    Topics: Adolescent; Adult; Adult Survivors of Child Adverse Events; Aged; Antineoplastic Agents; Bone Neopla

2017
Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303.
    Annals of surgical oncology, 2017, Volume: 24, Issue:13

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Female; Follow-Up Studies; Humans

2017
Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.
    Oncology, 2018, Volume: 95, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Co

2018
Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas.
    American journal of clinical oncology, 2018, Volume: 41, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad

2018
The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk.
    JAMA oncology, 2018, 09-01, Volume: 4, Issue:9

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Extremities;

2018
Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma.
    Lung cancer (Amsterdam, Netherlands), 2018, Volume: 122

    Topics: Adult; Aged; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Midd

2018
ASO Author Reflections: Chemoradiation for High-Risk Soft Tissue Sarcomas.
    Annals of surgical oncology, 2018, Volume: 25, Issue:Suppl 3

    Topics: Chemoradiotherapy; Epirubicin; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms

2018
Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
    Cancer letters, 2019, 06-01, Volume: 451

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Ani

2019
(Neo)adjuvant chemotherapy and interdigitated split-course hyperfractionated radiation in high risk soft tissue sarcoma - Results from a large single-institution series.
    Scientific reports, 2019, 05-13, Volume: 9, Issue:1

    Topics: Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy

2019
Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2013, Volume: 189, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Combined Modal

2013
Chemotherapy influences the pseudocapsule composition in soft tissue sarcomas.
    Clinical orthopaedics and related research, 2014, Volume: 472, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy;

2014
Successful treatment of recurrent pediatric inflammatory myofibroblastic tumor in a single patient with a novel chemotherapeutic regimen containing celecoxib.
    Journal of pediatric hematology/oncology, 2013, Volume: 35, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Humans; Ifosfamide; Lung Neoplasms

2013
Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall.
    International journal of radiation oncology, biology, physics, 2013, Aug-01, Volume: 86, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemothera

2013
Embryonal sarcoma of the liver.
    Pediatric surgery international, 2013, Volume: 29, Issue:12

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chil

2013
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp

2013
Targeted imaging of α(v)β(3) expressing sarcoma tumor cells in vivo in pre-operative setting using near infrared: a potential tool to reduce incomplete surgical resection.
    Bone, 2014, Volume: 62

    Topics: Animals; Diagnostic Imaging; Humans; Ifosfamide; Integrin alphaVbeta3; Lung Neoplasms; Preoperative

2014
Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy.
    Cancer medicine, 2014, Volume: 3, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival;

2014
Neoadjuvant treatment with preoperative radiotherapy for extremity soft tissue sarcomas: long-term results from a single institution in Turkey.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas

2014
An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015, Volume: 21, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Cancer Care Facilities; Cisplatin; Female; Humans

2015
[End-stage renal disease after sarcoma therapy - case 3/2014].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:15

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential

2014
The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
    American journal of clinical oncology, 2016, Volume: 39, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad

2016
Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.
    International journal of cancer, 2015, Feb-15, Volume: 136, Issue:4

    Topics: Adenoviridae; Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Combined Modali

2015
Undifferentiated sarcoma of the orbit with angiomyxoid features.
    Journal of pediatric ophthalmology and strabismus, 2014, Feb-25, Volume: 51 Online

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Female; Huma

2014
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
    Future oncology (London, England), 2015, Volume: 11, Issue:11 Suppl

    Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; C

2015
[Systemic therapy of soft tissue sarcomas].
    Voprosy onkologii, 2015, Volume: 61, Issue:2

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad

2015
Multivariate Markov models for the conditional probability of toxicity in phase II trials.
    Biometrical journal. Biometrische Zeitschrift, 2016, Volume: 58, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biometry; Calibration; Clinic

2016
Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma.
    American journal of clinical oncology, 2018, Volume: 41, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Disease

2018
Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience.
    Journal of cancer research and clinical oncology, 2016, Volume: 142, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2016
Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children.
    Journal of neurosurgery. Pediatrics, 2016, Volume: 17, Issue:3

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

2016
Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience.
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2016, Volume: 20, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Doxorubici

2016
Severe toxicity of chemotherapy against advanced soft tissue sarcoma in Werner's syndrome: Ifosfamide-induced encephalopathy with central diabetes insipidus.
    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2016, Volume: 21, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Diabetes Insipidus, Neurogenic; Doxo

2016
Singapore Cancer Network (SCAN) Guidelines for the Initial Evaluation, Diagnosis, and Management of Extremity Soft Tissue Sarcoma and Osteosarcoma.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Chemotherapy, Adjuvan

2015
Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients.
    Medicine, 2016, Volume: 95, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin

2016
Primary proximal epithelioid sarcoma of the lung successfully treated with pneumonectomy and adjuvant chemotherapy.
    BMJ case reports, 2016, Apr-04, Volume: 2016

    Topics: Adult; Chemotherapy, Adjuvant; Doxorubicin; Hemoptysis; HIV Infections; Humans; Ifosfamide; Lung Neo

2016
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:7

    Topics: Adult; Aged; Carcinoma; Carcinosarcoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Human

2016
A successful case of an anaplastic meningioma treated with chemotherapy for soft tissue sarcomas.
    CNS oncology, 2016, Volume: 5, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child, Preschool; Doxorubicin; Huma

2016
Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017, Volume: 25, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropeni

2017
Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy.
    Medicine, 2016, Volume: 95, Issue:49

    Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Do

2016
Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma.
    Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Indazole

2017
VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma.
    Medicine, 2017, Volume: 96, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp

2017
The risk of postoperative complications and functional impairment after multimodality treatment for limb and trunk wall soft-tissue sarcoma: Long term results from a monocentric series.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, Volume: 43, Issue:6

    Topics: Abdominal Wall; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplast

2017
Undifferentiated sarcoma of the maxillary sinus: report of a rare case in an adult.
    Auris, nasus, larynx, 2009, Volume: 36, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outc

2009
Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2008, Volume: 14, Issue:3

    Topics: Antidotes; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Delirium; Female; Humans; Ifo

2008
Childhood undifferentiated embryonal liver sarcoma: clinical features and immunohistochemistry analysis.
    Journal of pediatric surgery, 2008, Volume: 43, Issue:10

    Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protoc

2008
Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers; Child; Cyclophosphamide; Dose-Resp

2009
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Apr-15, Volume: 15, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-U

2009
Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2010, Mar-15, Volume: 76, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxo

2010
Late effects surveillance system after childhood cancer in Germany, austria and parts of Switzerland--update 2009.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2009, Volume: 185 Suppl 2

    Topics: Adolescent; Aftercare; Antineoplastic Combined Chemotherapy Protocols; Austria; Bone Neoplasms; Card

2009
Aprepitant-associated ifosfamide neurotoxicity.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:2

    Topics: Adult; Antidepressive Agents; Antineoplastic Agents, Alkylating; Aprepitant; Case-Control Studies; F

2010
[Positron emission tomography as a tool for early prediction of therapy outcome in soft tissue sarcoma].
    Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:39

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Doxorubicin; Etoposide;

2009
Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy?
    The oncologist, 2009, Volume: 14, Issue:10

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod

2009
Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32

    Topics: Antineoplastic Agents, Alkylating; Child; Follow-Up Studies; Humans; Ifosfamide; Kidney; Kidney Dise

2009
Stroke due to undifferentiated aortic intimal sarcoma with disseminated metastatic lesions.
    Circulation, 2009, Dec-22, Volume: 120, Issue:25

    Topics: Antineoplastic Agents; Aorta; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxorubicin; Echoca

2009
Undifferentiated sarcoma of the thyroid in a child.
    Pediatric blood & cancer, 2010, Jul-01, Volume: 54, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactinomycin;

2010
Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors.
    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2010, Volume: 15, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cisplatin; Dose-R

2010
Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study.
    Bone marrow transplantation, 2010, Volume: 45, Issue:12

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera

2010
[Lung metastases of epithelioid sarcoma revealed by bilateral spontaneous pneumothorax: a pathological diagnosis].
    Annales de pathologie, 2010, Volume: 30, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Doxorubicin; Drainage; Fatal Outc

2010
Extraskeletal Ewing's sarcoma family of tumours in adults: analysis of 57 patients from a single institution.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2010, Volume: 22, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactin

2010
Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
    Taiwanese journal of obstetrics & gynecology, 2010, Volume: 49, Issue:1

    Topics: Aged; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Methylene Blue; Middle Aged; Ne

2010
Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis.
    Radiation oncology (London, England), 2010, Jun-16, Volume: 5

    Topics: Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Female; Follow-Up Studies; Huma

2010
Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma.
    Pediatric blood & cancer, 2010, Volume: 55, Issue:4

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Female; Humans; Ifosfamide;

2010
Continuously improving ifosfamide/mesna: a winning combination.
    Pediatric blood & cancer, 2010, Volume: 55, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Mesna; Sarcoma

2010
Large primary cardiac sarcoma on the left ventricular free wall: is total excision contraindicated?
    Interactive cardiovascular and thoracic surgery, 2010, Volume: 11, Issue:5

    Topics: Aged; Antineoplastic Agents, Alkylating; Cardiac Surgical Procedures; Cardiac Tamponade; Chemotherap

2010
Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall.
    International journal of radiation oncology, biology, physics, 2011, Dec-01, Volume: 81, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Ex

2011
Role of palliative chemotherapy in advanced epithelioid sarcoma.
    American journal of clinical oncology, 2012, Volume: 35, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Fema

2012
Determinants of toxicity, patterns of failure, and outcome among adult patients with soft tissue sarcomas of the extremity and superficial trunk treated with greater than conventional doses of perioperative high-dose-rate brachytherapy and external beam r
    International journal of radiation oncology, biology, physics, 2011, Nov-15, Volume: 81, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemo

2011
Ifosfamide nephropathy in patients with sarcoma.
    Iranian journal of kidney diseases, 2011, Volume: 5, Issue:4

    Topics: Adolescent; Adult; Age Distribution; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Coh

2011
High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Oncology, 2011, Volume: 80, Issue:3-4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease-Free Survival; Female; Human

2011
Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case.
    Surgery today, 2011, Volume: 41, Issue:8

    Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Female; Humans; Ifosfamide; Lung Neopla

2011
A case of intimal sarcoma of the pulmonary artery successfully treated with chemotherapy.
    International journal of clinical oncology, 2012, Volume: 17, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Doxorubicin; Female; Humans;

2012
Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas.
    International journal of clinical oncology, 2013, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Di

2013
Modified vaccinia virus Ankara delivers a robust surrogate marker for immune monitoring to sarcoma cells even if cells are being exposed to chemotherapy and heat treatment.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2012, Volume: 28, Issue:1

    Topics: Antigen Presentation; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Green Fluo

2012
Maintenance therapy in the treatment of sarcoma.
    Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Agents; Child; Disease-Free Survival; Doxorubicin; Humans; Ifosfam

2011
Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Epi

2013
Spindle cell rhabdomyosarcoma of the prostate.
    International journal of urology : official journal of the Japanese Urological Association, 2013, Volume: 20, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Doxorubicin; Humans; Ifosfamide; Magne

2013
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma.
    Anticancer research, 2013, Volume: 33, Issue:2

    Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Epirubicin; Female; Granulocyte Colony-S

2013
Salvage chemotherapy for advanced sarcoma patients: a single-institution experience survey.
    Journal of experimental & clinical cancer research : CR, 2002, Volume: 21, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; D

2002
Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency.
    Thrombosis research, 2002, Apr-15, Volume: 106, Issue:2

    Topics: ADAM Proteins; ADAMTS13 Protein; Adenocarcinoma; Anemia, Hemolytic; Antineoplastic Combined Chemothe

2002
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Cancer, 2002, Sep-15, Volume: 95, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali

2002
[Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2002, Volume: 21, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Female

2002
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.
    Annals of surgery, 2003, Volume: 237, Issue:2

    Topics: Amputation, Surgical; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Do

2003
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.
    Annals of surgery, 2003, Volume: 237, Issue:2

    Topics: Amputation, Surgical; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Do

2003
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.
    Annals of surgery, 2003, Volume: 237, Issue:2

    Topics: Amputation, Surgical; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Do

2003
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.
    Annals of surgery, 2003, Volume: 237, Issue:2

    Topics: Amputation, Surgical; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Do

2003
Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?
    Oncology, 2003, Volume: 64, Issue:2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Gastrointestinal Neopla

2003
Chemotherapy of soft tissue sarcoma--a clinical evaluation of treatment over ten years.
    Acta oncologica (Stockholm, Sweden), 2003, Volume: 42, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dacarbazin

2003
Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases.
    Urology, 2003, Volume: 61, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant;

2003
Has "MAID" made it in the management of high-risk soft-tissue sarcoma?
    International journal of radiation oncology, biology, physics, 2003, Jul-15, Volume: 56, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Ex

2003
Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group.
    Oncology, 2003, Volume: 65, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp

2003
Extended total sacrectomy and reconstruction for sacral tumor.
    Spine, 2004, Mar-15, Volume: 29, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combi

2004
Influence of age upon Ifosfamide-induced nephrotoxicity.
    Pediatric blood & cancer, 2004, Volume: 42, Issue:5

    Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Do

2004
Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).
    Journal of surgical oncology, 2004, Oct-01, Volume: 88, Issue:1

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Bias; Clinical Trials,

2004
Sarcomas of the head and neck. Results from the treatment of 25 patients.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2005, Volume: 31, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2005
Successful treatment of pulmonary artery sarcoma by a two-drug combination chemotherapy consisting of ifosfamide and epirubicin.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; Ifosfamide; Progno

2005
Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas.
    European journal of gynaecological oncology, 2005, Volume: 26, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Mesn

2005
Decision-theoretic designs for dose-finding clinical trials with multiple outcomes.
    Statistics in medicine, 2006, May-30, Volume: 25, Issue:10

    Topics: Algorithms; Anti-HIV Agents; Antineoplastic Agents, Alkylating; Child, Preschool; Clinical Trials, P

2006
Multimodal treatment using surgery, radiotherapy, and chemotherapy in a patient with a perivascular epithelioid cell tumor of the uterus.
    Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Doxorubicin; Epith

2005
Preoperative chemotherapy and split-course radiation therapy for patients with localized soft tissue sarcomas: home run, base hit, or strike out?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-01, Volume: 24, Issue:4

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine;

2006
Langerhans cell sarcoma.
    The American Journal of dermatopathology, 2006, Volume: 28, Issue:1

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Disease-Free Survival; Doxoru

2006
Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
    Pediatric blood & cancer, 2007, Volume: 48, Issue:4

    Topics: Abdomen; Adolescent; Age Factors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth

2007
Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.
    Pediatric blood & cancer, 2007, Volume: 48, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Carboplatin; Child; Child, Preschool; Cisplatin; Creatinine; Fema

2007
Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature.
    Annals of diagnostic pathology, 2006, Volume: 10, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Dendritic Cells, Fol

2006
[A case of the treatment in an adult with hepatic undifferentiated (embryonal) sarcoma].
    The Korean journal of hepatology, 2007, Volume: 13, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Doxorubicin; Female; Humans; Ifosfamid

2007
Thyroid function in paediatric and young adult patients after sarcoma therapy: a report from the Late Effects Surveillance System.
    Clinical endocrinology, 2007, Volume: 66, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; F

2007
Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience.
    European journal of gynaecological oncology, 2007, Volume: 28, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined

2007
Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma.
    Clinical orthopaedics and related research, 2007, Volume: 462

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combin

2007
Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.
    Drugs & aging, 2007, Volume: 24, Issue:11

    Topics: Abdominal Neoplasms; Aged; Antidotes; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che

2007
Does ifosfamide affect gonadal function?
    Pediatric blood & cancer, 2008, Volume: 50, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Female; Humans; Ifosf

2008
[Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe

2007
F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
    Clinical nuclear medicine, 2008, Volume: 33, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Female; Fluorodeoxyglucose F18

2008
Mediastinal sarcoma with deviated tracheal anatomy.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Doxorubicin; Female; Humans; Ifosfam

2008
Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation.
    The oncologist, 2008, Volume: 13, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Disease-Free Surviva

2008
Experimental basis and clinical experience with non-cross-resistant combinations in solid tumours.
    Cancer treatment reviews, 1984, Volume: 11 Suppl A

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bro

1984
High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Adolescent; Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna;

1983
High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
    Cancer chemotherapy and pharmacology, 1983, Volume: 11, Issue:2

    Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Human

1983
Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans;

1983
Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide.
    Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Etoposide; Female; F

1995
Comparison of continuous infusion and bolus administration of ifosfamide in children.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:5

    Topics: Adolescent; Child; Child, Preschool; Female; Humans; Ifosfamide; Infant; Infusion Pumps; Infusions,

1995
Mesna, doxorubicin, ifosfamide, and dacarbazine chemotherapy for ovarian mixed müllerian sarcoma: report of four cases.
    Gynecologic oncology, 1995, Volume: 58, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Combined Modality Therapy; Da

1995
The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.
    Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:1

    Topics: Adolescent; Child; Child, Preschool; Chromatography, Thin Layer; Female; Half-Life; Humans; Ifosfami

1995
[Peri-operative chemotherapy during resection of pulmonary metastases of sarcoma].
    Bulletin du cancer, 1994, Volume: 81, Issue:2

    Topics: Adult; Combined Modality Therapy; Female; Humans; Ifosfamide; Infusions, Intravenous; Intraoperative

1994
Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma.
    Cancer research, 1994, Oct-15, Volume: 54, Issue:20

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Combine

1994
Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy.
    Cancer chemotherapy and pharmacology, 1994, Volume: 35, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; C

1994
Renal function in children and adolescents following 72 g/m2 of ifosfamide.
    Cancer chemotherapy and pharmacology, 1994, Volume: 34, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Female; Glomerular Filtrat

1994
Discussion: the Satellite Symposium on "Ifosfamide in the treatment of sarcomas" of the 6th European Conference on Clinical Oncology and Cancer Nursing, Firenze, October 27, 1991.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Humans; Ifosfamide; Sarcoma

1993
Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats.
    Cancer research, 1994, Apr-01, Volume: 54, Issue:7

    Topics: Animals; Bone Neoplasms; Cell Line; Doxorubicin; Female; Femur; Ifosfamide; Male; Melanoma, Amelanot

1994
Ifosfamide-induced hyperpigmentation.
    Cancer, 1994, Jan-01, Volume: 73, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposide; Female; Humans;

1994
Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Doxorubicin; Gra

1993
[Intensive chemotherapy for alveolar soft part sarcoma with lung metastasis in a child].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Cyclophosphamide; Dactinomycin; Do

1993
Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
    Cancer research, 1993, Aug-15, Volume: 53, Issue:16

    Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Ifosfamide; Infan

1993
Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Grou
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Disea

1993
Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31, Issue:5

    Topics: Adult; Aged; Humans; Ifosfamide; Magnetic Resonance Spectroscopy; Middle Aged; Phosphorus; Phosphory

1993
[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:4

    Topics: Administration, Intravesical; Adolescent; Adult; Aluminum Hydroxide; Bone Neoplasms; Child, Preschoo

1993
Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F

1993
Ifosfamide combination regimens for soft-tissue sarcoma.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fem

1993
Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Dru

1993
A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu

1993
Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone

1993
Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy;

1993
The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Doxorubicin; Fema

1993
A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.
    Cancer, 1995, Dec-15, Volume: 76, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; beta 2-Microglobulin; Child; Child, Preschool;

1995
High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas.
    Cancer investigation, 1996, Volume: 14, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Doxorubicin; Female;

1996
Ifosfamide in sarcomas: is it a schedule-dependent drug?
    Cancer investigation, 1996, Volume: 14, Issue:3

    Topics: Doxorubicin; Drug Administration Schedule; Humans; Ifosfamide; Sarcoma

1996
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agen

1996
[Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
    Harefuah, 1996, Apr-15, Volume: 130, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C

1996
The use of combined chemotherapy for the treatment of advanced sarcoma of the uterus.
    European journal of gynaecological oncology, 1996, Volume: 17, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C

1996
Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:4

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo

1997
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
    Cancer chemotherapy and pharmacology, 1997, Volume: 40, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Breast Neoplasms; Carcinoma, Transitional Cell; D

1997
Treatment of childhood post-irradiation sarcoma of bone in cancer survivors.
    Medical and pediatric oncology, 1997, Volume: 29, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

1997
The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and Bone Sarcoma Group.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Data Collection; Doxorubicin; Granul

1997
[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:14

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Drug Administration Sch

1997
Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial.
    Medical and pediatric oncology, 1998, Volume: 30, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

1998
Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide).
    European journal of gynaecological oncology, 1998, Volume: 19, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad

1998
[Chemotherapy for pulmonary metastases of soft tissue sarcoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administra

1998
Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
    International journal of radiation oncology, biology, physics, 1998, Sep-01, Volume: 42, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos

1998
High-dose ifosfamide for soft tissue sarcomas: set the scene, or senescence?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dose-Response Relationship, Drug; Human

1998
Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
    Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biot

1998
Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclopho

1998
Treatment of soft-tissue sarcomas: high-dose ifosfamide or combination of ifosfamide and etoposide?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

1999
Advanced soft tissue sarcoma: how many more trials with anthracyclines and ifosfamide?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:2

    Topics: Antibiotics, Antineoplastic; Humans; Ifosfamide; Randomized Controlled Trials as Topic; Sarcoma

1999
Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness.
    Prescrire international, 1998, Volume: 7, Issue:34

    Topics: Adult; Antineoplastic Agents, Alkylating; Breast Neoplasms; Child; Clinical Trials as Topic; Cycloph

1998
Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study.
    International journal of radiation oncology, biology, physics, 1999, Jun-01, Volume: 44, Issue:3

    Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow

1999
[Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1999, Volume: 175, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali

1999
Comments on: Should patients with advanced soft tissue sarcomas be treated with chemotherapy? Arbiter: Van Hoesel, Q.G.C.M. Eur J Cancer 1998, 34(7), 964-965.
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Sarcoma

1999
Role of the combination of ifosfamide and etoposide in the treatment of soft tissue sarcomas.
    Oncology, 1999, Volume: 57, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

1999
Efficacy of docetaxel in the second-line treatment of locally advanced or metastatic soft tissue sarcoma after failure of chemotherapy with anthracycline or ifosfamide.
    American journal of clinical oncology, 1999, Volume: 22, Issue:5

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents,

1999
A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients.
    British journal of cancer, 1999, Volume: 81, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Div

1999
Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
    Journal of surgical oncology, 2000, Volume: 73, Issue:1

    Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Co

2000
Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2000
Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia.
    Journal of cancer research and clinical oncology, 2000, Volume: 126, Issue:3

    Topics: Adolescent; Adult; Aged; Albuminuria; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phyt

2000
Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma.
    Medical and pediatric oncology, 2000, Volume: 34, Issue:4

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti

2000
Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
    Gynecologic oncology, 2000, Volume: 78, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide;

2000
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Oct-01, Volume: 18, Issue:19

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy

2000
Large, deep, high-grade extremity sarcomas: treating tumors of the flexor fossae.
    Surgical oncology, 1999, Volume: 8, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Combined Modality Therapy; Dose Fractionatio

1999
Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials.
    Biometrics, 1999, Volume: 55, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Biometry; Clinical Trials as Topic; Humans; Ifosfamide; Leukemia,

1999
Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jul-01, Volume: 19, Issue:13

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C

2001
Adult testicular sarcoma: presentation, evaluation, and treatment.
    Urology, 2002, Volume: 59, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Male; Middle Aged;

2002
Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine).
    Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Female; Human

2002
Systemic therapy for advanced soft-tissue sarcomas.
    Current oncology reports, 2002, Volume: 4, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Doxorubicin; G

2002
The oncogenic effect of immunosuppressive (cytotoxic) agents in (NZB x NZW) mice. II. Emergence of tumors in young animals treated with azathioprine and ifosfamide, including a histologic assessment of the neoplasms.
    Arzneimittel-Forschung, 1979, Volume: 29, Issue:4

    Topics: Animals; Azathioprine; Carcinogens; Carcinoma; Cyclophosphamide; Female; Hyperplasia; Ifosfamide; Ly

1979
High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases.
    Bone marrow transplantation, 1992, Volume: 10, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chil

1992
Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Epirubicin; Fe

1992
A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy.
    The Journal of pharmacology and experimental therapeutics, 1992, Volume: 260, Issue:3

    Topics: Body Fluids; Humans; Ifosfamide; Magnetic Resonance Spectroscopy; Sarcoma; Soft Tissue Neoplasms

1992
Extra-uterine endometrial stromal sarcoma with DNA flow cytometric analysis.
    European journal of obstetrics, gynecology, and reproductive biology, 1992, Jan-31, Volume: 43, Issue:2

    Topics: Adult; Colonic Neoplasms; DNA; Doxorubicin; Endometriosis; Female; Flow Cytometry; Follow-Up Studies

1992
Epirubicin plus ifosfamide and dacarbazine (EID) in advanced soft tissue sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3 Suppl 2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Epirubicin; Follow-U

1992
Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteine.
    Anti-cancer drugs, 1992, Volume: 3, Issue:1

    Topics: Acetylcysteine; Agranulocytosis; Bone Marrow; Humans; Ifosfamide; Sarcoma

1992
Ifosfamide vs cyclophosphamide in cancer therapy.
    Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:5

    Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cyclophosphamide; Female; Genital Neoplasms,

1991
Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:12

    Topics: Acute Kidney Injury; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc

1991
Local hyperthermia enhances cyclophosphamide, ifosfamide and cis-diamminedichloroplatinum cytotoxicity on human-derived breast carcinoma and sarcoma xenografts in nude mice.
    Journal of cancer research and clinical oncology, 1992, Volume: 118, Issue:2

    Topics: Animals; Body Temperature; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cyclophosphamide;

1992
Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients.
    Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi

1991
Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma.
    Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther

1990
Interstitial pneumonitis associated with ifosfamide therapy.
    Cancer, 1990, May-15, Volume: 65, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide

1990
Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl

    Topics: Antineoplastic Agents; Carcinoma; Drug Evaluation; Female; Humans; Ifosfamide; Mercaptoethanol; Mesn

1990
Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co

1990
Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1990, Volume: 1, Issue:5

    Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Drug

1990
Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide.
    Onkologie, 1990, Volume: 13, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Dos

1990
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio

1990
Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Epirubicin; Femal

1990
Primary chemosensitivity and secondary drug resistance of xenografted soft part sarcomas.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1989, Volume: 165, Issue:7

    Topics: Animals; Bleomycin; Doxorubicin; Drug Resistance; Female; Histiocytoma, Benign Fibrous; Humans; Ifos

1989
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Humans; Ifosfamide; Infant; Mercaptoethanol; M

1989
Mesna: continuous or bolus infusion?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:6

    Topics: Drug Administration Schedule; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; M

1989
Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas.
    Journal of the National Cancer Institute, 1989, Jun-07, Volume: 81, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide;

1989
Characterization and chemotherapy of human soft tissue sarcoma (STS) lines grown in nude mice.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1989, Volume: 165, Issue:7

    Topics: Animals; Cyclophosphamide; Doxorubicin; Female; Fibrosarcoma; Histiocytoma, Benign Fibrous; Humans;

1989
Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group.
    Journal of the National Cancer Institute, 1989, Oct-04, Volume: 81, Issue:19

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F

1989
Ifosfamide/mesa and encephalopathy.
    Lancet (London, England), 1985, Mar-30, Volume: 1, Issue:8431

    Topics: Brain Diseases; Carcinoma, Small Cell; Cyclophosphamide; Female; Humans; Ifosfamide; Lung Neoplasms;

1985
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre

1986
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb

1987
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb

1987
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb

1987
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb

1987
A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
    Cancer chemotherapy and pharmacology, 1988, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Doxorubicin; Drug Ev

1988
A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio

1988
[Results of whole lung irradiation and chemotherapy in comparison with partial lung irradiation in metastasizing, undifferentiated soft tissue sarcomas].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1988, Volume: 164, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F

1988
Ifosfamide: an old drug recently rediscovered.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:6

    Topics: Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Neoplasms; Sarcoma; Soft Tissue

1988
Phase II study of ifosfamide + adriamycin in advanced soft tissue sarcoma in adults. A preliminary analysis.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio

1986
Alternatives to CYVADIC combination therapy of soft tissue sarcomas.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dacarbazin

1986
The role of ifosfamide in paediatric soft tissue sarcomas.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dactinomycin; Drug Evaluation; Humans; Ifosfa

1986
A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Drug Evaluation; Femal

1986
Alternatives to CYVADIC-combination therapy of soft tissue sarcomas.
    Klinische Wochenschrift, 1985, Nov-15, Volume: 63, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dacarbazin

1985
Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
    Cancer treatment reports, 1985, Volume: 69, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cystitis; Drug

1985
chemdatabank.com